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ABSTRACT OF DISSERTATION 
 
 
 
 
 
CHRONIC OPIOID USE IN FIBROMYALGIA SYNDROME: 
CHARACTERISTICS AND OUTCOMES 
 
Fibromyalgia syndrome (FMS) is a chronic pain condition with 
significant societal and personal burdens of illness. Chronic 
opioid therapy in the treatment of chronic nonmalignant pain has 
increased drastically over the past decade. This is a worrisome 
trend in general, but specifically, given the pathophysiologic 
characteristics seen in fibromyalgia syndrome patients, the use 
of this class of medication deserves special scrutiny. Although 
the theoretical case against this therapy choice is strong, 
little empirical evidence exists. In order to supplement this 
literature, retrospective analysis methods are utilized to 
examine the association of state-, provider-, and patient level 
characteristics with the prevalence of chronic opioid use in this 
disease state. Data gathered through this analysis is then used 
to develop a propensity index for the identification of an 
appropriate control group for fibromyalgia patients, a task that 
has proven difficult in the literature to date. Using propensity 
stratification and matching techniques analysis of the impact of 
fibromyalgia, chronic opioid use, and the interaction of these 
two variables are undertaken. 
 
Several key findings and updates to the understanding of chronic 
opioid use and fibromyalgia syndrome are reported. Wide 
geographic variation in chronic opioid utilization between states 
is seen. The role of diagnosing provider type in the rate of 
chronic opioid prescribing is significant and can be aggregated 
at various levels. Demographic characteristics, comorbid 
conditions, and concurrent medication use are all important 
associates of chronic opioid use in fibromyalgia syndrome. 
Additionally, chronic opioid use in fibromyalgia patients, 
independent of propensity to receive that therapy choice is a 
significant correlate with healthcare costs. A diagnosis of 
fibromyalgia is a statistically significant source of healthcare 
costs, though the clinical significance of its impact when 
compared to a closely matched control group is minimized. Despite 
the minimization of the role of this diagnosis the impact of the 
interaction of chronic opioid use with fibromyalgia, despite 
control for myriad regressors, is significant both statistically 
and clinically. 
 
KEYWORDS: Cost of illness (COI), Evidence-based medicine (EBM), 
Fibromyalgia syndrome (FMS), Geographic variation, Opioid 
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Chapter 1: A review of fibromyalgia syndrome and the consequences 
of chronic opioid use 
A: Introduction 
According to Relieving Pain in America, a recent report 
published by the Institute of Medicine, pain is the leading 
affliction affecting Americans and costs the nation over 635 
billion dollars annually in medical costs and lost production.1 
The Institute stresses the importance of increased research into 
the translation of effective treatments into practice and into 
the occurrence and cost of pain.1 Chronic pain research is a 
difficult endeavor because of the subjective and heterogeneous 
nature of the disorder.  One approach to pursuing answers to some 
of these difficult research questions is to look at individual 
chronic pain ailments. Fibromyalgia syndrome, due to the nature 
of the disorder, the recent development of medication with proven 
safety and efficacy, the significant burden of illness it 
inflicts on sufferers, and the wide range of treatment 
alternatives currently in use without efficacy evidence, is an 
ideal disease state for this goal. 
Fibromyalgia syndrome, also labeled FMS or simply 
fibromyalgia, is an idiopathic, functional disorder characterized 
by chronic widespread pain and diffuse tenderness.2 This disorder 
affects over 6 million patients in the United States and is 
associated with significant clinical and economic burden to 
patients, the healthcare system, and society as a whole. Over the 
past decade a troubling trend has manifested, the increased 
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prescribing and utilization of opioids for the treatment of 
chronic nonmalignant pain.  
In his book Powerful Medicines, Dr. Jerry Avorn describes 
medication use according to a triad of characteristics: benefits, 
risks, and costs. By applying this theoretical framework to 
chronic opioid use in fibromyalgia syndrome, a clear case against 
their use can be formulated. The benefits of use of these 
medications in this disorder are not clear.  There is no evidence 
supporting the efficacy of opioid use in this disorder. The risks 
associated with use of these medications are severe and varied; 
both personal and societal risks are described in detail below. 
Finally the costs of opioid use in this population are negligible 
when only the prescription cost is considered.  However, when 
considering treatment failure, adverse effects, and indirect 
costs, both to the individual and to society the cost becomes a 
serious concern. 
There are several characteristics, physiological and 
clinical, that separate fibromyalgia patients from those with 
general chronic nonmalignant pain. Though the theoretical case, 
which is presented in detail in the following pages, is strong, 
there is a lack of evidence specifically comparing utilization 
and cost characteristics of patients using opioids chronically in 
this disease state and those receiving evidence-based therapy. 
Although the hallmark symptom of fibromyalgia is dispersed 
pain, the syndrome is also characterized by fatigue, non-
restorative sleep, and cognitive difficulties.2 There are many 
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unanswered questions regarding both etiology and treatment of 
fibromyalgia. Although the literature has increased due to the 
recent introduction of medications approved for the indication of 
fibromyalgia, research addressing issues such as cost of care, 
off-label treatment patterns, or healthcare utilization for 
patients receiving medications other than those currently under 
patent is less than rigorous, outdated, or nonexistent.  The 
purpose of this review is to describe fibromyalgia syndrome and 
highlight the consequences of use of chronic opioid therapy for 
the symptomatic control of patients with fibromyalgia.  Use of 
opioids in this disease state is of particular interest due to 
the lack of evidence supporting utilization and the growing 
concern over the clinical and societal consequences of 
utilization of these drugs. Many of these consequences are unique 
to or elevated in patients with fibromyalgia when compared to 
those suffering from other nonmalignant pain syndromes.  
In this literature review we first describe the complicated 
etiology and pathophysiology of fibromyalgia.  Then, we discuss 
diagnosis, burden of illness, and treatment options for the 
disorder.  Next, we highlight the various consequences of opioid 
use and their application to fibromyalgia patients. Finally, we 
analyze the outcomes of chronic opioid use, specifically in 
patients suffering from fibromyalgia.  
The conclusion of this literature review outlines a plan 
for addressing the identified gap in the literature regarding use 
of opioids chronically in fibromyalgia patients. Briefly, this 
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plan examines contributing factors associated with chronic opioid 
use in fibromyalgia syndrome including geographic variation, 
physician characteristics, and patient characteristics. These 
characteristics will provide information regarding the inputs 
that are present when the clinical decision is made to use 
opioids chronically in a patient. We then will examine the 
outputs of this clinical decision; comparing fibromyalgia 
patients using opioids chronically to those receiving evidence-
based therapy. We will also make pairwise comparison with each of 
these groups to similar control patients using opioid chronically 
for nonmalignant pain and those similar controls not using 
opioids chronically. 
B: Fibromyalgia and its relation to other disorders 
The understanding of fibromyalgia has developed greatly 
since the early 20th century when Sir William Gowers assigned the 
term fibrositis to muscular pain seen in clinic. Fibromyalgia did 
not develop in the nomenclature of this presentation until the 
mid-1970s.3 This shift represented the growing notion that the 
presentation represented pain but not inflammation of the fibrous 
tissue. Although the etiology of fibromyalgia remains unclear, it 
is becoming increasingly evident that disordered central pain 
processing is the primary source of the syndrome.4 Research has 
shown that fibromyalgia patients have shifted pain response 
profiles when exposed to either pressure5 or thermal6 stimuli. 
Fibromyalgia is not an organic disorder characterized by a 
structural or functional abnormality; rather it is considered a 
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functional somatic syndrome.  These disorders are identified by 
symptoms, suffering, and disability.7 Other examples of somatic 
pain syndromes include irritable bowel syndrome, 
temporomandibular disorder, and vulvodynia.  Each of these 
syndromes is characterized by nondescript, regional pain without 
an underlying mechanistic cause.4 
Idiopathic chronic generalized musculoskeletal pain is 
present in 10% to 12% of the general population.8 Most patients 
suffering from this type of chronic pain also meet the clinical 
criteria often used to identify patients suffering from 
fibromyalgia syndrome.  Despite the similarities in description 
however fibromyalgia is only diagnosed in approximately 5% of 
women9 and 1.6% of men10 in the general population. The difference 
in diagnosis rates seen between chronic nonmalignant pain and 
fibromyalgia syndrome can partially be attributed to the nature 
of fibromyalgia, which is not a homogeneous pain condition. 
Rather, the disorder can be observed along a spectrum where at 
one end pain and tenderness are the exclusive symptoms, and at 
the other, pain is accompanied by significant psychological and 
cognitive detriment.11 This spectrum is multidimensional and is 
not a definite indicator of severity. Patients may exhibit severe 
pain symptoms exclusively or have moderate pain but suffer from 
mental clouding, irritable bowel symptoms, or numerous other 
symptoms.  
Fibromyalgia is generally considered a disorder that occurs 
in women between 20 and 50 years of age. Although this is the 
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typical presentation, fibromyalgia occurs in males, children, 
adolescents and the elderly.  Fibromyalgia is increasingly 
prevalent until age 80, after which prevalence declines.12 Higher 
prevalence rates are seen in relatives of patients suffering from 
fibromyalgia suggesting both environmental and genetic factors 
leading to the disorder.9 
C: Difficulties in diagnosing fibromyalgia patients 
The diagnosis of fibromyalgia is generally a difficult and 
tenuous endeavor, which involves ruling out differential 
diagnoses such as rheumatoid arthritis, systemic lupus 
erythematosus, and other conditions that present with nondescript 
pain as a major complaint. In 1990, the American College of 
Rheumatology developed diagnostic criteria for fibromyalgia 
syndrome.13 These criteria focus on the pain and tenderness 
associated with the disease. They were initially developed for 
use as inclusion criteria for fibromyalgia research, but have 
been adopted as the de facto diagnosis criteria in practice.  
Practitioners palpate 18 pressure points throughout the body; 
patients exhibiting abnormal tenderness in 11 of the 18 points, 
in addition to a three-month history of bilateral, widespread 
pain in multiple segments of the body, are said to have 
fibromyalgia.13 These criteria are difficult to implement in 
practice, and are inadequate for use by clinicians for several 
reasons.  First, the exclusive focus on pain and tenderness 
ignores the varied presentation of fibromyalgia patients seen in 
practice.  Second, the tender point exam is rarely performed in 
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primary care, where many potential fibromyalgia patients are seen 
initially, and when performed is often incorrect.14 Finally, 
because the diagnosis is symptomatic in nature, when patients 
improve and are not afflicted in as many areas of the body, they 
no longer meet the diagnostic criteria.15  
Although patients suffering from fibromyalgia are generally 
diagnosed based on symptomatic reports, over the past decade the 
further development of observation techniques has allowed the 
medical community to better understand the pathophysiology of 
fibromyalgia syndrome. Functional magnetic resonance imaging 
(fMRI) has been utilized to show that cerebral blood flow 
patterns differ between patients with fibromyalgia and control 
subjects when exposed to low-pressure stimuli.  Increased flow in 
the secondary somatosensory cortex in patients suggests an 
augmented pain response to these stimuli.16 More recent work using 
fMRI shows fibromyalgia patients have augmented pain processing 
as well as impaired mechanisms for descending pain inhibition.17 
Further, when compared to age-matched controls, fibromyalgia 
patients have been shown to have disruptions in intrinsic 
connectivity within multiple brain networks, suggesting central 
nervous system hyperexcitability.18 These advances in brain 
imaging support the hypothesis that fibromyalgia patients have 
brain chemistry that differs from controls; many of these 
differences affect the way treatment should be approached for 
this disorder. 
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D: Burden of illness 
Patients suffering from fibromyalgia have been shown to be 
burdened with increased healthcare utilization and costs compared 
to similar controls. The London Fibromyalgia Epidemiology Study 
compared four groups: fibromyalgia patients, patients with 
widespread pain but no fibromyalgia diagnosis, patients accessing 
healthcare without widespread pain, and a group of controls. This 
study showed fibromyalgia patients accessing pain-related 
medication more often and having significantly greater average 
healthcare cost than those with general widespread pain.10 Another 
study, utilizing a US-based health-insurance database, found that 
total annual healthcare costs for fibromyalgia sufferers averaged 
$9573 versus $3291 for age and sex matched controls.19 
Statistically significant differences were seen across all cost 
types including: inpatient care, outpatient care, pain-related 
medications, other medications, and other medical care.19 These 
totals ignore the increased personal and societal burden due to 
pain and interference of the illness on the patients’ daily lives.   
This may be a large omission considering one cost of 
illness study showed that up to four-fifths of the illness cost 
for fibromyalgia are from indirect sources, such as employment 
losses.19,20 Moreover, a review examining quality of life 
considered 37 studies of fibromyalgia patients and showed that 
patients had mental health summary scores one standard deviation 
below the general population, and physical health summary scores 
two standard deviations below the general population. The 
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literature shows that fibromyalgia is a significantly impairing 
disorder with increased direct and indirect healthcare costs 
compared both to controls and other pain conditions. 
E: Pharmaceutical treatment alternatives 
Treatment of fibromyalgia syndrome typically focuses on the 
two most troublesome aspects of the disorder: pain and lack of 
restorative sleep.  Treatment is generally multimodal, consisting 
of pharmacologic agents and non-pharmacologic therapies such as 
massage or acupuncture. According to a 2004 review published in 
the Journal of the American Medical Association pharmacologic 
therapies for fibromyalgia can be divided according to the level 
of existing efficacy evidence: strong, modest, weak, or none.21  
Only a very limited number of medications are considered to 
have strong evidence for efficacy in fibromyalgia. These include 
amitriptyline, a tri-cyclic antidepressant, and cyclobenzaprine, 
a muscle relaxant.  Amitriptyline has been shown to be effective 
at reducing pain, fatigue and sleep disturbances, each of these 
results having large effect sizes in fibromyalgia patients.22 A 
meta-analysis of cyclobenzaprine use in patients with 
fibromyalgia showed significant short-term benefit, though a 
troublesome adverse effect profile hampers increased use of this 
medication.23 
Many medications have shown modest evidence of efficacy in 
fibromyalgia.  Among these are selective serotonin reuptake 
inhibitors (SSRIs), serotonin and norepinephrine reuptake 
inhibitors (SNRIs), and tramadol. Selective serotonin reuptake 
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inhibitors, particularly fluoxetine and paroxetine, have been 
shown to be effective in reducing pain associated with 
fibromyalgia; however, no significant effect on mood or fatigue 
has been demonstrated.24 Although pure analgesics in general have 
not proven efficacious in the treatment of fibromyalgia, tramadol 
has shown efficacy in several randomized controlled trials.25,26 
This is due to its complicated mechanistic action combining mu-
receptor agonistic activity with serotonin and norepinephrine 
reuptake inhibition. Despite the efficacy evidence supporting the 
use of tramadol for treatment of fibromyalgia, recent warnings 
from the Food and Drug Administration (FDA) concerning suicide 
risk associated with the use of this medication suggest that 
other treatment alternatives may be preferable.27 
Since publication of this review, three medications have 
been approved for use in the US for treatment of fibromyalgia 
syndrome.  In 2007, the FDA approved pregabalin, an alpha-2 delta 
ligand, which reduces calcium influx at nerve terminals and 
therefore reduces the release of several relevant 
neurochemicals.28 Pregabalin has been shown to be superior to 
placebo in reducing pain and fatigue, improving sleep index 
scores, improving both patient and clinician global impression of 
change, and improving four of eight SF-36 domains.29 One year 
following the approval of pregabalin, the FDA approved duloxetine. 
Duloxetine, a balanced nor-epinephrine, serotonin reuptake 
inhibitor, has been shown in two randomized placebo controlled 
trials to improve fibromyalgia symptoms across many domains in 
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women with and without major depressive disorder.30 In 2009, the 
FDA approved a third drug for use in fibromyalgia known as 
milnacipran.  Milnacipran is another balanced norepinephrine, 
serotonin reuptake inhibitor, which was shown to be superior to 
placebo in pain response, patient global impression of change, 
fatigue, cognition, and several SF-36 domains.31 Although the 2004 
clinical review of fibromyalgia was published before these 
medications were approved, all three were classified at the time 
as having moderate evidence to support efficacy. Based on the 
criteria used in the review and considering the increased body of 
literature surrounding their use, they would now be classified as 
medications with strong evidence. 
In addition to classifying medications with moderate and 
strong evidence for efficacy, the authors of the 2004 clinical 
review on fibromyalgia treatment also described a class of 
medications with no evidence for efficacy.  Included in this 
class were corticosteroids, non-steroidal anti-inflammatory drugs, 
benzodiazepines, and other hypnotics.  Opioid analgesics are also 
included in this category.  However, despite the lack of evidence 
supporting the use of opioids for the treatment of fibromyalgia, 
evidence suggests widespread and increasing clinical 
utilization.4 For a summary of efficacy evidence for medications 
commonly used in fibromyalgia syndrome see Table 1. 
F: Various consequences of opioid use 
The use of chronic opioid therapy for the control of 
chronic nonmalignant pain has increased tremendously over the 
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past decade.32 Between 2005 and 2009, the rate of emergency 
department visits due to misuse or abuse of oxycodone products 
increased by 242.2%, the leading agent in a problem that spans 
the entire opioid class; morphine, hydrocodone, and fentanyl 
products all more than doubled in their rates of emergency 
department visits over the same period.33 In 2007, misuse of abuse 
of pharmaceuticals surpassed illicit drugs becoming the second 
leading cause of drug related emergency department visit.33 
Concurrent with this trend, the US has seen a steep rise in 
opioid abuse, misuse, and diversion.34 With the increased 
availability of opioids, the consequences of their use have led 
to increases in many negative outcomes associated with 
utilization.  Increased utilization is especially concerning 
because it leads to an increased propensity for opioid 
addiction.35  
Beyond the obvious risks presented to those using opioid 
medications, there is also an increased risk to those within 
their households.  Poison control data gathered between 2003 and 
2006 show nearly 10,000 children with inadvertent exposure to 
opioid medications, nearly all of these exposures occurred within 
the child’s home.36 Increased crime such as theft from pharmacies 
and individuals is also a concern, as is diversion between 
household members.37  
In addition to the immense societal concerns posed by 
increased opioid utilization, there are the individual adverse 
effects seen in patients treated with these medications. Common 
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complications due to opioid administration include constipation, 
pruritus, respiratory depression, nausea, vomiting, delayed 
gastric emptying, sexual dysfunction, muscle rigidity and 
myoclonus, sleep disturbance, pyrexia, diminished psychomotor 
performance, cognitive impairment, dizziness, and sedation.38 
Beyond the effects seen with short-term administration, another 
set of adverse effects is seen with administration of opioids for 
the treatment of chronic pain.  Long-term utilization of opioids 
is associated with hormonal and immune effects, abuse and 
addiction, tolerance, and hyperalgesia.38 
Both tolerance and opioid-induced hyperalgesia are concerns 
with any chronic pain condition. Opioid treatment generally is 
characterized by the need for increased dosing over time.  The 
need for this increase is typically attributed clinically to 
tolerance due to cellular adaptation resulting in the reduction 
of either opioid receptors or turnover rate, or the 
desensitization of receptors.39 An alternative, or possibly 
additional, explanation for the apparent decreased response to 
these medications, however, is opioid-induced hyperalgesia.  
G: Increasing concern around opioid-induced hyperalgesia 
The idea of opioid-induced hyperalgesia has been present in 
the literature for over a century, labeled as hyperesthesia, 
opioid abstinence syndrome or other terms that failed to fully 
grasp the etiology of the disorder.40 Clinical research into 
opioid-induced hyperalgesia today is due, in large part, to a 
number of studies performed in the 1970’s showing that in animal 
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models administration of opioids may paradoxically result in 
increased sensitivity to, and aggravation of, preexisting pain.40 
Opioid-induced hyperalgesia manifests as reduced nociceptive 
threshold, and is primarily thought to be the result of central 
sensitization of pronociceptive pathways.41 Opioid-induced 
hyperalgesia presents as heightened atypical pain sensations 
distinct from the original pain stimulus, with a separate 
location and altered distribution from the original complaint.42 
The presentation of opioid-induced hyperalgesia has many 
complicating factors.  First, the extent of presentation may 
differ depending on an individual opioid’s mu- or kappa- receptor 
activity.  Another consideration is the varying evidence 
available for opioid-induced hyperalgesia based on type of 
stimulus.  There is literature supporting the presence of opioid-
induced hyperalgesia to different extents for cold,43 
electrical,43 mechanical,44 and thermal45 stimuli.  In addition, 
there is conflicting evidence regarding the reversibility of the 
condition once opioid exposure is removed.46,47 
The defining difference between tolerance and opioid-
induced hyperalgesia is the increased baseline pain sensitivity 
seen in opioid-induced hyperalgesia.  Unfortunately, clinically 
this requires removing the opioid exposure to clearly demonstrate 
which phenomenon is occurring. Clinical manifestation of opioid-
induced hyperalgesia is typically seen within one month of 
therapy initiation, and may present as reports of new unexplained 
pain or diffuse allodynia. This presentation is very similar to 
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the classic pain and tenderness seen in fibromyalgia.  In fact, 
the possibility of opioid-induced hyperalgesia is of particular 
concern in patients suffering from fibromyalgia. Studies suggest 
that patients with fibromyalgia have dysregulated opioiergic 
pathways.34 The low mu-opioid receptor binding activity seen in 
these patients suggests decreased central mu-opioid receptor 
availability.48 The concern regarding development of this 
complication in fibromyalgia patients is also increased due to 
the complicated neuropathic nature of the pain seen in these 
patients. The current understanding of fibromyalgia pain 
implicates both efferent and afferent modulation systems. 
Possible altered functioning in descending cortical structures of 
fibromyalgia patients may decrease efficacy of strong opioids 
that ignore the noradrenergic aspect of pain seen in 
fibromyalgia.42 
H: Specific concerns regarding opioid use in fibromyalgia  
 Opioid use in chronic nonmalignant pain is a divisive 
subject in the current literature. Current guidelines suggest 
guarded use of opioids chronically in nonmalignant pain and these 
recommendations are based on moderate quality evidence at best.32 
The use of opioids chronically in fibromyalgia patients deserves 
extra scrutiny for several reasons. First, the use of opioids in 
fibromyalgia patients ignores the complicated presentation of the 
disorder discussed above.  Although opioids may temporarily 
control the pain experienced in the disorder, their use ignores 
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the other aspects of the disorder including non-restorative sleep, 
fatigue, and irritable bowel. 
 Patients suffering from fibromyalgia may also have altered 
endogenous opioid activity.  A study utilizing positron emission 
tomography found that patients suffering from fibromyalgia 
syndrome exhibit decreased mu-opioid receptor availability in 
areas of the brain key to pain and nociception processing.48 There 
are two possible explanations for the demonstrated reduced 
availability. First, endogenous enkephalins levels are elevated 
in patients with fibromyalgia, even when compared to patients 
suffering from chronic low back pain.49 Elevated endogenous 
ligands in these patients may explain the reduced availability of 
receptors to opioids, decreasing their effectiveness in 
fibromyalgia patients. Another possible explanation is the 
increased presence of endogenous ligands may lead to down 
regulation of opioid receptors. 
Not only is the failure rate of opioid use a greater 
concern in patients with fibromyalgia, there is also an increased 
concern of misuse or abuse among this population due to 
characteristics commonly seen in these patients. Risk factors 
commonly associated with nonmedical use of opioids include 
anxiety and mood disorders, each a common comorbidity seen in 
patients with fibromyalgia.50 In addition low self-rated health 
status, commonly seen in fibromyalgia, increases the propensity 
toward misuse or abuse of opioids.50 
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 Beyond these reasons there is also increased concern of 
adverse effect presentation in patients with fibromyalgia for 
several reasons. Fibromyalgia patients report adverse effects and 
intolerance to treatment at elevated rates.51 In addition to the 
increased reporting of adverse effects in general there are also 
concerns with the way certain specific adverse effects seen with 
opioid use may affect fibromyalgia patients.  Constipation is a 
hallmark effect seen with opioid use and may be of increased 
concern in patients suffering from the irritable bowel symptoms 
commonly associated with fibromyalgia.  Other adverse effects 
such as sedation and mental clouding are also of particular 
concern in patients with fibromyalgia due to the possible pre-
existing presence of these problems due to the disorder. 
I: Time for an evidence-based approach 
Given the profound lack of controlled or anecdotal efficacy 
evidence supporting the use of opioids in fibromyalgia, their 
prevalence as a treatment option is mysterious.  Couple this lack 
of efficacy with the increasing armamentarium that does have 
evidence of safety and efficacy supporting use, and with the 
clear societal and personal adverse effects of chronic use of 
opioids, and the prevalence of their use in fibromyalgia becomes 
very troubling.  Beyond all of these concerns, which are common 
to the treatment of most chronic non-malignant pain conditions, 
the pathophysiology of fibromyalgia and the increased risk of 
opioid-induced hyperalgesia that results from this 
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pathophysiology, make the use of opioids in this condition ill 
advised. 
J: Future research directions 
 Although the body of literature focusing on fibromyalgia 
continues to increase, much of the most recent literature is 
funded through pharmaceutical companies and focuses on recently 
approved medications. Unfortunately this focus ignores a large 
portion of fibromyalgia patients who are receiving therapy that 
does not meet current treatment guidelines.  Recent evidence 
suggests that nearly one-third of fibromyalgia patients are 
receiving opioid therapy as at least part of their therapy.52 This 
includes both acute and chronic opioid therapy, which does not 
address the fact that opioids are appropriate for short-term use 
to alleviate acute pain conditions. There is no evidence 
currently available to answer questions specifically comparing 
healthcare utilization and costs associated with fibromyalgia 
patients receiving chronic opioid therapy versus fibromyalgia 
patients receiving evidence-based therapy. 
 To address this gap in evidence there are multiple research 
questions that must be addressed.  The following are specific 
aims associated with each of these research questions. 
Specific Aim 1: Identify factors contributing to the utilization 
of chronic opioid therapy for the treatment of fibromyalgia 
syndrome 
Factors contributing to the prescribing and utilization of 
chronic opioid therapy for the treatment of fibromyalgia syndrome 
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can be divided into three categories. Each of these categories 
will be addressed in this research plan. 
1.A. Geographic variation of contextual variables 
Geographic trends will allow us to examine if chronic 
opioid use in fibromyalgia is a national phenomenon or if the use 
is localized by state. Differing rates of use among states may 
signal overuse in certain populations. A nationally 
representative cross-section allows us to examine a large number 
of patients at a certain point in time to examine opioid 
utilization. Various factors such as average sex, age, and 
fibromyalgia prevalence within a state can be examined to 
determine what macro level factors are associated with the use of 
opioids chronically in fibromyalgia patients. 
A more advanced approach to geographic variation includes 
the examination of an annual panel of the same characteristics 
mentioned above for states. This will allow us to control for 
state and time effects to see if characteristics significant 
within the cross-section are statistically significant 
independent of state identity and year. State fixed effects allow 
comparison between those states with large levels of chronic 
opioid use and those with lower levels. In addition examination 
of fixed effects and the between estimator allows within the 
regression of panel data allows for estimates of effects of 
changes in independent variables overtime and the means of 
variables during the period.  
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1.B. Prescriber characteristics 
Geographic variation is a small part of the concern for 
opioid use in fibromyalgia. Macro trends are important, but 
analysis of individual level prescriber characteristics will 
provide information regarding who is prescribing these 
medications despite strong caution against it in the literature 
and treatment guidelines. Characteristics such as gender, age, 
years in practice, practice specialty, urbanicity, state of 
practice, and practice site all help to form a more detailed 
picture how patients are receiving these medications. 
1.C. Patient characteristics 
Perhaps more important that who is prescribing the 
medication is who is receiving them. Patient characteristics of 
interest include gender, age, comorbidities, concurrent 
medications, severity, urbanicity, and state of residence. All of 
these individual-level factors allow for a more robust picture of 
both who is prescribing opioids for chronic use in fibromyalgia 
and who is using this medication for treatment. 
Specific Aim 2: Analyze the effect of chronic opioid use in 
fibromyalgia syndrome on healthcare costs and utilization 
 Identification of who is prescribing and receiving opioids 
is an intermediary step on the way to addressing the questions 
that may provide the most clinically significant answers. These 
questions deal with the outcomes associated with chronic opioid 
use in patients suffering from fibromyalgia syndrome.  Ultimately 
these questions are best answered through the identification of 
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four groups of patients.  Patients with fibromyalgia receiving 
chronic opioid therapy, patients with fibromyalgia treated 
without chronic opioids, similar patients without fibromyalgia 
treated with opioids chronically, and similar patients without 
fibromyalgia not receiving chronic opioid therapy. Identification 
of these groups allows two-way comparisons analyzing various 
outcomes of interest. These outcomes include cost and utilization 
measures typical in this area of research: hospital admissions, 
outpatient visits, prescription costs, medical costs, etc. 
Completion of this research track will provide answers to 
key outstanding questions in the current fibromyalgia research. 
Research addressing geographic variation, patient and prescriber 
characteristics, and utilization and cost outcomes associated 
with chronic opioid use in fibromyalgia patients would provide 
much needed evidence. This evidence could be used to further 
inform evidence-based guidelines influencing the future treatment 
of patients suffering from fibromyalgia syndrome.  
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Table 1.1: Pharmaceutical treatment options for fibromyalgia 
syndrome 
Strong Evidence for Efficacy:  
Amitriptyline 
Cyclobenzaprine 
*Pregabalin 
*Duloxetine (SNRI) 
*Milnacipran (SNRI) 
Modest Evidence for Efficacy: 
Tramadol 
Serotonin reuptake inhibitors (SSRIs): 
Fluoxetine 
Dual-reuptake inhibitors (SNRIs): Venlafaxine 
No Evidence for Efficacy: 
Opioids, corticosteroids, nonsteroidal anti-
inflammatory drugs, benzodiazepines, 
hypnotics, melatonin, calcitonin, thyroid 
hormone, guiafenesin, dehydroepiandrosterone, 
magnesium 
Table adapted from Goldenberg et al., 2004 
*Denotes difference from Goldenberg due to 
evidence sufficient for FDA approval since 
2004 
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Chapter 2: Cross-sectional analysis of geographic variation of 
chronic opioid use in fibromyalgia syndrome 
 Given the gaps in literature identified in Chapter 1, 
Chapter 2 begins an analysis of the factors determined at the 
lowest level of granularity considered. These factors are state-
specific, and this chapter specifically considers these factors 
in a time-invariant approach. 
A: Background 
Fibromyalgia syndrome, also labeled FMS or simply 
fibromyalgia, is an idiopathic, functional disorder characterized 
by chronic widespread pain and diffuse tenderness.2 Although the 
etiology of fibromyalgia remains unclear, it is becoming 
increasingly evident that disordered central pain processing is 
the primary source of the syndrome. Fibromyalgia is diagnosed in 
approximately 5% of women in the US9 and 1.6% of men.53 In the US 
this translates to more than 6 million patients. Patients 
suffering from fibromyalgia are burdened with significantly 
increased healthcare utilization and costs compared to similar 
controls.19  
Treatment of fibromyalgia syndrome typically focuses on the 
two most troublesome aspects of the disorder: pain and lack of 
restorative sleep. Treatment is generally multimodal, consisting 
of pharmacologic agents and non-pharmacologic therapies such as 
massage or acupuncture. Unfortunately, one of the increasingly 
common therapeutic classes of choice for the treatment of pain 
associated with fibromyalgia syndrome is the opioid analgesic 
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class. According to a 2004 review published in the Journal of the 
American Medical Association, opioids have no evidence of 
efficacy for use in fibromyalgia patients.21 Chronic opioid 
therapy, for the control of chronic nonmalignant pain of many 
types, has increased tremendously over the past decade.32 Despite 
the lack of evidence of efficacy for their use in fibromyalgia 
syndrome, the pattern of use in fibromyalgia has mirrored that of 
use in chronic non-malignant pain.4  
This elevated use is troublesome not only due to lack of 
efficacy presented by utilization but also because of the myriad 
societal and individual adverse effects associated with opioid 
use.34 These effects include the common adverse effects seen with 
acute (constipation, pruritus, respiratory depression, nausea, 
vomiting, delayed gastric emptying, sexual dysfunction, muscle 
rigidity and myoclonus, sleep disturbance, pyrexia, diminished 
psychomotor performance, cognitive impairment, dizziness, and 
sedation) as well as chronic (hormonal and immune effects, abuse 
and addiction, tolerance, and hyperalgesia) use of these 
medications. Opioid-induced hyperalgesia is of particular concern 
in fibromyalgia patients because treatment with these medications 
may not only be inefficacious, but also may result in the 
manifestation of a separate pain condition. Although opioid 
treatment may result in hyperalgesia in any patient, the 
dysregulated opioidergic pathways seen in fibromyalgia patients 
is cause for increased concern.32 Possible altered functioning in 
descending cortical structures of fibromyalgia patients may 
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decrease efficacy of strong opioids that ignore the noradrenergic 
aspect of pain seen in fibromyalgia.42  
Geographic variation in care patterns is well documented 
for some disease states and medication classes.  Notably, 
colorectal cancer54, cardiac care procedures55, antihypertensive 
medications56, and stimulant medications57 all have been examined 
and shown to have significant differences in utilization with 
respect to geography.  Several studies have recently shown that 
geographic variation exists in opioid prescribing for various 
disease states. Curtis et al. examined schedule II opioid 
analgesics and found significant variation at the county level, 
with the presence of a statewide prescription monitoring program 
being a factor significantly associated with less opioid 
utilization.58 Webster et al. examined opioid prescribing for 
acute lower back pain and found that geographic variation exists 
and that nearly four-fifths of the between-state variation can be 
explained by state level factors.59 
Many leading researchers in this literature have stated 
that geographic variation of an intervention is a sign of 
inappropriate use.60 In general, the interpretation of whether 
this inappropriate use is under- or overutilization is 
indeterminable using standard methods. However, the chronic use 
of opioids for the treatment of fibromyalgia provides a unique 
situation due to the current treatment guideline’s statement that 
“strong opioids are not recommended”.61  
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To date, no studies have been found that report on 
geographic variation in chronic opioid prescribing for patients 
with fibromyalgia. Providing detailed information regarding 
geographic treatment variation in opioid use for fibromyalgia 
patients is an important intermediate goal on the way to 
ultimately improving the quality of care for these patients. The 
current study aims to assess the extent of geographic variation 
at the state level for opioid utilization in patients suffering 
from fibromyalgia syndrome across the nation.  First, we will 
examine the prevalence and geographic variation of chronic opioid 
use in fibromyalgia syndrome patients. We hypothesize that 
significant geographic variation exists at the state level for 
opioid prescribing in this population. Second, we will examine 
the effect of prescription monitoring programs and various other 
factors on the rate of chronic opioid use at the state level. 
Based on previous work58, we hypothesize that prescription 
monitoring programs and the percent of patients between 45 and 64 
will be negatively associated, whereas female gender and prior 
illicit opioid use rate will be positively associated with 
chronic opioid use at the state level. 
B: Materials and methods 
Data Source 
 The University of Kentucky Institute for Pharmaceutical 
Outcomes and Policy has a licensing agreement for the i3 Invision 
Data Mart (IVDM) for the years 2007-2009. We obtained de-
identified patient information from January 1, 2007 to December 
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31, 2009 from the IVDM. The IVDM is a nationally representative 
de-identified sample of 15 million patients from a commercial 
health plan across the United States and includes commercially 
insured patients as well as patients in Medicaid managed care 
plans. The data are collected at the patient level, and consist 
of eligibility and enrollment information (eligibility date, 
eligibility span, health plan type), demographic information 
(gender, age, state), medical (inpatient, outpatient, 
professional services, including ICD-9-CM, DRG, CPT-4, revenue 
code and links to participating providers), pharmacy (prescriber, 
NDC, day supply, quantity), and laboratory (type of test and 
results) for approximately 15 million patients each year. 
Study Cohort Definitions 
 The dataset was searched for patients with fibromyalgia 
syndrome as identified by International Classification of Disease, 
Ninth Revision, Clinical Modification (ICD-CM-9) code 729.1 
(myalgia and myositis unspecified). Patients with at least one 
claim in between January 1, 2007 and December 31, 2009 were 
included in the sample. Only patients between ages 18-64 were 
considered for this study. The reasons for this restriction are 
utilization patterns may differ for children, and missing data 
problems are more common for those eligible for Medicare. 
Patients with malignancies were excluded from analysis because 
medical care patterns may differ for these patients. The 
University of Kentucky Institutional Review Board provided 
approval for this study via a blanket data use agreement for IVDM. 
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Outcome Variable 
 Chronic opioid therapy was the primary outcome of interest 
for this study. Chronic opioid therapy is defined as receiving a 
day supply in excess of one-half the total eligibility span for 
an individual patient.  Similar outcome measures have been used 
in the past to describe chronic opioid use.62 This individual 
level outcome variable is aggregated at the state level to 
provide a rate of chronic opioid use over the three-year cross-
section for each state. Receipt of opioids was based on paid 
prescription claims with National Drug Codes (NDC) for opioid 
medications. Each claim is associated with a day supply 
calculated at the pharmacy based on directions for use from the 
prescriber. Using American Hospital Formulary Service Codes63 and 
verifying with Pharmaprojects Therapeutics Class Codes64, drugs 
were divided into two classes, opioids and non-opioids (including 
tramadol). A secondary outcome presented in the findings is 
monthly opioid prescriptions per patient. 
Independent variables 
Individual-level variables 
 Collected patient characteristics include demographic 
variables age, gender, eligibility span, and insurance type 
(private vs. Medicaid). Means of individual level variables were 
calculated for each state for the entire cross-section and used 
as state level characteristics. 
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State level variables 
 State level variables were adapted from two previous 
studies measuring geographic variation in opioid use.  Curtis et 
al58 included proportion of females, rate of illicit drug use, 
state prevalence of surgeons, presence of a statewide 
prescription monitoring program, and proportion of population in 
younger and older age groups.  We adapted these variables for our 
data and outcome resulting in the following variables: proportion 
of female at the state level and within our patient sample, rate 
of illicit drug use and rate of illicit opioid use, state rate of 
physicians and surgeons, presence of statewide prescription 
monitoring program, and proportion of state population between 45 
and 64 years of age.  
Beyond these variables, economic and healthcare quality 
variables were added based on the work of Webster et al.59 State 
unemployment rate and median income were included from July 2008, 
the middle of the cross-section. Physician discipline sanction 
rates were taken from Public Citizen.65 Healthcare quality state 
rankings were taken from The Commonwealth Fund66 as an average of 
the 2007 and 2009 biannual rankings. Level of evidence based 
medicine was calculated based on an average of three quality 
indicators used by The Dartmouth Atlas.67 
Data Analysis 
 Individual level factors were aggregated and a descriptive 
analysis was performed. State level geographic variation was 
measured using the weighted coefficient of variation (wCOV), the 
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ratio of the standard deviation of the prevalence rates to the 
mean rate among states, weighted by the IVDM population in each 
state. To analyze potential contributing factors to chronic 
opioid use among fibromyalgia patients, we performed a robust 
multivariate linear regression. All calculations and analyses, 
including geographic variation analysis, were performed using 
Stata v11.2. Map generation was performed using ‘spmap’ and 
‘uscoord’ within Stata. For all analyses the entire three-year 
period is treated as a single cross-section. 
C: Results 
 State level analysis included 245758 patients with a 
diagnosis of fibromyalgia in the IVDM. Patients were selected 
from the 48 contiguous states and the District of Columbia. Of 
these patients, 11.3% received chronic opioid therapy during the 
study period (Table 1). Most patients were female (69.89%) and 
the average age was 44.7 years. Overall, patients received nearly 
70 prescriptions per year and about 10% of these were for opioids.  
The average eligibility span for patients in the sample was about 
two of the total three-year study period. 
Figure 1 illustrates the geographic distribution at the 
state level of the IVDM patient population. It is from this 
general population that we pulled our fibromyalgia syndrome 
patients. Figure 2 highlights the geographic variation seen in 
the distribution of fibromyalgia patients in the sample. 
Correlation IVDM population in a state and the distribution of 
FMS patients is 98%. 
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The overall prevalence of fibromyalgia for this sample is 
1.6% (Table 1). The minimum is 0.7% (Vermont) and a maximum is 
3.0% (North Dakota). It should be noted that each of these 
extrema are found in states with small samples. The geographic 
variation in the prevalence of fibromyalgia syndrome can be seen 
in Table 2 and Figure 3.  
Figure 4 illustrates the large variation seen in monthly 
opioid prescriptions per patient. The values for opioids per 
patient per year eligibility vary between 1.47 in New York and 
9.84 in Minnesota (Table 2). In this case it should be noted that 
the extrema each occur in states with large sample sizes. Also of 
note, Minnesota is one of three states (Rhode Island and New 
Mexico being the others) with a significant number of Medicaid 
patients included in the sample. Both Rhode Island and New Mexico 
fall within a standard deviation unit of the mean in this measure.  
Figure 5 shows the geographic variation in the primary 
outcome of interest, patients receiving chronic opioid therapy. 
The wCOV for chronic opioid therapy was 36.2%.  The states with 
the lowest proportion of chronic opioid use were South Dakota, 
North Dakota, and New York, each under 5%.  The states with the 
highest proportion of chronic opioid use in fibromyalgia patients 
were Utah, Nevada, and West Virginia, each around 20%. 
 The results of the multivariate regression (Table 3) 
examining factors associated with chronic opioid use in patients 
suffering from fibromyalgia syndrome were generally as predicted. 
The proportion of the state population between ages 45 and 64 was 
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negatively associated with chronic opioid use and both percent of 
fibromyalgia patients that are female and past illicit opioid use 
rates were positively associated.  However, the prediction that 
the presence of a statewide prescription-monitoring program would 
be negatively associated with chronic opioid use in this 
condition was not correct; this variable was not statistically 
significant. 
 In addition to the independent variables that were 
predicted to be related to chronic opioid use in fibromyalgia, 
there were also three variables with significant associations 
that were unpredicted. The prevalence of fibromyalgia diagnosis 
within a state, the population of a state, and physician 
prevalence within a state are all significantly (alpha=0.05) 
negative predictors of chronic opioid use in this population. 
D: Discussion 
Geographic Variation: Existence in Fibromyalgia 
The primary aim of this study was to assess the level of 
the geographic variation in chronic opioid use for patients with 
fibromyalgia syndrome. In order to do this, we examined data 
within the i3 Invision Data Mart, extracting a sub-population 
with a diagnosis for fibromyalgia syndrome. Using this data we 
found that nearly 1 in 8 patients with fibromyalgia were 
receiving chronic opioid therapy. This rate is similar to that 
seen in other studies.68 Between states there was an over 5-fold 
difference between the most conservative (South Dakota, 4.0%) and 
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liberal (Utah, 20.2%) opioid prescribers. The wCOV seen for 
chronic opioid therapy in this population was 36.2%.  
These rates of variation are similar to that seen in 
previous literature examining geographic variation of opioid use 
at the state level. Curtis et al. examined use of opioids for any 
condition across states using a similar data set and found wCOV 
of 45%.58 Zerzan et al. examined opioid prescribing in Medicaid 
population and found variation with a wCOV of 50%.69 Webster et al. 
examined variation in opioid prescribing for acute, work related 
low back pain and found a wCOV of 53%.59 Variation was found to be 
slightly higher in each of these studies, which may be a result 
of the outcome measures that were used. Each of these studies was 
looking at acute and chronic use of opioids, where variation 
among patients is expected to be greater.  
Geographic Variation: Explanatory Variables 
 The robust multivariate linear regression showed many state 
level variables are significantly associated with chronic opioid 
use.  These state level variables explain three-quarters of the 
variability in the data set. The remaining quarter is likely made 
up of within state variation that is not observable using cross-
sectional analysis. As seen in Webster et al59 the large 
proportion of between state variation explained with state level 
factors stresses the importance of characteristics not associated 
with patient, provider, or third party characteristics. 
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Statewide prescription monitoring program (PMP) 
 The presence of a statewide PMP was not significantly 
associated with chronic opioid use in fibromyalgia patients. This 
factor was significant in Curtis et al58 but not in Webster et 
al.59 One possible explanation for this is the simplicity of the 
variable. A state was considered positive for a PMP if it had an 
operational PMP for the study period, regardless of the details 
of the program. Much variation exists in characteristics of PMPs 
and the effectiveness of PMPs across states is currently debated 
in the literature.70 
Physicians per capita 
 The number of surgeons per capita was not found to be a 
significantly associated factor in this study as it was in Curtis 
et al.58, where it was explained as increased use in postoperative 
pain. The present study model is more closely related to Webster 
et al.59 due to the lack of importance of surgery as a treatment 
alternative for fibromyalgia. In agreement with the findings of 
Webster et al59 we found that although surgeons per capita was not 
a significantly associated factor, the number of physicians per 
capita was significantly and negatively associated. This could be 
explained by greater peer-to-peer interaction resulting in more 
information diffusion, or by reduced work burden resulting in 
better knowledge of or adherence to evidence based medicine. 
Fibromyalgia prevalence 
 An unexpected significantly negative associated variable is 
the level of fibromyalgia prevalence within a state. A similar 
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explanation to that proposed for the relationship of physicians 
per capita may apply here. As the level or fibromyalgia patients 
in a given geographic area increases, information regarding the 
proper treatment of the disorder may disseminate more fully. An 
alternate but related explanation is that geographic areas able 
to diagnose fibromyalgia better are able to treat fibromyalgia 
better, so as the diagnosis of a disease becomes more common so 
does evidence based treatment. There is no evidence of this 
effect either related to fibromyalgia syndrome or the rate of 
opioid use in the current literature. 
Other explanatory variables 
  The only other significantly associated variable was state 
population.  States with large population were less likely to 
prescribe opioid chronically for patients. Quality variables such 
as evidence based medicine use in states and healthcare quality 
rankings were not found to be significantly associated with 
chronic opioid use. Also state economic indicators such as median 
income and unemployment rate were not significantly related to 
use within fibromyalgia patients. 
Theoretical Implications 
The findings of this study back up those seen in previous 
studies looking at geographic variation of opioid use. These 
studies support the theory proposed by Westert and Groenewegen 
that social context and structural factors affect prescribing 
behavior.71 This study extends that theoretical framework by 
demonstrating the contribution of factors such as physician 
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prevalence, disease prevalence, and state population to the way a 
chronic disease is treated. 
E: Limitations 
There are limitations to this study. First, although the 
data are aggregated from individual patient level data the 
analysis is done by state. State levels of comorbid conditions 
are not considered as a confounding variable. As with 
fibromyalgia, treatment of chronic nonmalignant pain using opioid 
analgesics is strongly cautioned in current guidelines.32 Also the 
level of opioid use in the general population was not considered 
as an explanatory variable. Opioid use for nonmalignant pain is a 
controversial topic, in need of further study in various 
conditions. The present study is limited in scope to fibromyalgia 
patients due to unique physiological characteristics and 
literature stating the lack of efficacy evidence of opioids for 
treatment. The rate of chronic opioid therapy among fibromyalgia 
patients is an outcome of interest independent of opioid use 
among others within the state. 
The calculation of the chronic opioid use variable is also 
a concern.  Because the measure only considers day supply and 
span of eligibility there is a possibility that patients receive 
several opioid medications concurrently, bolstering their 
observed day supply. The main concern with this limitation is 
that ‘chronic’ may not be an adequate descriptive term to use for 
this measure, as patients may be receiving several medications 
over a short period of time.  However, for the majority of 
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patients this still results in having a day supply of greater 
than 183 days during a single year or 537 days over the entire 
period.  This measure has been used in similar studies in the 
past62, and although the labeling of this variable may not be 
completely satisfactory the clinical significance of what it 
measures is evident. 
Another possible limitation is seen in the various levels 
of Medicaid participation from state to state. The concern is 
minimal, however. The majority of states had no Medicaid 
participation in the study and only three states (Minnesota, New 
Mexico, and Rhode Island) had greater than 5% of their sample 
from Medicaid. Analysis of the findings accounting for the 
inclusion of a Medicaid variable was also completed and no 
significant differences were found in the results. 
Finally, the cross-sectional design of this study did not 
allow for the analysis of changes in contextual factors within 
states over time. Analysis of a longitudinal sample would be 
useful in determining the role of state fixed effects on chronic 
opioid use for the treatment of fibromyalgia syndrome. 
F: Conclusion 
Chronic opioid therapy for the treatment of fibromyalgia 
syndrome is a practice based, not on evidence, but on other 
factors that have been heretofore unreported in the literature. 
The current study reports on one set of such characteristics that 
result in wide geographic variation similar to that previously 
reported in other pain conditions. This large level of geographic 
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variation suggests that the prescribing decision is not based 
solely on physician-patient interaction, but also on contextual 
and structural factors at the state level. The level of physician 
and disease prevalence suggest that information dissemination and 
peer-to-peer interaction may play a key role in adopting evidence 
based medicine for the treatment of patients suffering from 
fibromyalgia syndrome. Level of disease prevalence as a predictor 
of evidence-based practice has not been reported in the 
literature previously and is an important contribution to not 
only the fibromyalgia literature, but also possibly other 
literatures where significant geographic variation in practice 
exists.  
Given the cross-sectional approach to this study the 
interpretation of the findings is limited. In order to better 
clarify the role of state-level factors and to ascertain the role 
of state identity in the rate of chronic opioid use in 
fibromyalgia patients the next chapter analyzes similar data 
using a longitudinal approach generally seen in the social 
sciences. 
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Table 2.1: State summary characteristics for fibromyalgia 
patients 
n=245758 Mean SD Median Min Max 
FMS prevalence (%) 1.56 0.39 1.57 0.72 2.98 
Annual prescriptions 
per patient 
66.8 22.0 67.0 45.8 193.8 
Annual opioids per 
patient 
6.9 2.6 6.5 2.8 18.7 
Female (%) 69.89 3.46 70.33 59.38 78.18 
Age (years) 44.7 1.3 44.8 41.9 47.5 
Eligibility span 
(months) 
24.1 1.3 24.3 22.0 26.4 
Chronic opioid 
therapy (%) 
11.65 4.16 11.60 3.95 20.18 
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Table 2.2: State characteristics for fibromyalgia patients 
State n Female 
(%) 
Age 
(years) 
FMS 
Preval
ence 
(%) 
Annual 
opioids 
per 
patient 
Eligibi
lity 
Span 
(month) 
Chronic 
Opioid 
Therapy 
(%)1 
AL 1759 72.1 44.7 1.48 8.92 22.4 16.71 
AR 2565 74.7 45.2 1.81 7.92 24.3 13.06 
AZ 8376 73.1 45.4 1.62 9.23 24.1 16.95 
CA 12053 64.9 43.7 1.58 4.33 25.4 7.35 
CO 7478 68.7 44.6 1.62 8.53 25.7 12.58 
CT 1667 69.2 44.4 1.57 5.38 25.2 8.76 
DC 269 70.6 42.5 0.76 3.95 22.3 5.58 
DE 175 66.3 45.5 0.90 6.03 22.4 14.86 
FL 27658 70.3 45.7 1.57 7.92 24.7 14.88 
GA 16962 72.8 46.4 1.70 6.45 24.7 9.81 
IA 2048 69.9 46.9 1.82 5.46 25.6 8.74 
ID 575 73.4 43.9 1.42 9.14 25.9 14.26 
IL 6480 67.6 44.3 1.25 4.86 24.2 7.81 
IN 4057 71.7 45.5 1.53 7.36 23.1 14.52 
KS 2443 68.0 44.3 1.84 5.96 23.6 9.01 
KY 2242 71.5 44.1 1.66 7.46 22.8 17.08 
LA 4099 69.0 44.7 1.52 6.95 25.1 11.34 
MA 2377 67.3 45.2 1.36 4.28 25.1 7.07 
MD 4971 68.4 44.1 1.47 5.57 22.1 10.28 
ME 238 73.1 46.3 1.62 4.28 24.5 7.56 
MI 1770 67.7 43.3 1.21 6.24 23.2 11.69 
MN 18219 72.7 43.6 2.29 18.73 22.8 9.49 
MO 8469 71.6 45.1 1.65 5.82 25.0 8.93 
MS 1969 71.6 44.8 1.57 8.03 22.6 14.07 
MT 165 78.2 46.8 1.38 6.11 22.6 15.76 
NC 8857 70.3 45.6 1.61 7.74 24.5 14.11 
ND 607 62.8 42.3 2.98 4.11 24.0 4.94 
NE 2325 69.8 45.0 1.92 5.89 25.9 7.35 
NH 411 74.9 46.2 1.38 5.31 24.3 8.03 
NJ 4287 63.2 42.9 1.40 3.96 25.8 6.04 
NM 2257 73.6 46.4 2.03 5.45 25.9 9.26 
NV 1152 67.1 43.5 1.18 8.62 21.9 19.79 
NY 8154 62.8 42.0 1.69 3.12 26.4 4.99 
OH 15101 72.8 45.5 1.75 7.01 25.2 12.85 
OK 1975 68.7 43.4 1.34 8.26 22.5 13.82 
OR 1553 72.9 45.5 1.51 9.01 23.5 17.84 
PA 3355 69.8 44.2 1.23 5.30 22.2 11.60 
RI 3911 71.9 45.8 2.18 10.52 25.9 13.63 
SC 2716 70.8 45.2 1.60 7.13 22.8 13.66 
SD 506 68.6 45.2 2.29 2.75 23.2 3.95 
TN 5021 70.9 44.3 1.71 8.60 24.5 7.31 
TX 24775 70.2 44.3 1.28 7.29 24.8 11.60 
UT 1670 71.2 41.9 1.17 12.30 23.9 20.18 
VA 5836 67.4 43.6 1.69 5.20 22.4 8.69 
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Table 2.2: State characteristics for fibromyalgia patients 
(continued) 
VT 32 59.4 47.5 0.72 5.28 25.1 9.38 
WA 2262 71.0 45.4 1.20 8.17 24.0 13.84 
WI 9215 68.8 45.6 1.79 6.63 25.9 9.38 
WV 545 73.6 45.5 1.38 8.54 22.4 19.63 
WY 151 68.2 43.8 1.01 5.44 23.1 10.60 
1: Opioid day supply is the sum of the day supplies of all opioid 
prescriptions for an individual patient. 
2: Chronic opioid therapy is defined as having a day supply 
greater than one-half of an individual patients eligibility span. 
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Table 2.3: Multivariate linear regression: state level chronic 
opioid analgesic use 
 Coef. (SE) P 
FMS prevalence (%) -5.300(0.797) 0.001 
FMS female (%) 0.300(0.123) 0.021 
Evidence based medicine (%) 0.197(0.136) 0.157 
Illicit drug use (%) -0.122(0.514) 0.815 
Surgeon prevalence (per 100k) -0.129(0.295) 0.665 
Prescription monitoring 
program 
1.266(1.044) 0.234 
Healthcare quality rank 0.045(0.037) 0.230 
State population (1000000) -0.220(0.063) 0.001 
State female (%) 0.239(0.579) 0.682 
Age 45-64 (year) -0.684(0.328) 0.045 
Unemployment rate (%) 0.749(0.507) 0.149 
Median income ($1000) -0.012(0.082) 0.888 
Illicit opioid use (%) 0.992(0.442) 0.032 
Physician prevalence (per 
100k) 
-0.022(0.007) 0.002 
Physician sanctions (per 
100k) 
0.002(0.030) 0.946 
Constant -5.856(26.658) 0.827 
[Observations=49]  [R2=0.749]  [Root MSE=2.512] 
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Figure 2.1: General patient distribution of i3 Invision Data Mart 
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Figure 2.2: Distribution of fibromyalgia patients in sample 
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Figure 2.3: Fibromyalgia prevalence by state 
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Figure 2.4: Monthly opioid prescriptions per fibromyalgia patient 
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Figure 2.5: Distribution of fibromyalgia patients receiving 
chronic opioid therapy 
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Chapter 3: Longitudinal analysis of geographic variation of 
chronic opioid use in fibromyalgia syndrome 
 Given the interesting findings reported in Chapter 2, and 
considering the limitations imposed by the use of a cross-
sectional design, Chapter 3 utilizes a longitudinal analysis 
approach to answer a similar research question. Longitudinal data 
analysis, commonly seen in the social sciences such as public 
policy research, allows for separation of within group variation 
from between group variation. In Chapter 3 we use this methods 
approach to control within state variation over the three-year 
observation period seen in Chapter 2. 
A: Background 
Geographic variation in care patterns is well documented 
for some disease states and medication classes.  Notably, 
colorectal cancer54, cardiac care procedures55, antihypertensive 
medications56, and stimulant medications57 all have been examined 
and shown to have significant differences in utilization with 
respect to geography.  Several studies have recently shown that 
geographic variation exists in opioid prescribing for various 
disease states. Curtis et al examined schedule II opioid 
analgesics and found significant variation at the county level, 
with the presence of a statewide prescription monitoring programs 
being a factor strongly associated with less opioid prescribing.58 
Webster et al examined opioid prescribing for acute lower back 
pain and found that geographic variation exists and that nearly 
four-fifths of the between-state variation can be explained by 
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state level factors.59 Recent unpublished work suggests that 
geographic variation in chronic opioid treatment for fibromyalgia 
syndrome is similar to that seen in other conditions treated with 
opioid analgesics.72 
Fibromyalgia syndrome, also labeled FMS or simply 
fibromyalgia, is an idiopathic, functional disorder characterized 
by chronic widespread pain and diffuse tenderness.2 Although the 
etiology of fibromyalgia remains unclear, it is becoming 
increasingly evident that disordered central pain processing is 
the primary source of the syndrome. Fibromyalgia is diagnosed in 
approximately 5% of women 9 and 1.6% of men in the US.53 This 
translates to more than 6 million patients in the US alone. 
Patients suffering from fibromyalgia are burdened with 
significantly increased healthcare utilization and costs compared 
to similar controls.19  
According to a 2004 review published in the Journal of the 
American Medical Association, opioids have no evidence of 
efficacy for use in fibromyalgia syndrome.21 Current guidelines 
for the treatment of fibromyalgia do not consider opioids a valid 
treatment alternative.61  Despite the lack of evidence of efficacy 
for their use in fibromyalgia syndrome, the pattern of 
prescribing in fibromyalgia has mirrored that chronic non-
malignant pain in general.4 This elevated use is troublesome not 
only due to the lack of efficacy presented, but also because of 
the myriad societal and individual adverse effects associated 
with opioid use.34 These include the common adverse effects seen 
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with acute (constipation, pruritus, respiratory depression, 
nausea, vomiting, delayed gastric emptying, sexual dysfunction, 
muscle rigidity and myoclonus, sleep disturbance, pyrexia, 
diminished psychomotor performance, cognitive impairment, 
dizziness, and sedation) as well as chronic (hormonal and immune 
effects, abuse and addiction, tolerance, and hyperalgesia) use of 
these medications. Opioid-induced hyperalgesia is of particular 
concern in fibromyalgia patients, because treatment with these 
medications may not only be inefficacious, but also may result in 
the manifestation of a separate pain condition. Although opioid 
treatment may result in hyperalgesia in any patient, the 
dysregulated opioidergic pathways seen in fibromyalgia patients 
creates greater concern.32 Furthermore, possible altered 
functioning in descending cortical structures of fibromyalgia 
patients may decrease efficacy of strong opioids that ignore the 
noradrenergic aspect of pain seen in fibromyalgia.42  
Only one study was found that examines geographic variation 
of opioid prescribing across time. Zerzan et al examined the 
variation in use of opiates in state Medicaid programs between 
1996 and 2002.69 This study showed significant increases in the 
level of opiate prescribing and in the variation seen in that 
prescribing. The coefficients of variation for the prescribing of 
opiates increased from 38.5% in 1996 to 49.6 in 2002.69 
Unpublished work shows that the coefficient of variation for 
chronic opioid use in fibromyalgia syndrome is 36.2%.72 This is 
slightly lower than other findings in geographic variation of 
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opioid prescribing due to the chronic nature of the outcome 
variable.  
Many leading researchers in the geographic variation 
literature have stated that geographic variation of an 
intervention is a sign of inappropriate use.60 In general, the 
interpretation of whether this inappropriate use is under- or 
overutilization is indeterminable using standard methods. However, 
the chronic use of opioids for the treatment of fibromyalgia 
provides a unique situation due to the current treatment 
guideline’s statement that “strong opioids are not recommended”.61  
The current study seeks to build on recent unpublished work, 
which found large state level geographic variation in chronic 
opioid use among fibromyalgia patients. This study found that 
contributing factors examined in fibromyalgia generally followed 
patterns established in other conditions treated with opioid. The 
percentage of patients that were female and the percentage of the 
population with previous illicit opioid use were both positive 
predictors of chronic opioid utilization; while state population, 
age between 45 and 64, physician prevalence, and fibromyalgia 
prevalence within a geography all were negatively associated with 
opioid use.  
Disease prevalence as a predictor of evidence-based 
medicine has not been studied in the literature previously, but 
may indicate increased dissemination of information and peer-to-
peer physician interaction for diseases such as fibromyalgia. By 
utilizing panel data methods more commonly seen in social 
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sciences, the current study seeks to isolate within state 
variation. We aim first to assess the extent of geographic 
variation at the state level for opioid utilization in patients 
suffering from fibromyalgia syndrome across the nation between 
the years 2007 and 2009. We hypothesize that significant 
geographic variation exists at the state level for opioid 
prescribing in this population and that both prevalence and 
variation will increase each year. Second, we aim to examine the 
effect of prescription monitoring programs and various other 
factors on the rate of chronic opioid use at the state level. 
Based on previous work72, we hypothesize that physician prevalence, 
fibromyalgia prevalence, state population and percent of patients 
between 45 and 64 will be negatively associated with chronic 
opioid use, whereas female gender and prior illicit opioid use 
rate will be positively associated at the state level. 
B: Materials and methods 
Data Source 
 The University of Kentucky Institute for Pharmaceutical 
Outcomes and Policy has a licensing agreement for the i3 Invision 
Data Mart (IVDM) for 2007 through 2009. We obtained de-identified 
patient information from January 1, 2007 to December 31, 2009 
from the IVDM. The IVDM is a nationally representative de-
identified sample of 15 million patients from a commercial health 
plan across the United States and includes commercially insured 
patients as well as patients in Medicaid managed care plans. The 
data are collected at the patient level, and consist of 
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eligibility and enrollment information (eligibility date, 
eligibility span, health plan type), demographic information 
(gender, age, state), medical (inpatient, outpatient, 
professional services, including ICD-9-CM, DRG, CPT-4, revenue 
code and links to participating providers), pharmacy (prescriber, 
NDC, day supply, quantity), and laboratory (type of test and 
results) data for approximately 15 million patients each year. 
Study Cohort Definitions 
 The dataset was searched for patients with fibromyalgia 
syndrome as identified by International Classification of Disease, 
Ninth Revision, Clinical Modification (ICD-CM-9) code 729.1 
(myalgia and myositis unspecified). Only patients between ages 
18-64 were considered for this study. The reasons for this 
restriction are utilization patterns may differ for children, and 
missing data problems are more common for those eligible for 
Medicare. Patients with malignancies were excluded from analysis 
because medical care patterns may differ for these patients. From 
this sample a sub-subsample of patients who had eligibility for 
the entire study period (January 1, 2007 to December 31, 2009) 
were selected as a panel. The University of Kentucky 
Institutional Review Board provided approval for this study via a 
blanket data use agreement for IVDM. 
Outcome Variable 
 Chronic opioid therapy was the primary outcome of interest 
for this study. Chronic opioid therapy is defined as receiving 
greater than 183 days of opioid therapy in a given calendar year.  
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Similar outcome measures have been used in the past to describe 
chronic opioid use.62 This individual level outcome variable is 
aggregated at the state level to provide a rate of chronic opioid 
use for each of the 3 years of the study for each state. Receipt 
of opioids was based on paid prescription claims with National 
Drug Codes (NDC) for opioid medications. Each claim is associated 
with a day supply calculated at the pharmacy level based on 
directions for use from the prescriber. Using American Hospital 
Formulary Service Codes63 and verifying with Pharmaprojects 
Therapeutics Class Codes64, drugs were divided into two classes, 
opioids and non-opioids (including tramadol).  
Independent variables 
 State level variables were adapted from two previous 
studies measuring geographic variation in opioid use.  Curtis et 
al58 included proportion of females, rate of illicit drug use, 
state rate of surgeons, presence of a statewide prescription 
monitoring program, and proportion of population in younger and 
older age groups.  Webster et al59 extended this framework by 
including other economic and quality variables including 
unemployment rates, median income, physician disciplinary 
sanctions, and healthcare quality rankings. We adapted these 
variables for longitudinal analysis of our data and outcome based 
on results from our previous cross-sectional analysis resulting 
in the following time variant variables: prevalence of 
fibromyalgia within a state, state prevalence of physicians, 
proportion of females within our patient sample, state population, 
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state unemployment rate, state median income, rate of illicit 
opioid use, rate of physician disciplinary sanctions, presence of 
statewide prescription monitoring program, healthcare quality 
ranking, and proportion of state between 45 and 64 years of age. 
State unemployment rate and median income were observed in July 
of each year. Physician discipline sanction rates were taken from 
Public Citizen.65 Healthcare quality state rankings were taken 
from The Commonwealth Fund66 for 2007 and 2009, an average of the 
two values was used for 2008. State demographic and economic data 
was taken from US Census and Department of Labor data. 
Data Analysis 
 State level geographic variation was measured using 
standard deviation, ratio of maximum to minimum, and coefficient 
of variation. The coefficient of variation is the ratio of the 
standard deviation of the prevalence rates to the mean rate among 
states. Dispersion statistics were calculated for each year. To 
analyze potential contributing factors to chronic opioid use 
among fibromyalgia patients we performed multiple time series 
regressions across states: between effects, fixed effects, and 
random effects. All calculations and analyses, including 
geographic variation analysis, were performed using Stata v11.2. 
Map generation was performed using ‘spmap’ and ‘uscoord’ within 
Stata. For all evaluations a three-year panel was analyzed for 
2007, 2008, and 2009. 
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C: Results 
 This panel included 107369 patients from the 48 contiguous 
states and the District of Columbia who were eligible for the 
entire 36 months of the study.  The patients were 68.2% female 
and average of 46.3 years of age in July 2008. Overall chronic 
opioid use did grow annually though not at a statistically 
significant rate.  Both bivariate and multivariate regression 
showed time as an insignificant contributor to chronic opioid use 
in fibromyalgia syndrome.  Mean chronic opioid therapy grew from 
9.13% in 2007 to 10.62% (Table 1). All three measures of 
dispersion showed large geographic variation, but no difference 
was seen in this variation across time. The coefficient of 
variation ranged from 36.3% in 2008 to 36.6% in 2009. There was 
an approximately fivefold difference between the state with the 
minimum amount of chronic opioid therapy (New York in 2007 and 
South Dakota in 2008 and 2009) and the maximum amount (West 
Virginia all three years). 
 Multivariate linear regression using the between effects 
estimator showed both the prevalence of fibromyalgia and the 
prevalence of physicians within a state had significant negative 
associations with chronic opioid use among fibromyalgia patients 
(Table 2).  In addition, median income was positively associated 
with chronic opioid use. Other predicted relationships were not 
found to be significant under this model.  
 When assuming a fixed effect model the results of the 
multivariate regression changes significantly. Neither 
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fibromyalgia nor physician prevalence are significantly 
associated with chronic opioid use. Chronic opioid use in 
fibromyalgia syndrome does continue to rise with the unemployment 
rate and fall with median income, however. Further analysis of 
state fixed effects can be seen in Table 5 and Figure 1. Although 
fixed effects are not appropriate for ranking, comparison of the 
top and bottom quartiles is possible. States in the Southeast and 
Western Unites States are generally liberal prescribers of 
chronic opioid therapy while those in the Northeast and Plains 
are conservative. 
 A random effects regression was performed and the results 
can be seen in Table 5. Results are similar to those seen in the 
between effects model though with the addition of the 
unemployment rate as a positive predictor of chronic opioid use. 
However, the results of the Hausman specification test indicate 
that the coefficients of the between effects estimation and those 
of the fixed effects estimation are significantly different 
(p>X2=0.01), making the random effects estimation inappropriate 
for this data. 
D: Discussion 
Geographic Variation: Existence in Fibromyalgia 
 The primary aim of this study was to highlight the 
geographic variation in chronic opioid use for patients with 
fibromyalgia syndrome. We examined a panel of over 100000 
fibromyalgia patients eligible for treatment within the i3 
Invision Data Mart for 36 consecutive months between January 2007 
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and December 2009. We found about 1 in 10 patients meeting these 
criteria received chronic opioid therapy over this period of time. 
This rate did not fluctuate significantly year-to-year. 
Utilization seen in this study is similar to the rate seen in a 
cross-sectional study of chronic opioid use in fibromyalgia 
syndrome (11.7%).72 Geographic variation in chronic opioid therapy 
did exist in this data. A fivefold difference was seen between 
patients in the state with the lowest use rate (New York in 2007 
and South Dakota in 2008 and 2009, 4%) and that with the highest 
use rate (West Virginia, 19-20%). The coefficient of variation 
was around 36.5% for each year. These differences were stable 
across time, consistent with that seen in the cross-sectional 
analysis, and similar to those seen in other studies analyzing 
geographic variation of opioid prescribing.58,59,69 Zerzan et al did 
see significant increases in both mean opioid prescribing and 
geographic variation over the study period.69 There are two 
important differences between that study and the present study, 
however. First, their study period spanned seven years versus the 
present study’s three years. This increased period of monitoring 
is better suited to picking up time dependent variation. Second, 
the outcome of interest in Zerzan et al was opioid prescribing in 
general, not chronic therapy for a specific disease. 
Geographic Variation: Effect of Various Models 
 In order to investigate the association of state-level 
variables with chronic opioid use in fibromyalgia syndrome we 
looked at three different models. The first was the between 
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effects model; in this model we average variation within states 
across time. This results in a similar model to the one seen in 
the cross-sectional analysis, where we do not attempt to observe 
within state variation; as such, the results are comparable to 
those seen in the cross-sectional analysis. The two prevalence 
factors of interest, physician and disease prevalence, are both 
significantly associated with less chronic opioid use.  This can 
be explained based on increased knowledge dissemination or peer-
to-peer physician interaction resulting in better practice. Also, 
the median income of a state is negatively associated with 
chronic opioid use; states with higher median income have fewer 
fibromyalgia patients receiving chronic opioid therapy. 
 The fixed effects model examines the within state variation, 
assuming that a state’s error component is correlated with the 
explanatory variables. In this study the independent variable 
coefficients generated by the fixed effects model are 
significantly different from those generated in the between 
effects model, as indicated by the rejection of the null 
hypothesis of the Hausman specification test. Findings of the 
fixed effect model indicate that only state level economic 
indicators are significantly associated with chronic opioid use 
in fibromyalgia syndrome.  States with lower median income and 
higher unemployment are more likely to have fibromyalgia patients 
treated with chronic opioid therapy. Fixed effects for each state 
relative to the District of Columbia can be seen in Figure 1 and 
Table 4. Although we are not able to directly rank states 
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according to fixed effects, a comparison of those with very low 
fixed effects to those with very high fixed effects is 
appropriate and enlightening. We can see a definite geographic 
pattern develop for states that liberally use chronic opioid 
therapy in the treatment of fibromyalgia syndrome. These states 
largely overlap with states identified by Curtis et al as high 
claim rate states for controlled-release oxycodone.58 
E: Strengths and weaknesses of specific models  
 Use of the between effects estimator is largely a repeat of 
the cross-sectional analysis previously performed.72 However, this 
study model is an appropriate one, and the reiteration shows that 
the results of the cross-sectional analysis are robust to 
inclusion of only patients eligible for the entire three-year 
study period. In addition, the between effects estimator is not 
required to meet the assumption that error terms of states be 
correlated with explanatory variables. However, the impetus for 
time-series analysis and the major weakness of the cross-
sectional approach is the requirement to ignore within state 
heterogeneity. The fixed-effects model adjusts for this 
heterogeneity using repeated measures of time variant factors for 
each state. The significant differences seen in the coefficients 
from these two models suggest that within state identity is a 
strong predictive factor for chronic opioid use in fibromyalgia 
syndrome. Given the inclusion of only three time periods for the 
study, the fixed effect coefficients may be biased. Considering 
the chronic nature of the outcome of interest and the large 
 61 
geographic units analyzed, a panel with more time-periods would 
be very informative. 
F: Conclusions 
 The goals of this study were to assess the level of 
geographic variation in chronic opioid therapy for the treatment 
of patients suffering from fibromyalgia syndrome and identify 
factors associated with this variation. Findings show that 
geographic variation of this outcome is similar to that seen in 
other studies of opioid prescribing. The present study also shows 
that geographic variation is stable over the study period (2007-
2009) for the panel. Using the between effects estimator in a 
multivariate time-series regression we showed that both the 
prevalence of fibromyalgia and the prevalence of physicians 
within a state are significantly associated with less chronic 
opioid use for the treatment of fibromyalgia syndrome. The 
relationship between disease prevalence and evidence-based 
practice has not been seen in the fibromyalgia or pain literature 
previously. However, an explanation used by Webster et al for the 
relationship between physician prevalence and opioid use may be 
applicable59: as the prevalence of the disease increases 
information dissemination and peer-to-peer interaction regarding 
the treatment of the disease may also increase. Analysis using 
the fixed effects estimator suggests that state identity is 
significantly associated with chronic opioid use in the treatment 
of fibromyalgia syndrome. 
 62 
 While these findings illustrate the role of characteristics 
outside of the individual patient that may partially determine 
the rate of chronic opioid use in certain populations, state-
level characteristics are only a small part of the a wider story. 
The next chapter will look at another characteristic outside of 
individual patient that may contribute to the level of chronic 
opioid therapy seen in fibromyalgia patients: provider type.  
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Table 3.1: Geographic variation in chronic opioid therapy for 
fibromyalgia 
Year Mean (%) SD Max/Min CoV 
2007 9.13 3.32 4.92 36.4 
2008 9.83 3.57 5.36 36.3 
2009 10.62 3.78 4.60 35.6 
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Table 3.2: Between effects regression, chronic opioid use 
 Coef. SE P 
FMS prevalence (%) -2.972 0.965 0.004 
FMS female (%) 0.218 0.116 0.067 
State population -0.001 0.001 0.061 
State age 45-64 (%) -0.310 0.220 0.168 
Unemployment rate 0.001 0.003 0.826 
Median income ($) -0.001 0.001 0.045 
Illicit opioid use (%) 0.007 0.004 0.140 
Physician prevalence (per 100k) -0.001 0.001 0.035 
Physician disciplinary action (per 100K) 0.001 0.001 0.823 
Healthcare quality rank 0.001 0.001 0.456 
Prescription monitoring program 0.016 0.009 0.098 
Constant 0.143 0.134 0.293 
R2=  [within=0.038]  [between=0.624]  [overall=0.527] 
[SD(ui+ei)=0.024]  [F(11,37)=5.58]  [Prob>F=0.001] 
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Table 3.3: Fixed effects regression, chronic opioid use 
 Coef. SE P 
FMS prevalence (%) 1.405 0.975 0.156 
FMS female (%) 0.003 0.225 0.990 
State population -0.001 0.001 0.986 
State age 45-64 (%) -0.406 0.546 0.461 
Unemployment rate 0.003 0.001 0.001 
Median income ($) -0.001 0.001 0.016 
Illicit opioid use (%) -0.001 0.002 0.743 
Physician prevalence (per 100k) -0.001 0.001 0.095 
Physician disciplinary action (per 100K) -0.001 0.001 0.107 
Healthcare quality rank -0.001 0.001 0.852 
Prescription monitoring program -0.007 0.004 0.076 
Constant 0.334 0.311 0.289 
R2: [within=0.422]  [between=0.142]  [overall=0.165] 
[sigma u=0.033]  [sigma e=0.012]  [rho=0.892] 
 
  
 66 
Table 3.4: Fixed effect of state on chronic opioid use in FMS 
 Coef. SE P 
South Dakota -0.010 0.034 0.774 
New York -0.010 0.023 0.679 
Minnesota -0.007 0.024 0.757 
New Jersey -0.006 0.018 0.739 
District of Columbia 0.000 0.000 1.000 
New Hampshire 0.001 0.014 0.932 
Massachusetts 0.004 0.016 0.789 
California 0.005 0.021 0.833 
North Dakota 0.005 0.048 0.909 
Nebraska 0.010 0.025 0.705 
Illinois 0.012 0.016 0.447 
Missouri 0.013 0.020 0.515 
Connecticut 0.015 0.018 0.399 
Virginia 0.016 0.022 0.475 
Iowa 0.021 0.022 0.349 
Georgia 0.022 0.018 0.224 
Maine 0.023 0.019 0.219 
Rhode Island 0.024 0.022 0.288 
Kansas 0.024 0.025 0.338 
Wisconsin 0.027 0.022 0.230 
Delaware 0.030 0.011 0.007 
Maryland 0.031 0.015 0.045 
New Mexico 0.031 0.026 0.236 
Pennsylvania 0.037 0.015 0.017 
Vermont 0.037 0.019 0.049 
Wyoming 0.037 0.013 0.005 
Texas 0.038 0.015 0.015 
Michigan 0.043 0.015 0.006 
Louisiana 0.046 0.020 0.024 
Arkansas 0.047 0.027 0.083 
Colorado 0.049 0.021 0.021 
Ohio 0.049 0.023 0.034 
Florida 0.058 0.020 0.004 
Indiana 0.060 0.019 0.002 
South Carolina 0.060 0.024 0.013 
North Carolina 0.060 0.022 0.009 
Oklahoma 0.063 0.017 0.001 
Washington 0.065 0.014 0.001 
Idaho 0.068 0.017 0.001 
Mississippi 0.071 0.023 0.001 
Montana 0.071 0.013 0.001 
Alabama 0.079 0.023 0.001 
Arizona 0.081 0.023 0.001 
Oregon 0.081 0.018 0.001 
Tennessee 0.086 0.024 0.001 
Kentucky 0.086 0.022 0.001 
Nevada 0.092 0.017 0.001 
Utah 0.111 0.013 0.001 
West Virginia 0.130 0.019 0.001 
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Table 3.5: Random effects regression, chronic opioid use 
 Coef. SE P 
FMS prevalence (%) -1.611 0.647 0.013 
FMS female (%) 0.107 0.147 0.466 
State population -0.001 0.001 0.107 
State age 45-64 (%) -0.149 0.376 0.692 
Unemployment rate 0.003 0.001 0.001 
Median income ($) -0.001 0.001 0.001 
Illicit opioid use (%) 0.003 0.002 0.167 
Physician prevalence (per 100k) -0.001 0.001 0.001 
Physician disciplinary action (per 100K) -0.001 0.001 0.225 
Healthcare quality rank 0.001 0.001 0.465 
Prescription monitoring program 0.002 0.004 0.616 
Constant 0.175 0.177 0.322 
R2=  [within=0.352]  [between=0.504]  [overall=0.486] 
[Wald-X2(11)=168.45]  [Prob>X2=0.001] 
[sigma_u=0.023]  [sigma_e=0.012]  [rho=0.796] 
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Figure 3.1: Fixed effect of state on chronic opioid use in 
fibromyalgia, relative to DC 
  -0.010 - 0.152 
  0.153 – 0.037 
   0.038 – 0.063 
  0.064 – 0.130 
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Chapter 4: The role of practitioner type in determining chronic 
opioid use in fibromyalgia syndrome 
 The previous two chapters focused on state-level, 
structural characteristics that may affect a large number of 
patients collectively. These factors as well as the identity of a 
state were shown to be significantly associated with chronic 
opioid use in fibromyalgia patients. However these high-level 
factors only explain part of the variation seen in this practice. 
This chapter focuses on another factor that is grouped outside of 
the individual patients but at a higher level of granularity than 
the state: diagnosing provider type. 
A: Background 
Fibromyalgia syndrome, also labeled FMS or simply 
fibromyalgia, is an idiopathic, functional disorder characterized 
by chronic widespread pain and diffuse tenderness.2 Although the 
etiology of fibromyalgia remains unclear, it is becoming 
increasingly evident that disordered central pain processing is 
the primary source of the syndrome. Fibromyalgia is diagnosed in 
approximately 5% of women in the US9 and 1.6% of men.53 In the US 
this translates to more than 6 million patients. Patients 
suffering from fibromyalgia are burdened with significantly 
increased healthcare costs and utilization compared to similar 
controls.19  
Treatment of fibromyalgia syndrome typically focuses on the 
two most troublesome aspects of the disorder: pain and lack of 
restorative sleep. Treatment is generally multimodal, consisting 
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of pharmacologic agents and non-pharmacologic therapies such as 
massage or acupuncture. Unfortunately, one of the increasingly 
common medication classes of choice for the treatment of pain 
associated with fibromyalgia syndrome is the opioid analgesics 
class. According to a 2004 review published in the Journal of the 
American Medical Association (JAMA), opioids have no evidence of 
efficacy for use in fibromyalgia patients.21 Chronic opioid 
therapy for the control of chronic nonmalignant pain of many 
types has increased tremendously over the past decade.32 Despite 
the lack of evidence of efficacy for their use in fibromyalgia 
syndrome, the pattern of use in fibromyalgia has mirrored that of 
use in chronic non-malignant pain.4  
Given the complicated and multifaceted nature of FMS it is 
not surprising that patients suffering from this disorder see a 
variety of providers. These providers include not only physicians, 
both primary care and various specialists, but also midlevel 
providers, such as nurse practitioners and physician assistants, 
and complementary providers, such as chiropractors.  This diverse 
group of providers makes up the integrated care team that a 
fibromyalgia patient may be exposed to in their course of care.  
There is a wealth of evidence in many disease states 
detailing different prescribing practices exhibited by various 
physician specialties and different care patterns exhibited by 
different provider types. Specialist care has been shown to be 
superior in myocardial infarction, stroke, asthma, and rheumatoid 
arthritis while primary care practitioners excel in care for 
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conditions such as hypertension, diabetes, and low back pain.73 
Furthermore, specialists have been shown to have better clinical 
scenario knowledge in their area of expertise, but are generally 
more expensive caregivers.73 Physician specialty has also been 
shown to be associated with the early utilization of new 
prescription drugs.74 This is especially relevant in fibromyalgia 
as the approved therapies are new to the market while more 
established medications such as opioids have utilization trends 
that are troubling given the lack of evidence supporting their 
use. 
There is some evidence in the literature that suggests the 
prescribing rate of opioid pain medications is affected by the 
specialty of the prescribing physician. In a study examining the 
prescribing of schedule II pain medications, Rose et al found 
that specialists were significantly more likely to prescribe 
opioid medications than their primary care counterparts.75 The 
authors attribute this difference to the possible reluctance of 
generalists to utilize certain medication classes due to an 
increased likelihood of review as a result of seeming overuse in 
a population that may not warrant the use of CII pain 
medications.75 Again this is especially relevant in the study of 
patients suffering from fibromyalgia syndrome due to the strong 
case against the use of opioid medications for treatment. Not 
only is the failure rate of opioid use a greater concern in 
patients with fibromyalgia, there is also an increased concern of 
misuse or abuse among this population due to characteristics 
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commonly seen in these patients. For example, risk factors 
commonly associated with nonmedical use of opioids include 
anxiety and mood disorders, each a common comorbidity seen in 
patients with fibromyalgia.50  
When examining a separate nonmalignant chronic pain 
condition, lower back pain, Carey et al found that healthcare 
utilization varied significantly depending on whether the primary 
provider was a generalist (primary care), orthopedic surgeon 
(specialist), or chiropractor (allied health).76 Patients seeing 
chiropractors were likely to have more healthcare visits and use 
fewer medications both in general and for pain. Primary care 
practitioners were found to be the most cost efficient provider 
for treatment of low back pain. Despite the apparent differences 
seen in the utilization of healthcare services no differences 
were found in health outcomes for the patients included in that 
study. Time to functional recovery, return to work, and complete 
recovery from low back pain were similar across all three 
groups.76 
The literature currently features studies highlighting 
differences in prescribing practices in fibromyalgia among 
physician specialties, including disparities in the level of 
prescribing of muscle relaxants, anxiolytics, hypnotics, and 
anti-epileptics;77 and also shows differences in opioid 
prescribing practices across physician specialties.75 However, no 
studies could be found that address the role of provider type in 
the prescribing of opioids chronically for patients suffering 
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from fibromyalgia syndrome. The research question posed in this 
study addresses the role of provider category and, more 
specifically, physician specialty on the prescribing of opioids 
chronically in patients suffering from fibromyalgia syndrome. 
Only provider category or specialty is considered in this 
analysis. Factors both at higher aggregation levels, such as 
state-level characteristics, and at lower aggregation levels, 
such as patient-specific characteristics (gender, age, etc.) are 
considered elsewhere. Using this strategy, two research goals are 
accomplished. First, the raw effect of provider type is examined, 
answering the very broad question of the effect of receiving a 
diagnosis from a certain provider type on patient care. There are 
limitations associated with this approach; these limitations are 
addressed later. The second research goal accomplished is the 
determination of propensity associated with various diagnosing 
provider types on the prescribing of opioid therapy in a patient. 
These propensities can be used in an overarching research program 
examining chronic opioid use in fibromyalgia patients in 
conjunction with variables captured at both greater and lesser 
levels of granularity to provide a propensity index that takes a 
broad look at patient identity rather than focusing on patient 
specific characteristics exclusively. The use of this propensity 
index can then be applied to similar patients for the 
identification of a suitable control group for fibromyalgia 
patients. This process is described elsewhere. 
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Given the unadjusted nature of the independent variables we 
hypothesize that specialists, especially those associated with 
pain treatment (e.g., anesthesiologists, physical medicine) will 
be correlated with higher levels of chronic opioid use. 
Furthermore, we predict that midlevel providers (i.e. nurse 
practitioners, physician assistants) will be associated with 
lower chronic opioid use due to limited opioid prescribing rights 
in general. Beyond these two predicted trends there is also a 
question as to the effect of having a chiropractor as diagnosing 
provider. Because there is no previous literature surrounding 
this topic we do not make a prediction as to what effect this may 
have. 
B: Materials and methods 
Data Source 
 The University of Kentucky Institute for Pharmaceutical 
Outcomes and Policy has a licensing agreement for the i3 Invision 
Data Mart (IVDM) for the years 2007-2009. We obtained de-
identified patient information from January 1, 2007 to December 
31, 2009 from the IVDM. The IVDM is a nationally representative 
de-identified sample of 15 million patients from a commercial 
health plan across the United States and includes commercially 
insured patients as well as patients in Medicaid managed care 
plans. The data are collected at the patient level, and consist 
of eligibility and enrollment information (eligibility date, 
eligibility span, health plan type), demographic information 
(gender, age, state), medical (inpatient, outpatient, 
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professional services, including ICD-9-CM, DRG, CPT-4, revenue 
code and links to participating providers), pharmacy (prescriber, 
NDC, day supply, quantity), and laboratory (type of test and 
results) for approximately 15 million patients each year.  
Study Cohort Definitions 
 The dataset was searched for patients with fibromyalgia 
syndrome as identified by International Classification of Disease, 
Ninth Revision, Clinical Modification (ICD-CM-9) code 729.1 
(myalgia and myositis unspecified). Patients with at least one 
claim between January 1, 2007 and December 31, 2009 were included 
in the sample. Only patients between ages 18-64 were considered 
for this study. The reasons for this restriction are utilization 
patterns may differ for children, and missing data problems are 
more common for those eligible for Medicare. Patients with 
malignancies were excluded from analysis because medical care 
patterns may differ for these patients. The University of 
Kentucky Institutional Review Board provided approval for this 
study via a data use agreement for the IVDM.  
 For each patient identified as having fibromyalgia syndrome 
a table containing information describing healthcare service 
utilization was compiled. This table contains the diagnoses 
assigned to the patient at each visit as well as the provider 
associated with these diagnoses. Patients were then assigned a 
diagnosing provider based on their first claim in the IVDM with a 
diagnosis of fibromyalgia syndrome (ICD-9 CM 729.1). 
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Outcome Variable 
Chronic opioid therapy was the primary outcome of interest 
for this study. Chronic opioid therapy is defined as receiving a 
day supply in excess of one-half the total eligibility span for 
an individual patient.  Similar outcome measures have been used 
in the past to describe chronic opioid use.62 This is a binary 
outcome with patients either being recipients of chronic opioid 
therapy or not.  
Independent variables 
 The structure of the i3 IVDM is such that several 
comparisons can be made at different levels of aggregation of 
provider type. The most aggregated level looks at the difference 
in patients diagnosed with fibromyalgia initially in the data by 
either a physician (primary care of specialist) versus an allied 
health professional (nurse practitioner, physician assistant, 
chiropractor, etc.). A second more detailed comparison can be 
made that divides physicians into primary care versus specialists 
and allied health professionals into various categories. Finally 
a comparison that divides physicians into various specialties can 
be examined at the highest level of granularity. The divisions 
used for this final division are: anesthesiologist, chiropractor, 
emergency medicine, family medicine, general surgeon, internal 
medicine, neurology, nurse practitioner, orthopedic surgeon, 
physical medicine, physician assistant, physiotherapist, and 
rheumatologist. Using each of these divisions we can examine the 
impact of various role identities as a diagnosing provider may 
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have on the prescribing practices of opioids chronically in 
patients. 
Data analysis 
 Because the outcome of interest is a binary variable 
assigning individual patients as either receiving opioid therapy 
chronically or not, a logistic regression is used to examine the 
contribution of various provider role divisions. Several logistic 
regressions are performed, due to the problem of multiple 
comparisons and multiple regressions being used, all alpha levels 
are assumed to be 0.001 with all intervals considered at the 
99.9% confidence level. In addition to multivariate logistic 
regression at multiple levels, a bivariate regression comparing 
provider division at the middle aggregation level is performed. 
Data aggregation and cleaning were done using Oracle SQL 
Developer and SAS v.10; data analysis was performed in STATA 11. 
C: Results 
 As can be seen in Table 1 the type of provider associated 
with the first diagnosis of fibromyalgia for a patient in the 
sample varies widely. The majority of the diagnosing providers 
are concentrated between primary care physicians and 
chiropractors, while the rest are spread among various physician 
specialties and midlevel providers. Of the total 571192 patients 
examined in the data, 213231 or nearly 40% had their first 
diagnosis of fibromyalgia in the data from a chiropractor. Of the 
physician specialties, rheumatologists were the most common 
diagnosing physicians for fibromyalgia, followed by 
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anesthesiologists (this includes pain management specialists). 
Neurologists only account for 1.6% of initial diagnoses. 
Examination of subsequent diagnoses for each patient shows a much 
greater proportion of specialist diagnoses compared to primary 
care and chiropractic diagnoses. 
 Table 2 highlights the association of physician versus 
allied health professional for prescribing opioids chronically in 
patients. If the entirety of the 571192 patients is included in 
the analysis then diagnosis by a physician versus an allied 
health professional is associated with a 6.62 odds ratio and a 
marginal effect of 0.12 representing an increased likelihood of 
receiving opioids chronically. This effect is statistically 
significant at an alpha level less than 0.001. However, much of 
this effect is likely due to inclusion of chiropractors with the 
midlevel practitioners. As seen in Table 3, if we exclude 
patients diagnosed by chiropractors and compare the diagnosis by 
a midlevel practitioner to a physician we see this difference 
disappear. Tables 2 and 3 display results from the highest level 
of aggregation, which compares physicians to non-physicians. 
 Table 4 increases the granularity of the data, breaking 
apart physicians into primary care and specialist and breaking 
allied health professionals into chiropractors, nurse 
practitioners, and physician assistants. Based on this division 
we can rank these various providers based on how likely patients 
diagnosed by them are to receive opioid therapy chronically. 
Based on this ranking scheme and the associated marginal effects, 
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patients diagnosed by chiropractors are far less likely to 
receive opioid therapy chronically than others; this is followed 
by primary care patients, then nurse practitioner and physician 
assistant patients (not significantly different), and finally 
patients seeing specialists. 
 Using this same level of granularity Table 5 shows head-to-
head bivariate odds ratios comparing each of these provider types. 
All of these comparisons are significantly different at an alpha 
of less than 0.001, except when looking at the difference between 
nurse practitioners and physician assistants, which is not 
significant. 
Finally, Table 6 examines provider grouping at the highest 
level of granularity. Allied health professionals and primary 
care physicians are not affected by this disaggregation but 
specialists are broken into several categories including 
rheumatology, anesthesiology, physical medicine, emergency 
medicine, neurology, orthopedics, and general surgery. The 
marginal effects of these categories are shown in Table 6. 
Provider types who are least likely to diagnose patients 
receiving chronic opioid therapy are seen at the top and those 
most likely at the bottom. With the exception again of the 
difference between nurse practitioner and physician assistant 
each bivariate comparison is statistically significant at a p-
value less than 0.001.  
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D: Discussion 
The aim of this study was twofold. First, we sought to 
highlight the role of diagnosing practitioner in the prescribing 
of opioids for chronic use in patients suffering from 
fibromyalgia syndrome. In order to show the correlation of 
various provider groups with chronic opioid prescribing we broke 
the data down in several ways highlighting different levels of 
granularity available in the i3 Invision Data Mart. Using these 
categorizations we were able to support both of the research 
hypotheses. First, specialists were more likely to diagnose 
patients receiving chronic opioid therapy. This is not unexpected 
as no control for patient severity or other patient 
characteristics is attempted. A gatekeeper has likely referred a 
patient who receives a diagnosis of fibromyalgia from a 
specialist to that specialist either for management of 
fibromyalgia or a comorbid condition. This theory is supported by 
the very large proportion of subsequent diagnoses by specialists 
following primary diagnosis from another provider in the data. 
This is an unfortunate effect of treating the data as one three-
year cross-section of data. The prediction that midlevel 
practitioners would be less likely to see patients receiving 
chronic opioid therapy was not supported by this data. Exclusion 
of chiropractic patients in Table 3 shows that midlevel 
practitioners are very similar to physicians as a whole in this 
when it comes to opioid prescribing. Further as the level of 
granularity increases these midlevel practitioners remain 
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moderate prescribers of chronic opioid therapy for fibromyalgia 
patients. 
Given the lack of previous literature on the topic, 
patients receiving chiropractic care was the most surprising 
finding. Patients whose initial diagnosis in the data was from a 
chiropractor were much less likely to receive chronic opioid 
therapy. There are several possible explanations for this. First, 
chiropractors do not have prescribing rights for medications. 
This could reduce the total number of medication and also the 
likelihood of receiving chronic opioid therapy. Second, patients 
visiting chiropractors may be suffering from less severe symptoms 
than others who are seeing a specialist for instance. Finally, 
patients seeing a chiropractor may be patients receiving more 
integrated team-based care. If this is the case the members of 
this team may also be more likely to follow evidence-based 
guidelines in the treatment of fibromyalgia, which strongly 
caution against the use of opioids in this disease state. The 
percentage of patients receiving chiropractic treatment in this 
study is surprising given the small amount of evidence supporting 
its use in the literature. However studies have shown that 
patients suffering from musculoskeletal pain disorders show 
similar outcomes and greater satisfaction when seeing a 
chiropractor.78 
In addition to these findings the second research goal of 
this study was to examine the role of diagnosing provider 
category on the overall propensity of fibromyalgia patients to 
 82 
receive chronic opioid therapy. To this end, raw effects of 
provider type ignoring patient level characteristics were used. 
Integration of provider type into a propensity index for chronic 
opioid use will help to identify an appropriate control group 
when examining fibromyalgia patients, a task that has proven 
difficult in the existing literature.  
E: Limitations 
 There are several limitations to this study that threaten 
the internal and external validity. First, the identification of 
the first diagnosing provider may not be strongly linked to the 
prescribing provider. This is a limitation of the dataset itself, 
as prescribing physician data is encrypted and cannot be linked 
directly to diagnosing provider data. This is a problem of 
construct validity; however, the large study population used 
supports the assumption that, on average, patients diagnosed by a 
certain physician will be treated by the same physician. This 
assumption supported by the fact that four-fifths of the patients 
in the study sample saw only one provider for fibromyalgia during 
the entire three-year cross-section. 
 Second, the generalizability of these findings is 
questionable. What does it mean that patients diagnosed by 
specialists are more likely to receive chronic opioid therapy? 
This may signal that these patients are either suffering from 
more severe fibromyalgia symptoms or have higher rates of 
comorbid conditions. As discussed, however, the use of opioid 
medications in patients suffering from fibromyalgia is not 
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recommended in the literature. Moreover, the use of these 
medications even for comorbid conditions is inadvisable due to 
the pathophysiology of the disease that compounds the deleterious 
effects of this medication class.  
F: Conclusions  
 Although patient level characteristics such as demographics, 
severity of condition, and comorbid conditions are extremely 
important in the study of drug utilization patterns, focus on 
this level of factors exclusively ignores aggregated factors at 
the provider or geographic level.  To this effect, geographic 
variation of chronic opioid use in the fibromyalgia patient 
population has been examined previously and the current study 
looks at the effect of diagnosing provider categorization on the 
prescribing of these medications. Findings from this study 
indicate that the level of chronic opioid use in patients is 
highly correlated with the diagnosing provider type. Patients 
undergoing chiropractic care are much less likely to receive 
chronic opioid therapy while those diagnosed by specialists are 
much more likely when compared to midlevel and primary care 
practitioners. Based on these findings further study into the 
effects of chiropractic care on patients suffering from 
fibromyalgia is warranted, due to the lack of evidence currently 
available.  
Beyond these independent findings this study also provides 
an important building block in the aggregation of a propensity 
index that will identify fibromyalgia patients likely to receive 
 84 
chronic opioid therapy. In addition to state- and patient-level 
factors these findings will be used to identify an adequate 
control group for comparison in healthcare costs and outcomes 
associated with evidence based medicine versus chronic opioid 
therapy in this patient population. This chapter, and the two 
previous, highlighted the association of group characteristics 
determined above the patient level; however, these group 
characteristics are not able to explain fully the variation seen 
in chronic opioid use among fibromyalgia patients. The following 
chapter looks at the role of patient-level characteristics such 
as demographics, comorbid conditions, and concurrent medication 
use.  
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Table 4.1: Patient count by provider type 
Specialty N=571912 
Allied Health 37.9%   
--Chiropractor  98.4%  
--Nurse Practitioner  1.0%  
--Physician Assistant  0.6%  
Physician 62.1%   
--Primary Care  67.7%  
----Family Practice   63.5% 
----Internal Medicine   36.5% 
--Specialist  32.3%  
----Rheumatology   24.5% 
----Anesthesiology   22.4% 
----Physical Medicine   19.7% 
----Emergency Medicine   17.0% 
----Neurology   8.4% 
----Orthopedics   4.6% 
----General Surgery   3.4% 
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Table 4.2: Chronic opioid prescribing by diagnosing provider type, 
high aggregation 
Provider Type OR SE CI Low 
(99.9%) 
CI High 
(99.9%) 
MFX 
Physician 6.62 0.09 6.31 6.93 0.12 
Allied Health Reference 
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Table 4.3: Chronic opioid prescribing by diagnosing provider type, 
high aggregation (excluding chiropractors) 
Provider Type OR SE CI Low 
(99.9%) 
CI High 
(99.9%) 
MFX 
Physician 0.93 0.04 0.80 1.09 -0.01 
Allied Health Reference 
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Table 4.4: Chronic opioid prescribing by diagnosing provider type, 
medium aggregation 
Provider Type OR SE CI Low 
(99.9%) 
CI High 
(99.9%) 
MFX 
Primary care 0.62 0.05 0.48 0.79 -0.03 
Specialist 1.69 0.13 1.12 2.17 0.04 
Chiropractor 0.13 0.01 0.10 0.16 -0.12 
Nurse practitioner 0.99 0.09 0.72 1.35 -0.01 
Physician assistant Reference 
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Table 4.5: Comparison of chronic opioid utilization by diagnosing 
provider type, bivariate odds ratio (standard error), medium 
aggregation 
 Primary 
care 
Specia-
list 
Chiropr-
actor 
Nurse 
practi-
tioner 
Physician 
Assistant 
Primary care - 0.403 4.794 0.550 0.615 
- (0.003) (0.075) (0.030) (0.046) 
Specialist 2.480 - 11.889 1.365 1.5224 
(0.023) - (0.186) (0.075) (0.115) 
Chiropractor 0.209 0.084 - 0.115 0.128 
(0.003) (0.001) - (0.006) (0.010) 
Nurse 
practitioner 
1.817 0.733 8.711 - 1.117 
(0.100) (0.040) (0.490) - (0.104) 
Physician 
assistant 
1.627 0.656 7.800 0.895 - 
(0.123) (0.049) (0.596) (0.083) - 
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Table 4.6: Chronic opioid prescribing by diagnosing provider type, 
low aggregation 
Provider Type OR SE CI Low 
(99.9%) 
CI High 
(99.9%) 
MFX 
Chiropractor 0.13 0.01 0.10 0.16 -0.12 
General surgeon 0.29 0.02 0.24 0.35 -0.05 
Emergency medicine 0.46 0.04 0.35 0.60 -0.04 
Family practitioner 0.63 0.05 0.49 0.80 -0.03 
Internal medicine 0.61 0.05 0.48 0.78 -0.03 
Orthopedic surgeon 0.89 0.08 0.67 1.18 -0.01 
Nurse practitioner 0.99 0.09 0.72 1.35 -0.01 
Physician assistant Reference 
Rheumatologist 1.34 0.10 1.05 1.73 0.02 
Neurologist 1.59 0.13 1.23 2.06 0.04 
Physical medicine 1.66 0.13 1.29 2.14 0.04 
Anesthesiologist 4.56 0.35 3.55 5.85 0.18 
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Chapter 5: The role of patient characteristics in determining 
chronic opioid use in fibromyalgia syndrome 
 The previous three chapters focused on high-level factors 
that are shown to be associated with chronic opioid use in 
fibromyalgia patients. However, no analysis of the 
characteristics surrounding this practice would be complete 
without looking closely at individual patients and the variation 
seen in demographics, comorbid conditions, and concurrent 
medication use between them. 
A: Background 
Fibromyalgia syndrome, also labeled FMS or simply 
fibromyalgia, is an idiopathic, functional disorder characterized 
by chronic widespread pain and diffuse tenderness.2 Fibromyalgia 
is only diagnosed in approximately 5% of women9 and 1.6% of men10 
in the general population. This disorder affects over 6 million 
patients in the United States. Fibromyalgia syndrome is 
associated with significant clinical and economic burden to 
patients, the healthcare system, and society as a whole. 
Fibromyalgia is generally considered a disorder that occurs in 
women between 20 and 50 years of age; while this is the typical 
presentation, fibromyalgia occurs in males, children, adolescents 
and the elderly.  Prevalence of fibromyalgia syndrome increases 
until age 80, after which it declines.12 Higher prevalence rates 
are seen in relatives of patients suffering from fibromyalgia 
suggesting both environmental and genetic factors leading to the 
disorder.9 
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The primary clinical characteristic of fibromyalgia is 
diffuse, widespread pain often accompanied by tenderness and 
fatigue. The diagnosis of fibromyalgia is generally a difficult 
and tenuous endeavor, which involves ruling out differential 
diagnoses such as rheumatoid arthritis, systemic lupus 
erythematosus, and other conditions that present with nondescript 
pain as a major complaint. In 1990, the American College of 
Rheumatology developed diagnostic criteria for fibromyalgia 
syndrome.13 These criteria focus on the pain and tenderness 
associated with the disease. Practitioners palpate 18 pressure 
points throughout the body; patients exhibiting abnormal 
tenderness in 11 of the 18 points, in addition to a three-month 
history of bilateral, widespread pain in multiple segments of the 
body, are said to have fibromyalgia.13 
Patients suffering from fibromyalgia have been shown to be 
burdened with increased healthcare utilization and costs compared 
to similar controls. The London Fibromyalgia Epidemiology Study 
compared four groups: fibromyalgia patients, patients with 
widespread pain but no fibromyalgia diagnosis, patients accessing 
healthcare without widespread pain, and a group of controls. This 
study showed fibromyalgia patients accessing pain-related 
medication more often and having significantly greater average 
healthcare costs than those with general widespread pain.10 
Another study, utilizing a US-based health-insurance database, 
found that total annual healthcare costs for fibromyalgia 
sufferers averaged $9573 versus $3291 for age and sex matched 
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controls.19 Statistically significant differences were seen across 
all cost types including: inpatient care, outpatient care, pain-
related medications, other medications, and other medical care.79 
Treatment of fibromyalgia syndrome typically focuses on the 
two most troublesome aspects of the disorder: pain and lack of 
restorative sleep.  Management is generally multimodal, 
consisting of pharmacologic agents and non-pharmacologic 
therapies such as massage or acupuncture. According to a 2004 
review published in the Journal of the American Medical 
Association, pharmacologic therapies for fibromyalgia can be 
divided according to the level of existing efficacy evidence: 
strong, modest, weak, or none.21  
Medications considered to have strong efficacy evidence 
include amitriptyline and possibly other tri-cyclic 
antidepressants (TCA) and cyclobenzaprine (though cyclobenzaprine 
is associated with a significant adverse drug effect profile that 
makes use less than ideal). In addition, the Food and Drug 
Administration (FDA) has approved three medications for the 
treatment of fibromyalgia syndrome. In 2007, the FDA approved 
pregabalin, an alpha-2 delta ligand, which reduces calcium influx 
at nerve terminals and therefore reduces the release of several 
relevant neurochemicals.28 Pregabalin has been shown to be 
superior to placebo in reducing pain and fatigue, improving sleep 
index scores, improving both patient and clinician global 
impression of change, and improving four of eight SF-36 domains.29 
One year following the approval of pregabalin, the FDA approved 
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duloxetine. Duloxetine, a balanced serotonin, norepinephrine 
reuptake inhibitor (SNRI), has been shown in two randomized 
placebo controlled trials to improve fibromyalgia symptoms across 
many domains in women with and without major depressive 
disorder.30 In 2009, the FDA approved a third drug for use in 
fibromyalgia known as milnacipran.  Milnacipran is another 
balanced serotonin, norepinephrine reuptake inhibitor (SNRI), 
which was shown to be superior to placebo in pain response, 
patient global impression of change, fatigue, cognition, and 
several SF-36 domains.31 In addition to medications with strong 
evidence of efficacy, selective serotonin reuptake inhibitors 
(SSRIs) are considered to have modest evidence of efficacy.  
Many medications are considered to have no evidence of 
efficacy in the treatment of fibromyalgia syndrome. Classes of 
medication that fall into this category include opioids, 
glucocorticoids, non-steroidal anti-inflammatory drugs, 
benzodiazepines, and hypnotics.21 Although not included in this 
review, serotonin antagonist reuptake inhibitors (SARI) such as 
trazadone and nefazadone have no evidence of efficacy in 
treatment of fibromyalgia, though they have shown efficacy in 
symptoms associated with the disorder such as pain.80 Bupropion, 
the only FDA approved member of the norepinephrine, dopamine 
reuptake inhibitor (NDRI) class, has shown efficacy in the 
treatment of neuropathic pain,81 but was not included in the 
review either. Anticonvulsants also are not included in the JAMA 
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review, but atypical anticonvulsants such as gabapentin have 
shown efficacy in treatment of fibromyalgia.82 
Many of these medication classes see widespread use among 
patients suffering from fibromyalgia despite the lack of efficacy 
evidence. One of the most concerning trends associated with this 
over the past decade is the increased use of opioids in 
nonmalignant pain in general and fibromyalgia in particular. Not 
only is the failure rate of opioid use a greater concern in 
patients with fibromyalgia compared to the general nonmalignant 
pain population, there is also an increased concern of misuse or 
abuse among this population due to characteristics commonly seen 
in these patients. Risk factors commonly associated with 
nonmedical use of opioids include anxiety and mood disorders, 
each a common comorbidity seen in patients with fibromyalgia.50 In 
addition low self-rated health status, commonly seen in 
fibromyalgia, increases the propensity toward misuse or abuse of 
opioid medications.50 Beyond these reasons there is also increased 
concern of adverse effect presentation in patients with 
fibromyalgia for several reasons. Fibromyalgia patients report 
adverse effects and intolerance to treatment at elevated rates.51 
 Given this increased concern it is important to study the 
contributing factors associated with chronic opioid use in the 
fibromyalgia patient population. Past work has highlighted 
contributing factors at the geographic- and provider-level, 
providing insight into associations that affect the propensity 
for a patient to receive opioid therapy chronically, independent 
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of characteristics specific to that individual. The current study 
seeks to extend this knowledge by showing associations between 
chronic opioid use in patients suffering from fibromyalgia 
syndrome and patient-specific characteristics including 
demographics, comorbidities, and concurrent medications. 
Specifically, comorbid conditions examined in patients can be 
seen in Table 1 and concurrent medication classes can be seen in 
Table 2. Given the related nature of fibromyalgia with mental and 
mood disorders, musculoskeletal diseases, and ill-defined 
conditions we predict each of these classes of comorbid 
conditions will be associated with increased complexity of 
presentation and therefore increased propensity for chronic 
opioid use in patients. Additionally, considering the adverse 
drug effect profiles and lack of evidence supporting use of 
benzodiazepines, hypnotics, and muscle relaxants, we predict 
increased chronic opioid use in patients receiving these 
medication classes. Conversely, we predicts patients receiving 
selective-serotonin reuptake inhibitors, anticonvulsants 
(including pregabalin and gabapentin), selective-norepinephrine 
reuptake inhibitors, and tricyclic antidepressants will be 
associated with lower levels of chronic opioid use because use of 
these medications is supported by evidence in the current 
literature. 
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B: Materials and methods 
Data Source 
 The University of Kentucky Institute for Pharmaceutical 
Outcomes and Policy has a licensing agreement for the i3 Invision 
Data Mart (IVDM) for the years 2007-2009. We obtained de-
identified patient information from January 1, 2007 to December 
31, 2009 from the IVDM. The IVDM is a nationally representative 
de-identified sample of 15 million patients from a commercial 
health plan across the United States and includes commercially 
insured patients as well as patients in Medicaid managed care 
plans. The data are collected at the patient level, and consist 
of eligibility and enrollment information (eligibility date, 
eligibility span, health plan type), demographic information 
(gender, age, state), medical claims (inpatient, outpatient, 
professional services, including ICD-9-CM, DRG, CPT-4, revenue 
code and links to participating providers), pharmacy claims 
(prescriber, NDC, day supply, quantity), and laboratory claims 
(type of test and results) for approximately 15 million patients 
each year.  
Study Cohort Definitions 
 The dataset was queried for patients with fibromyalgia 
syndrome as identified by International Classification of Disease, 
Ninth Revision, Clinical Modification (ICD-CM-9) code 729.1 
(myalgia and myositis unspecified). Patients with at least one 
claim between January 1, 2007 and December 31, 2009 were included 
in the sample. Only patients between ages 18-64 were considered 
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for this study. The reasons for this restriction are utilization 
patterns may differ for children, and missing data problems are 
more common for those eligible for Medicare. Patients with 
malignancies were excluded from analysis because medical care 
patterns may differ for these patients. The University of 
Kentucky Institutional Review Board provided approval for this 
study via a data use agreement for the IVDM. For each patient 
identified as having fibromyalgia syndrome, tables containing 
demographic, comorbidity, and concurrent medication use were 
created for the entirety of the three-year cross-section of data.  
Outcome Variable 
Chronic opioid therapy was the primary outcome of interest 
for this study. Chronic opioid therapy is defined as receiving a 
day supply in excess of one-half the total eligibility span for 
an individual patient.  Similar outcome measures have been used 
in the past to describe chronic opioid use.62 This is a binary 
outcome with patients either being recipients of chronic opioid 
therapy or not.  
Independent Variables 
Independent variables are divided into three categories: 
demographics, comorbidities, and concurrent medications. 
Demographic variables include gender (male or female) and age. 
Age was calculated from the date of birth to the eligibility 
start date in the data. Patients were excluded from analysis if 
they were less than 18 years of age or greater than 64 years of 
age. Comorbidities were determined by having a positive diagnosis 
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determined by International Classification of Disease 9 (ICD-9) 
in the data during eligibility. Codes included in each 
comorbidity class can be seen in Table 1. Concurrent medications 
were determined using each patient’s prescription history for the 
entire cross-section. A single prescription for a medication was 
considered positive. Medication classifications were determined 
using Therapeutic Class Codes (TCC). Categorization these 
therapeutic class codes can be seen in Table 2.  
Data analysis  
Because the outcome of interest is a binary variable 
assigning individual patients as either receiving opioid therapy 
chronically or not, a logistic regression is used to examine the 
association of various types of patient characteristics to 
chronic opioid use in this patient population. Logistic 
regressions using robust standard errors are performed for each 
category of patient characteristic; due to the problem of 
multiple comparisons and multiple regressions being used all 
alpha levels are assumed to be less than 0.01 with all intervals 
being at the 99% confidence level. Data aggregation and cleaning 
were done using Oracle SQL Developer and SAS v.10 while data 
analysis was performed in STATA 11. 
C: Results 
The study sample included 619302 patients suffering from 
fibromyalgia syndrome. Mean age was 44.4 years, and two-thirds of 
the patients were women. Patient sex and age were both 
statistically positive associates of chronic opioid use. 
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Demographic factors only account for about one-tenth the variance 
attributed to comorbid conditions and about one-twentieth that of 
concurrent medications. Table 3 shows the number of patients 
prescribed a medication falling into each of the categories 
highlighted in Table 1. The majority of patients in the study 
population had at least one prescription for an opioid medication. 
Other interesting medication classes include benzodiazepines 
where one-fourth of the patients had received a prescription, and 
hypnotics where almost one-fifth had received a prescription. 
Neither of these medications have demonstrated efficacy in the 
treatment of fibromyalgia syndrome. Also of interest from Table 3 
is selective serotonin reuptake inhibitors (SSRIs), a class of 
medication recommended for use in fibromyalgia patients, were 
used in 23% or patients. Selective norepinephrine reuptake 
inhibitors such as duloxetine and minalcipran, FDA approved 
medications for fibromyalgia, were used in 12% of patients. The 
anticonvulsant class also was present in over one-fifth of 
patients, which can be explained by the presence of gabapentin 
and pregabalin, two medications commonly used in fibromyalgia 
patients. 
Table 4 shows the logistic regression that displays odds 
ratios for each medication class representing association between 
that medication class and chronic opioid use in patients. Classes 
containing opioids were excluded from this regression. Table 4 is 
arranged with medication classes independently and negatively 
associated with chronic opioid use in patients at the top and 
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those independently and positively associated with chronic opioid 
use at the bottom. Although marginal effects cannot be directly 
compared for magnitude the arrangement of the medication classes 
from top to bottom allows relative comparisons for contributions 
to chronic opioid use in patients. Given the very large sample 
size we are examining, each of the medication classes is 
statistically significant at the 99.9% confidence level except 
selective norepinephrine, reuptake inhibitors (NDRIs), which are 
only used in 7% of the sample. Of the medication classes 
mentioned in Table 3, benzodiazepines and hypnotics each are in 
the bottom half of Table 4. Also at the bottom of the table is 
the anticonvulsant class with a large positive marginal effect 
for chronic opioid use. Another interesting point is non-
steroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids 
are at the top of Table 4 with a slightly negative marginal 
effect. Other classes associated with predicted directions are 
SNRIs and TCAs; each of these classes is seen in the middle of 
Table 4. 
Beyond looking at drug classes we also examined the 
association of the presence of various comorbid conditions with 
chronic opioid use. Table 5 has these comorbid conditions listed 
and the number and portion of patients suffering from each 
disease category. The top of this table has chronic opioid use. 
This is the outcome of interest and is seen in just over 10% of 
patients in the data. This means that over 10% of patients in the 
study population received a day supply of opioids greater than 
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one-half of their eligibility period in the data. Nearly 90% of 
patients in this data suffered from another condition classified 
as “Symptoms, signs and ill-defined conditions”. This class 
contains many common ailments including fatigue, which afflicted 
nearly half of these patients and other nondescript conditions 
such as anxiety or gastric related symptoms. Conditions unrelated 
to pain, the musculoskeletal system, or neurology were also 
abundant. Diseases of the respiratory, circulatory, and digestive 
system, were present in 70%, 48%, and 46% of patients, 
respectively. Other conditions affecting the musculoskeletal 
system were present in nearly 70% of patients including back pain 
in over 30% and arthritis in one-fourth. 
Table 6 shows the logistic regression with odds ratios for 
the association of comorbid conditions with chronic opioid use in 
this patient population. Independent variables are ordered in 
Table 6 according to their relative marginal effect. Diseases at 
the top of the table such as diseases of the respiratory system 
and others have little association and possibly slightly negative 
associations with chronic opioid use in fibromyalgia patients. 
Diseases at the bottom of Table 6, including migraine, back pain 
with neuropathic involvement, arthritis, and depression, are each 
associated with increased chronic opioid use. Again, given the 
very large sample size nearly every association, with the 
exception of those with very small marginal effects, is 
statistically significant at the 99.9% confidence level. One 
exception to this is diabetes, which has an extremely small 
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marginal effect but due to prevalence greater than 10% in the 
population still is significantly and positively associated with 
chronic opioid use in this population. 
D: Discussion 
 This study was undertaken to accomplish two research goals. 
The first is an independent objective that seeks to fill a gap in 
the literature. Although studies have looked at predictors of 
medication use in fibromyalgia patients at the patient level no 
study to date has looked specifically at the effect of geographic, 
provider, and patient characteristics on the utilization of 
opioid medications chronically; this study fills that gap. 
Secondly, the results of this study serve to show the 
contribution of patient-level factors to chronic opioid use in 
this patient population. The contribution of demographic 
information, comorbid conditions, and concurrent medication use 
when combined with previously gathered information on the 
contribution of physician-level factors and structural factors 
can be used to identify an appropriate control group to assess 
the effect chronic opioid use in patients suffering from 
fibromyalgia syndrome, a significant gap in the current 
literature. 
 Concurrent medication use is very high in this population 
with four-fifths receiving a medication other than an opioid in 
the data. Nearly three-fifths received an opioid prescription 
during their eligibility, a number significantly elevated over 
the general population, which generally sees rates of about 20% 
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for annual opioid prescription receipt. Non-steroidal anti-
inflammatory drugs (NSAIDs), such as ibuprofen and naproxen, were 
used in nearly 45% of patients and glucocorticoids in over 30%. 
Neither class was associated with increased chronic opioid use 
however. This is likely due to the myriad uses for these 
medications. Both muscle relaxants and benzodiazepines are 
associated with significant side effect profiles; although muscle 
relaxants are not currently considered a scheduled substance each 
of these medication classes has literature supporting their 
potential as drugs of abuse.83 This can be said of hypnotics as 
well, though hypnotics fall in the middle of the classes when it 
comes to marginal effect on chronic opioid use. The use of 
multiple classes of potential drugs of abuse is troubling 
especially given the increased propensity for misuse that is 
reported in this patient population.51 Medications with efficacy 
evidence are seen spread throughout the table, each with positive 
marginal effects, but seen at various magnitudes. This suggests 
no association between utilization of evidence supported 
medications and chronic opioid use, and not a strict substitution 
of one for the other. 
 Comorbid conditions examined included a wide range of 
disease states. In general, those diseases associated with an 
independent pain condition are found to have large and positive 
marginal effects on chronic opioid use in this patient population. 
This is as predicted, as many patients with fibromyalgia are also 
afflicted with other central and musculoskeletal pain disorders 
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that require treatment. However, given the increased concern for 
many adverse effects from these medications in this population, 
opioids should still be considered a line of last defense even in 
other independent conditions. Additionally, many of the diseases 
considered are chronic and neuropathic in nature increasing the 
concern for use even in the absence of fibromyalgia syndrome. 
This is due to the constantly increasing dose required for 
treatment over long periods of time as well as the significant 
short- and long-term adverse effects seen in patients. Generally 
diseases with little correlation with pain such as diseases of 
the respiratory, digestive, and circulatory system were found 
near the top of the table with marginal effects being either very 
small or negative.  
 Overall, it can be seen that the presence of comorbid 
conditions and concurrent medications increases the likelihood of 
chronic opioid use in patients suffering from fibromyalgia 
syndrome. This likely represents a latent disease severity 
variable. Although the combination of demographic data, 
comorbidities, and concurrent medications represent explanations 
of nearly one-fourth of the variance seen in chronic opioid use 
in this population, over 75% of this variation is not explained 
by this variable set. This is likely due to the contribution of 
factors at larger levels of aggregation such as provider-level 
factors and structural factors such as geographic variation, but 
there are also unobserved and unobservable factors in this 
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patient population due to the secondary database nature of this 
study. This is one of several limitations seen in this study. 
E: Limitations 
 As mentioned, the presence of comorbid conditions and 
concurrent medications likely represents partial explanation of a 
latent disease severity variable. No retrospective fibromyalgia 
severity index currently exists for use in studies of this type, 
however. The inclusion of these patient-level variables in a 
broader analysis could partially compensate for this. Another 
limitation of the data source is the records used exclusively 
refer to prescription medications and ignore over-the-counter 
(OTC) drugs. This could significantly alter the use of NSAIDs 
medications specifically but may also have effects on diagnosis 
of conditions such as GERD, depression, migraine and others which 
may be controlled using medication available OTC. Finally, all 
weaknesses generally associated with secondary database such as 
only being able to observe which medications are filled, not 
which are actually taken, apply to this study as well. 
F: Conclusions 
 Previous work has focused on characteristics of the 
fibromyalgia patient population at lower levels of granularity, 
specifically the provider- and structural-level. These 
characteristics are able to explain large amounts of variation 
seen in chronic opioid use in fibromyalgia patients. However, 
patient-level characteristics such as demographics, comorbid 
conditions, and concurrent medications are an important part of 
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understanding the factors that are associated with chronic opioid 
use in fibromyalgia patients. The current study shows that 
comorbid conditions are present at high levels in this patient 
population and medications, including opioids, are being utilized 
at an elevated rate compared to the general population. 
 These results are important not only as independent 
findings, but also because they demonstrate the need for an 
adequate comparison group when studying outcomes in fibromyalgia 
patients. Comparison to the general population or even to 
patients diagnosed with another pain disorder is not sufficient 
for outcomes research in this disease state. Given these findings, 
the development of a propensity index utilizing the contribution 
of factors captured at the structural, provider, and patient 
level is needed. In the following chapters the use of a 
propensity index for comparisons of healthcare costs associated 
with chronic opioid use by fibromyalgia patients, of the 
healthcare costs associated with fibromyalgia, and of the costs 
associated with the interaction of chronic opioid use and 
fibromyalgia will be presented. 
 
 
 
 
 
 
Copyright © Jacob T. Painter 2012 
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Table 5.1: Comorbid conditions and associated ICD-9 codes 
Variable ICD-9 
Diabetes 250-250.xx 
Mental and mood disorders  
--Anxiety 300.01, 300.3, 309.81, 300.23, 300.21, 300.22, 300.2, 300.20, 
300.29, 300.02, 293.84, 309.21, 
300.0, 300.00, 300.09, 300.10 
--Depression 300.4, 309.0, 309.1, 296.5, 296.2, 296.3, 290.21, 282.84, 286.20, 
296.xx, 298.0 
--Tension headache 307.81 
Migraine 346-346.xx 
Diseases of the circulatory system 390-459.xx 
Diseases of the respiratory system 460-519.x 
Diseases of the digestive system  
--GERD 530.11, 530.81 
--Gastritis 535.0-535.5 
Diseases of the musculoskeletal 
system 
 
--Back pain 722.92-722.93, 722.4-722.5, 722.81, 722.91, 723.1, 723.5-723.6 
--Arthritis 711.00-716.xx 
Symptoms, signs and ill-defined 
conditions 
 
--Fatigue 780.71, 780.79 
--Headache 784 
--Chest pain 786.5-786.5x 
--Abdominal pain 789.0-789.0x 
--Anxiety-related symptoms 780.4, 785.0-785.1, 786.01, 786.05, 786.09 
--Gastric-related symptoms 787.0, 787.01-787.03, 787.1-787.3, 787.9, 787.91, 787.99 
Painful neuropathic disorders  
--Diabetic neuropathy 250.6x, 357.2 
--Post-herpetic neuropathy 531.x 
--Back pain with neuropathic 
involvement 
721.41-721.42, 721.91, 722.1, 
722.10, 722.11, 722.2, 722.70, 
722.72-722.73, 724.0x, 724.3, 724.4 
--Neck pain with neuropathic 
involvement 
721.1, 722.0, 722.71, 723.0, 723.4 
--Causalgia 337.2x, 353.2-353.4, 354.4, 355.7x, 355.9, 729.2 
--Phantom limb pain 353.6 
--Trigeminal neuralgia 350.1 
--Atypical facial pain 350.2, 352.1 
--Other painful neuropathies 353.0, 353.1, 353.8, 353.9, 354.0-354.5, 354.8, 354.9, 355.0-355.6, 
355.8 
Sleep disorders 780.51-780.52, 307.41, 307.42, 307.49, 780.53, 780.57, 786.03, 
347.0x-47.1x, 780.5, 780.50, 
780.54-780.56, 780.58-780.59 
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Table 5.2: Concurrent medications and Therapeutic Class Codes 
Medication class Therapeutics Class Codes 
Opioids H3A 
NSAIDs S2B, H3E 
Glucocorticoids P5A 
Muscle Relaxants H6H 
Benzodiazepines H2F 
SSRIs H3S 
Anticonvulsants H4B 
Hypnotics H2E 
SNRIs H7C 
TCAs H2U 
Triptans H3F 
Codeine Combinations H3U, H3X 
NDRIs H7D 
SARIs H7E 
Migraine Combinations H3K, H3L, H3M, H3R 
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Table 5.3: Concurrent medication use prevalence 
Medication class Users Mean SD 
Opioids 354860 0.573 0.495 
NSAIDs 267538 0.432 0.495 
Glucocorticoids 203750 0.329 0.470 
Muscle Relaxants 203750 0.329 0.470 
Benzodiazepines 148632 0.240 0.427 
SSRIs 143059 0.231 0.422 
Anticonvulsants 130053 0.210 0.408 
Hypnotics 105281 0.170 0.376 
SNRIs 73697 0.119 0.323 
TCAs 47067 0.076 0.264 
Triptans 44590 0.072 0.259 
Codeine Combinations 41493 0.067 0.250 
NDRIs 43351 0.070 0.255 
SARIs 33442 0.054 0.230 
Migraine Combinations 22295 0.036 0.187 
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Table 5.4: Logistic regression, effect of concurrent medications 
on chronic opioid use 
 OR SE P MFX 
NSAIDs 0.828 0.009 0.001 -0.011 
Glucocorticoids 0.950 0.010 0.001 -0.003 
NDRIs 0.956 0.015 0.005 -0.003 
SSRIs 1.054 0.012 0.001 0.003 
SARIs 1.348 0.022 0.001 0.019 
Migraine Combinations 1.492 0.029 0.001 0.027 
TCAs 1.525 0.022 0.001 0.029 
Hypnotics 1.598 0.018 0.001 0.031 
SNRIs 1.686 0.020 0.001 0.036 
Triptans 2.032 0.030 0.001 0.054 
Benzodiazepines 2.162 0.023 0.001 0.054 
Muscle Relaxants 2.867 0.030 0.001 0.073 
Anticonvulsants 3.255 0.035 0.001 0.095 
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Table 5.5: Comorbid condition prevalence 
Variable Number Mean SD 
Chronic opioid use 63655 0.103 0.304 
Diabetes 72387 0.117 0.321 
Mental and mood disorders 180102 0.291 0.454 
--Anxiety 119674 0.193 0.395 
--Depression 94819 0.153 0.360 
--Tension headache 19661 0.032 0.175 
Migraine 69938 0.113 0.317 
Diseases of the circulatory system 298227 0.482 0.500 
Diseases of the respiratory system 430823 0.696 0.460 
Diseases of the digestive system 288307 0.466 0.499 
--GERD 129198 0.209 0.406 
--Gastritis 320 0.001 0.023 
Diseases of the musculoskeletal 
system 
420582 0.679 0.467 
--Back pain 199454 0.322 0.467 
--Arthritis 152452 0.246 0.431 
Symptoms, signs and ill-defined 
conditions 
540386 0.873 0.333 
--Fatigue 236056 0.381 0.486 
--Headache 118 0.000 0.014 
--Chest pain 164204 0.265 0.441 
--Abdominal pain 191973 0.310 0.462 
--Anxiety-related symptoms 187117 0.302 0.459 
--Gastric-related symptoms 145307 0.235 0.424 
Painful neuropathic disorders 257744 0.416 0.493 
--Diabetic neuropathy 9099 0.015 0.120 
--Post-herpetic neuropathy 4263 0.007 0.083 
--Back pain with neuropathic 
involvement 
159916 0.258 0.438 
--Neck pain with neuropathic 
involvement 
95003 0.153 0.360 
--Causalgia 54553 0.088 0.283 
--Phantom limb pain 95 0.000 0.012 
--Trigeminal neuralgia 2180 0.004 0.059 
--Atypical facial pain 3154 0.005 0.493 
--Other painful neuropathies 62306 0.101 0.301 
Sleep disorders 118569 0.191 0.393 
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Table 5.6: Logistic regression, effect of comorbid condition on 
chronic opioid use 
  OR SE P MFX 
Diseases of the respiratory 
system 
0.732 0.007 0.001 -0.023 
Anxiety-related symptoms 0.851 0.009 0.001 -0.011 
Chest pain 0.931 0.010 0.001 -0.005 
Tension headache 0.931 0.021 0.002 -0.005 
Fatigue 0.942 0.009 0.001 -0.004 
Gastritis 0.971 0.162 0.860 -0.002 
GERD 0.991 0.011 0.449 -0.001 
Abdominal pain 1.016 0.011 0.137 0.001 
Diabetes 1.079 0.015 0.001 0.006 
Headache 1.160 0.323 0.595 0.011 
Diseases of the circulatory 
system 
1.207 0.012 0.001 0.013 
Gastric-related symptoms 1.209 0.013 0.001 0.014 
Other painful neuropathies 1.203 0.063 0.001 0.014 
Atypical facial pain 1.252 0.015 0.001 0.017 
Neck pain with neuropathic 
involvement 
1.299 0.081 0.001 0.021 
Trigeminal neuralgia 1.339 0.013 0.001 0.021 
Back pain 1.404 0.015 0.001 0.026 
Sleep disorders 1.421 0.045 0.001 0.029 
Diabetic neuropathy 1.581 0.017 0.001 0.036 
Anxiety 1.578 0.021 0.001 0.038 
Causalgia 1.676 0.069 0.001 0.045 
Post-herpetic neuropathy 1.727 0.020 0.001 0.045 
Depression 2.160 0.021 0.001 0.065 
Arthritis 2.223 0.021 0.001 0.067 
Back pain with neuropathic 
involvement 
2.598 0.030 0.001 0.092 
Migraine 9.810 2.303 0.001 0.371 
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Chapter 6: The association between chronic opioid use in 
fibromyalgia syndrome and healthcare costs 
 Chapter 2 through Chapter 5 focuses on revealing 
characteristics associated with chronic opioid use in 
fibromyalgia syndrome. This chapter attempts to control these 
characteristics to find the true effect of chronic opioid use on 
healthcare costs in fibromyalgia patients. Control of these 
characteristics through stratification of the patients sample 
allows for comparison of similar patients and therefore a more 
accurate measure of costs differences associated with this 
therapy choice. 
A: Background 
Fibromyalgia syndrome, also labeled FMS or simply 
fibromyalgia, is an idiopathic, functional disorder characterized 
by chronic widespread pain and diffuse tenderness.2 Although the 
hallmark symptom of fibromyalgia is dispersed pain, the syndrome 
is also characterized by fatigue, non-restorative sleep, and 
cognitive difficulties.2 There are many unanswered questions 
regarding both etiology and treatment of fibromyalgia. Although 
the literature has increased due to the recent introduction of 
medications approved for the indication of fibromyalgia, research 
addressing issues such as cost of care and healthcare utilization 
for patients receiving medications other than those currently 
under patent is less than rigorous, outdated, or nonexistent.  
 Fibromyalgia is only diagnosed in approximately 5% of 
women9 and 1.6% of men10 in the general population affecting over 
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6 million patients in the United States. Fibromyalgia syndrome is 
associated with significant clinical and economic burden to 
patients, the healthcare system, and society as a whole. 
Fibromyalgia is generally considered a disorder that occurs in 
women between 20 and 50 years of age; while this is the typical 
presentation, fibromyalgia occurs in males, children, adolescents 
and the elderly.  Prevalence of fibromyalgia syndrome increases 
until age 80, after which it declines.12 Higher prevalence rates 
are seen in relatives of patients suffering from fibromyalgia 
suggesting involvement of both environmental and genetic factors 
in development of the disorder.9 In 1990, the American College of 
Rheumatology developed diagnostic criteria for fibromyalgia 
syndrome.13 These criteria focus on the pain and tenderness 
associated with the disease. Practitioners palpate 18 pressure 
points throughout the body; patients exhibiting abnormal 
tenderness in 11 of the 18 points, in addition to a three-month 
history of bilateral, widespread pain in multiple segments of the 
body, are said to have fibromyalgia.13 
Treatment of fibromyalgia syndrome typically focuses on the 
two most troublesome aspects of the disorder: pain and lack of 
restorative sleep.  Management is generally multimodal, 
consisting of pharmacologic agents and non-pharmacologic 
therapies such as massage or acupuncture. According to a 2004 
review published in the Journal of the American Medical 
Association pharmacologic therapies for fibromyalgia can be 
divided according to the level of existing efficacy evidence: 
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strong, modest, weak, or none.21 Many medications are considered 
to have no evidence of efficacy in the treatment of fibromyalgia 
syndrome. Classes of medication that fall into this category 
include opioids, glucocorticoids, non-steroidal anti-inflammatory 
drugs, benzodiazepines, and hypnotics.21  
Despite this lack of efficacy evidence, several of these 
medication classes see widespread use among patients suffering 
from fibromyalgia. One of the most concerning trends associated 
with medication utilization over the past decade is the increased 
use of opioids in nonmalignant pain in general and fibromyalgia 
in particular. Not only is the failure rate of opioid use a 
greater concern in patients with fibromyalgia compared to the 
general nonmalignant pain population, there is also an increased 
concern of misuse or abuse among this population due to 
characteristics commonly seen in these patients. Risk factors 
commonly associated with nonmedical use of opioids include 
anxiety and mood disorders, each a common comorbidity seen in 
patients with fibromyalgia.50 In addition low self-rated health 
status, commonly seen in fibromyalgia, increases the propensity 
toward misuse or abuse of opioid medications.50 Beyond these 
reasons there is also increased concern of adverse effect 
presentation in patients with fibromyalgia for several reasons, 
including reports of adverse effects and intolerance to treatment 
at elevated rates.51 
 Patients suffering from fibromyalgia are burdened with 
increased healthcare costs and utilization patterns compared to 
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similar controls. The London Fibromyalgia Epidemiology Study 
compared four groups: fibromyalgia patients, patients with 
widespread pain but no fibromyalgia diagnosis, patients accessing 
healthcare without widespread pain, and a group of controls. This 
study showed fibromyalgia patients accessing pain-related 
medication more often and having significantly greater average 
healthcare cost than those with general widespread pain.10 Another 
study, utilizing a US-based health-insurance database, found that 
total annual healthcare costs for fibromyalgia sufferers averaged 
$9573 versus $3291 for age and sex matched controls.19 
Statistically significant differences were seen across all cost 
types including: inpatient care, outpatient care, pain-related 
medications, other medications, and other medical care.79 These 
totals ignore the increased personal and societal burden due to 
pain and interference of the illness on the patients’ daily lives.   
Although costs associated with chronic opioid use have not 
been examined in fibromyalgia syndrome specifically, the economic 
burden of chronic opioid use in general chronic pain patients 
compared to nonusers matched on characteristics such as age, sex, 
geographic region, insurance type, and Charlson comorbidity index 
has been examined.84 Leider et al found that medical and 
prescription costs each differed significantly when comparing 
chronic opioid users to nonusers. Annualized medical costs 
averaged $18092 for users and only $3565 for nonusers. Annualized 
prescription costs mirrored this trend, averaging $4956 for 
chronic opioid users and only $1410 for nonusers.84 
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Based on this literature and findings previously discussed, 
we predict fibromyalgia patients receiving chronic opioid therapy 
to have medical and prescription costs that are elevated 
significantly over nonusers. However, the existence of this 
difference would not be very informative, as the cause of the 
increase may have little to do with the disease itself but may 
instead be the result of other factors at the geographic-, 
provider-, or patient-level as previously described.72,85,86 In 
order to control for these differences, stratification based on 
propensity to receive chronic opioid therapy determined by 
factors at multiple levels will be used.  
Using this approach, fibromyalgia patients can be 
stratified into deciles based on their propensity to received 
chronic opioid therapy. We predict that as the propensity to 
receive chronic opioid therapy increases the differences seen in 
healthcare costs, both medical and prescription, will decrease 
though still remain elevated for chronic opioid users. The 
rationale for this prediction is that the propensity to receive 
chronic opioid therapy is an indicator of latent variables such 
as disease severity and patient overall health that are 
unobservable in a secondary database study.  For instance, as 
propensity for chronic opioid use increases fibromyalgia severity 
likely increases; refractory patients may receive a therapy not 
supported by evidence because other, more appropriate, choices 
have not been successful. Another example, as overall health 
decreases and patient presentation becomes complicated by other 
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comorbidities and concurrent medications propensity to receive 
chronic opioid therapy for the control of one or more symptoms 
will increase. 
This study will examine the raw difference in medical and 
prescription costs between chronic opioid users and nonusers with 
fibromyalgia syndrome. It will then detail the development of a 
propensity index for chronic opioid use in fibromyalgia patients. 
Finally, it will examine the difference in medical and healthcare 
costs seen in fibromyalgia patients receiving chronic opioid 
therapy from those not controlling for the propensity to receive 
this therapy. 
B: Materials and methods 
Data source 
The University of Kentucky Institute for Pharmaceutical 
Outcomes and Policy has a licensing agreement for the i3 Invision 
Data Mart (IVDM) for the years 2007-2009. We obtained de-
identified patient information from January 1, 2007 to December 
31, 2009 from the IVDM. The IVDM is a nationally representative 
de-identified sample of 15 million patients from a commercial 
health plan across the United States and includes commercially 
insured patients as well as patients in Medicaid managed care 
plans. The data are collected at the patient level, and consist 
of eligibility and enrollment information (eligibility date, 
eligibility span, health plan type), demographic information 
(gender, age, state), medical (inpatient, outpatient, 
professional services, including ICD-9-CM, DRG, CPT-4, revenue 
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code and links to participating providers), pharmacy (prescriber, 
NDC, day supply, quantity), and laboratory (type of test and 
results) for approximately 15 million patients each year.  
Study cohort definitions 
The dataset was queried for patients with fibromyalgia 
syndrome as identified by International Classification of Disease, 
Ninth Revision, Clinical Modification (ICD-CM-9) code 729.1 
(myalgia and myositis unspecified). Patients with at least one 
claim between January 1, 2007 and December 31, 2009 were included 
in the sample. Only patients between ages 18 and 64 were 
considered for this study. The reasons for this restriction are 
utilization patterns may differ for children, and missing data 
problems are more common for those eligible for Medicare. 
Patients with malignancies were excluded from analysis because 
medical care patterns may differ for these patients. The 
University of Kentucky Institutional Review Board provided 
approval for this study via a blanket data use agreement for the 
IVDM.  
Outcome variables 
  Two outcome variables of interest were collected: medical 
costs and prescription costs. These were collected based on 
medical and prescription charges collected in the IVDM. Charged 
amounts were used in all analyses of healthcare costs. Charges 
were summed at the patient level and then annualized to control 
for differing eligibility spans across patients. 
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Independent variables 
 Independent variables were collected at the state, provider, 
and patient level as described previously. The variables were 
used to develop a propensity index using logistic regression 
coefficients. Propensity to receive chronic opioid therapy was 
then used to divide patients into deciles. 
Data analysis 
Median medical and prescription costs were examined due to 
the skewness of cost data unless otherwise noted. The statistical 
significance of cost data between chronic opioid users and 
nonusers was calculated using two-group t-tests without an 
assumption of homoscedasticity. Data extraction was completed 
using Oracle SQL Developer and SAS v10, while statistical 
analyses were all completed in STATA v11. 
C: Results 
The study sample consisted of 549340 patients suffering 
from fibromyalgia syndrome taken from the IVDM; of these 
approximately 10% were chronic opioid users. Mean age was 44 
years and approximately two-thirds were women. Table 1 shows 
patient characteristics for chronic opioid users and nonusers. To 
determine which characteristics differed between these two groups 
two-group t-tests were used assuming heteroskedasticity. In 
general, chronic opioid users were older and more likely to be 
female. They also suffered from more comorbid conditions and were 
more likely to be taking concurrent medications whether these 
medications were pain related or not. Chronic opioid users were 
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less likely to be diagnosed by a chiropractor, and more likely, 
in general, to be diagnosed by a physician specialist. This is 
especially true of anesthesiology, which according to the 
definitions included in the IVDM includes pain management 
physicians. States also varied widely in the proportion of their 
patients receiving chronic opioid therapy, this can be seen more 
clearly in Table 2. 
Due to the vast differences seen between chronic opioid 
users and nonusers in this population a propensity score was 
developed. This index assigns a score for each patient in the 
fibromyalgia sample from the IVDM that represents his or her 
propensity toward receiving chronic opioid therapy. The 
contribution of each variable independent of the others can be 
seen in Table 2. The vast majority of variables are significantly 
and independently correlated either negatively or positively with 
chronic opioid use. In general these associations agree at least 
in direction with findings previously reported.72,85,86 
Comorbid conditions that are neuropathic or pain-related 
increase the likelihood of receiving opioids chronically while 
more general disease states are either not associated or 
negatively associated in general. Concurrent medications used in 
the treatment of fibromyalgia or other neuropathic or pain-
related disorders are also positively associated with chronic 
opioid use, while medications such as NSAIDs or glucocorticoids 
that are used for a wide variety of indications are negatively 
associated. As previously reported,85 chiropractors are strongly 
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and negatively associated with chronic opioid use while many 
specialists, especially in anesthesiology, are positively 
associated. State correlations varied widely with states in the 
Northeast being negatively associated with chronic opioid use 
while states in the South and Mountain West were positively 
associated with it, generally. 
Figure 1 shows the k-density plot of the propensity score. 
Nonusers of chronic opioid therapy have propensity scores with 
slightly lower variance and increased right skewness when 
compared to chronic opioid users, although the range of scores 
seen for the two groups was similar. Mean propensity overall was 
-2.99, for opioid nonusers it was -3.24, and for chronic opioid 
users it was -0.88. Table 3 shows the results of the propensity 
score being broken into deciles. There is a clear association 
between the propensity score identification as either a chronic 
opioid user or as a nonuser, as the proportion of chronic opioid 
users increases from less than 1% in the first decile to 50% in 
the tenth with a smooth increase over the deciles.  
In Figure 2 the difference between annualized medical 
charges between chronic opioid nonusers and users can be seen. 
Chronic opioid users have annualized medical costs about three 
times higher than nonusers in fibromyalgia syndrome ($18193 vs. 
$6130). However, if each of these groups is broken apart 
according to their propensity to receive chronic opioid therapy 
we can see the groups are heterogeneous. While chronic opioid 
nonusers display medical charge characteristic that increase in a 
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clear trend, the chronic opioid users have medical charges that 
resemble a positive parabola. 
Similar to Figures 2 and 3, which illustrate the 
differences in annualized medical charges between chronic opioid 
users and nonusers Figures 4 and 5 show differences in annualized 
prescription charges. In Figure 4, we see that prescription 
charges are about six times greater for fibromyalgia patients who 
are also chronic opioid users than for nonusers ($6087 vs. $935). 
Looking at Figure 5, however, illustrates again that these groups 
are different. Again chronic opioid users show a steady increase 
in prescriptions costs over the deciles, but users show a 
parabolic trend that decreases in general between deciles one and 
four before increasing between deciles five and ten. 
Finally Figure 6 shows the ratio of healthcare costs 
between the two groups for each decile. We can see that over the 
deciles from one to ten the ratio of annualized prescription 
charges for users decreases consistently (7.2 to 2.2). A similar 
but less pronounced change is seen in medical charges (2.4 to 
1.4). 
D: Discussion 
The goals of this research study are twofold: to highlight 
the increased healthcare costs associated with chronic opioid use 
in fibromyalgia syndrome and to develop a propensity index for 
identification of fibromyalgia patients at increased risk of 
receiving opioid therapy chronically.  
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To address the first goal, overall differences in medical 
and prescription costs between fibromyalgia patients receiving 
chronic opioid therapy versus those who are not receiving this 
therapy were examined. There is a clear distinction between these 
groups seen in Figures 2 and 4. Chronic opioid users had medical 
charges three times higher than nonusers and prescription charges 
six times higher. This is consistent with the literature 
discussed previously which shows in other disease states both 
medical and prescription costs are significantly elevated in 
chronic opioid users. 
However, attribution of this difference in cost purely to 
chronic opioid use is not possible using this simple comparison. 
As shown in Table 1 chronic opioid users and nonusers are 
different in many ways: comorbidity prevalence, medication use, 
provider type, and geographic location. To more effectively 
compare these groups like patients must be grouped. 
The second research goal helps to clarify this difference. 
Using a set of independent variables that describe patient 
demographics, comorbid conditions, concurrent medications, 
diagnosing provider, and state of residence we developed a 
propensity index with an outcome variable of chronic opioid use. 
The two groups have propensity scores that overlap greatly and 
allow for the stratification of the study sample into deciles 
describing their propensity to receive chronic opioid therapy. 
The cost trends are highly varied and the disparities seen from 
decile to decile in both medical and prescription costs differ 
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between chronic opioid users and nonusers. Figures 3 and 5 
illustrate this heterogeneity. 
Using this propensity index and dividing the groups into 
deciles based on likelihood of receiving chronic opioid therapy 
we are able to see a comparison of patients with a high or low 
propensity for receiving chronic opioid therapy. Using these 
comparisons we can see that a clear trend is present. Figure 6 
shows that differences seen in both medical and prescription 
costs between chronic opioid users and nonusers are present in 
each decile. However, it is evident that as the propensity toward 
chronic opioid use increases these differences decrease. In 
chronic opioid users with a very small propensity for chronic 
opioid use prescription costs are over seven times higher than 
nonusers and medical costs nearly 2.5 times greater while those 
with a high propensity for use have differences of only two and 
1.5, respectively. This shows that propensity to receive chronic 
opioid therapy plays a significant role in the accumulation of 
medical and prescription costs and that this role differs 
depending on whether patients actually receive this therapy or 
not.  
E: Limitations 
  As with other claims-based retrospective database studies 
our research is subject to errors in coding, the IVDM is 
primarily a claims database and data gathered is not done so with 
specific research in mind. Another limitation specific to claims-
based research in fibromyalgia syndrome is the lack of a specific 
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ICD-9 code to identify these patients, though the coding scheme 
used is generally accepted in this literature area. In addition, 
patient charges were used as the healthcare cost markers in this 
data. Although the median charges for users and nonusers of 
chronic opioids and for fibromyalgia patients in general agree 
with those seen previously in the literature,19,79,84 the affect of 
chronic opioid use in fibromyalgia patients has not previously 
been studied.  Finally, the generalizability of this study is 
also questionable. Because a large number of variables were used 
to create a propensity score to balance patients according to 
likelihood of receiving chronic opioid use, only the propensity 
itself is balanced on average. This does nothing to answer 
questions as to what factors in particular should caution 
practitioner to be especially wary of prescribing opioids in 
fibromyalgia patients.  
F: Conclusions  
This study shows both that in fibromyalgia patient chronic 
opioid use is associated with higher medical and prescription 
costs and that propensity to receive chronic opioid therapy is 
associated with these costs and varies according to whether the 
patient actually receives this therapy choice. The findings show 
that even after balancing observable factors between opioid users 
and nonusers (demographic, comorbidities, concurrent medications, 
provider type, geographic location) healthcare costs will be 
higher for fibromyalgia patients receiving this chronic opioid 
therapy.  
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While chronic opioid use is already strongly discouraged 
for patients suffering from fibromyalgia syndrome in the 
literature, there are no previous economic outcomes studies in 
the literature to support this caution. This study adds to that 
literature and also develops a propensity index that can be used 
for comparing fibromyalgia patients receiving chronic opioid 
therapy to control patients with similar propensities for 
receiving that therapy choice. Using a patient’s propensity to 
receive a fibromyalgia diagnosis, the following chapter creates a 
matching algorithm to select similar control patients from a 
nationally representative database. Chapter 7 is a comparison of 
healthcare costs between fibromyalgia patients and this well-
matched control group. 
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Table 6.1: Patient characteristics, by chronic opioid use 
Variable Nonuser 
n=491134 
SD User 
n=58206 
SD P 
Demographics 
Age 43.754 11.82
 
46.912 9.99
 
0.00
 Female 0.652 0.476 0.740 0.43
 
0.00
 Comorbid conditions Diabetes 0.106 0.308 0.156 0.36
 
0.00
 Anxiety 0.177 0.382 0.351 0.47
 
0.00
 Depression 0.138 0.345 0.306 0.46
 
0.00
 Tension headache 0.031 0.174 0.051 0.21
 
0.00
 Migraine 0.097 0.296 0.271 0.44
 
0.00
 Circulatory system 0.454 0.498 0.606 0.48
 
0.00
 Respiratory system 0.692 0.462 0.714 0.45
 
0.00
 GERD 0.196 0.397 0.294 0.45
 
0.00
 Gastritis 0.000 0.022 0.001 0.02
 
0.01
 Back pain 0.314 0.464 0.496 0.50
 
0.00
 Arthritis 0.217 0.412 0.453 0.49
 
0.00
 Fatigue 0.364 0.481 0.467 0.49
 
0.00
 Headache 0.000 0.014 0.000 0.01
 
0.04
 Chest pain 0.250 0.433 0.338 0.47
 
0.00
 Abdominal pain 0.295 0.456 0.406 0.49
 
0.00
 Anxiety-related 
 
0.288 0.453 0.377 0.48
 
0.00
 Gastric-related 
 
0.217 0.412 0.347 0.47
 
0.00
 Diabetic neuropathy 0.012 0.108 0.030 0.17
 
0.00
 Post-herpetic 
 
0.006 0.075 0.016 0.12
 
0.00
 Back pain with 
 
0.239 0.427 0.488 0.50
 
0.00
 Neck pain with 
 
0.145 0.352 0.283 0.45
 
0.00
 Causalgia 0.078 0.268 0.193 0.39
 
0.00
 Trigeminal neuralgia 0.003 0.055 0.008 0.08
 
0.00
 Atypical facial pain 0.005 0.067 0.011 0.10
 
0.00
 Other neuropathic 
 
0.093 0.291 0.176 0.38
 
0.00
 Sleep disorders 0.178 0.382 0.333 0.47
 
0.00
 Concurrent medications Anticonvulsants 0.168 0.374 0.597 0.49
 
0.00
 Benzodiazepines 0.206 0.405 0.536 0.49
 
0.00
 Glucocorticoids 0.313 0.464 0.457 0.49
 
0.00
 NSAIDS 0.418 0.493 0.549 0.49
 
0.00
 Muscle relaxants 0.295 0.456 0.676 0.46
 
0.00
 Hypnotics 0.147 0.354 0.395 0.48
 
0.00
 TCAs 0.063 0.243 0.202 0.40
 
0.00
 SSRIs 0.214 0.410 0.394 0.48
 
0.00
 SNRIs 0.098 0.297 0.328 0.46
 
0.00
 NDRIs 0.064 0.245 0.135 0.34
 
0.00
 SARIs 0.045 0.208 0.154 0.36
 
0.00
 Triptans 0.058 0.233 0.215 0.41
 
0.00
 Anti-migraine 
 
0.028 0.166 0.107 0.30
 
0.00
 Provider type Anesthesiology 0.026 0.159 0.192 0.39
 
0.00
 Chiropractor 0.365 0.481 0.079 0.26
 
0.00
 General surgery 0.007 0.084 0.006 0.07
 
0.00
 Emergency medicine 0.033 0.178 0.025 0.15
 
0.00
 Family medicine 0.255 0.436 0.258 0.43
 
0.10
 Internal medicine 0.148 0.355 0.146 0.35
 
0.29
 Orthopedic surgery 0.008 0.091 0.012 0.11
 
0.00
 Nurse practitioner 0.002 0.050 0.004 0.06
 
0.00
 Physician assistant 0.002 0.045 0.003 0.05
 
0.00
 Rheumatology 0.043 0.202 0.092 0.28
 
0.00
 Neurology 0.014 0.117 0.036 0.18
 
0.00
 Physical medicine 0.032 0.176 0.087 0.28
 
0.00
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Table 6.1: Patient characteristics, by chronic opioid use 
(continued) 
Variable Nonuser 
n=491134 
SD User 
n=58206 
SD P 
State 
Alabama 0.007 0.084 0.012 0.10
 
0.00
 Arkansas 0.009 0.097 0.013 0.11
 
0.00
 Arizona 0.037 0.189 0.047 0.21
 
0.00
 California 0.055 0.227 0.033 0.17
 
0.00
 Colorado 0.036 0.185 0.036 0.18
 
0.91
 Connecticut 0.007 0.081 0.005 0.07
 
0.00
 District of Columbia 0.001 0.034 0.001 0.02
 
0.00
 Delaware 0.001 0.027 0.001 0.02
 
0.53
 Florida 0.098 0.298 0.137 0.34
 
0.00
 Georgia 0.079 0.269 0.070 0.25
 
0.00
 Iowa 0.009 0.094 0.007 0.08
 
0.00
 Idaho 0.003 0.051 0.003 0.05
 
0.27
 Illinois 0.029 0.169 0.019 0.13
 
0.00
 Indiana 0.016 0.125 0.021 0.14
 
0.00
 Kansas 0.010 0.101 0.009 0.09
 
0.00
 Kentucky 0.008 0.090 0.012 0.11
 
0.00
 Louisiana 0.015 0.120 0.017 0.13
 
0.00
 Massachusetts 0.009 0.097 0.006 0.07
 
0.00
 Maryland 0.018 0.131 0.020 0.13
 
0.00
 Maine 0.001 0.030 0.001 0.02
 
0.07
 Michigan 0.007 0.083 0.007 0.08
 
0.25
 Minnesota 0.055 0.228 0.036 0.18
 
0.00
 Missouri 0.038 0.190 0.030 0.17
 
0.00
 Mississippi 0.008 0.087 0.011 0.10
 
0.00
 Montana 0.001 0.027 0.001 0.02
 
0.26
 North Carolina 0.033 0.179 0.043 0.20
 
0.00
 North Dakota 0.003 0.055 0.001 0.03
 
0.00
 Nebraska 0.008 0.091 0.006 0.07
 
0.00
 New Hampshire 0.001 0.038 0.001 0.03
 
0.02
 New Jersey 0.022 0.146 0.011 0.10
 
0.00
 New Mexico 0.007 0.084 0.007 0.08
 
0.63
 Nevada 0.006 0.075 0.009 0.09
 
0.00
 New York 0.039 0.193 0.016 0.12
 
0.00
 Ohio 0.054 0.226 0.070 0.25
 
0.00
 Oklahoma 0.009 0.096 0.012 0.10
 
0.00
 Oregon 0.005 0.072 0.008 0.09
 
0.00
 Pennsylvania 0.013 0.113 0.014 0.11
 
0.01
 Rhode Island 0.010 0.099 0.009 0.09
 
0.08
 South Carolina 0.010 0.100 0.012 0.11
 
0.00
 South Dakota 0.003 0.053 0.001 0.03
 
0.00
 Tennessee 0.021 0.143 0.030 0.17
 
0.00
 Texas 0.126 0.331 0.118 0.32
 
0.00
 Utah 0.007 0.083 0.012 0.10
 
0.00
 Virginia 0.022 0.148 0.020 0.13
 
0.00
 Vermont 0.000 0.013 0.000 0.00
 
0.02
 Washington 0.008 0.090 0.011 0.10
 
0.00
 Wisconsin 0.035 0.183 0.032 0.17
 
0.00
 West Virginia 0.002 0.040 0.004 0.05
 
0.00
 Wyoming 0.001 0.029 0.001 0.02
 
0.07
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Table 6.2: Logistic regression, propensity for chronic opioid use 
Variable Coef SE P 
Demographics 
Age -0.184 0.012 0.001 
Female 0.006 0.001 0.001 
Comorbid conditions 
Diabetes 0.046 0.016 0.005 
Anxiety 0.005 0.013 0.724 
Depression 0.010 0.014 0.459 
Tension headache -0.183 0.026 0.001 
Migraine 0.245 0.016 0.001 
Circulatory system 0.066 0.012 0.001 
Respiratory system -0.319 0.012 0.001 
GERD -0.111 0.013 0.001 
Gastritis 0.106 0.194 0.584 
Back pain 0.048 0.012 0.001 
Arthritis 0.550 0.012 0.001 
Fatigue -0.187 0.011 0.001 
Headache 0.118 0.314 0.706 
Chest pain -0.142 0.013 0.001 
Abdominal pain -0.050 0.012 0.001 
Anxiety-related symptoms -0.203 0.012 0.001 
Gastric-related symptoms 0.026 0.013 0.045 
Diabetic neuropathy 0.172 0.036 0.001 
Post-herpetic neuralgia 0.481 0.047 0.001 
Back pain with neuropathy 0.551 0.012 0.001 
Neck pain with neuropathy 0.022 0.014 0.119 
Causalgia 0.181 0.015 0.001 
Trigeminal neuralgia -0.150 0.066 0.022 
Atypical facial pain 0.031 0.058 0.591 
Other neuropathic disorders -0.055 0.015 0.001 
Sleep disorders -0.091 0.013 0.001 
Concurrent medications 
Anticonvulsants 0.916 0.012 0.001 
Benzodiazepines 0.757 0.012 0.001 
Glucocorticoids -0.085 0.011 0.001 
NSAIDS -0.340 0.011 0.001 
Muscle relaxants 0.754 0.012 0.001 
Hypnotics 0.477 0.012 0.001 
TCAs 0.360 0.015 0.001 
SSRIs 0.146 0.012 0.001 
SNRIs 0.492 0.013 0.001 
NDRIs 0.026 0.017 0.127 
SARIs 0.311 0.017 0.001 
Triptans 0.816 0.017 0.001 
Anti-migraine combinations 0.485 0.021 0.001 
Provider type 
Anesthesiology 1.572 0.026 0.001 
Chiropractor -0.992 0.026 0.001 
General surgery -0.201 0.068 0.003 
Emergency medicine 0.117 0.037 0.002 
Family medicine 0.216 0.022 0.001 
Internal medicine 0.153 0.024 0.001 
Orthopedic surgery 0.294 0.050 0.001 
Nurse practitioner 0.550 0.084 0.001 
Physician assistant 0.729 0.093 0.001 
Rheumatology 0.460 0.027 0.001 
Neurology 0 356 0 035 0 001 Physical medicine 0.871 0.028 0.001 
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Table 6.2: Logistic regression, propensity for chronic opioid use 
(continued) 
State 
Alabama 0.452 0.202 0.025 
Arkansas 0.205 0.201 0.309 
Arizona 0.365 0.198 0.065 
California -0.102 0.198 0.607 
Colorado 0.104 0.198 0.598 
Connecticut -0.230 0.209 0.270 
District of Columbia -0.588 0.283 0.038 
Delaware 0.086 0.268 0.747 
Florida 0.215 0.197 0.273 
Georgia -0.117 0.197 0.551 
Iowa -0.065 0.205 0.751 
Idaho 0.318 0.219 0.146 
Illinois -0.166 0.199 0.406 
Indiana 0.350 0.199 0.079 
Kansas 0.050 0.204 0.806 
Kentucky 0.529 0.202 0.009 
Louisiana 0.033 0.200 0.871 
Massachusetts -0.268 0.206 0.193 
Maryland 0.003 0.200 0.987 
Maine 0.005 0.271 0.984 
Michigan 0.299 0.205 0.144 
Minnesota -0.132 0.198 0.505 
Missouri -0.062 0.198 0.756 
Mississippi 0.246 0.203 0.226 
Montana 0.336 0.265 0.204 
North Carolina 0.182 0.198 0.357 
North Dakota 0.009 0.236 0.968 
Nebraska -0.174 0.207 0.401 
New Hampshire -0.528 0.246 0.032 
New Jersey -0.488 0.202 0.016 
New Mexico -0.009 0.205 0.966 
Nevada 0.667 0.204 0.001 
New York -0.673 0.200 0.001 
Ohio 0.272 0.197 0.168 
Oklahoma 0.529 0.202 0.009 
Oregon 0.607 0.205 0.003 
Pennsylvania 0.332 0.201 0.098 
Rhode Island -0.191 0.203 0.348 
South Carolina 0.192 0.202 0.341 
South Dakota -0.084 0.242 0.727 
Tennessee 0.418 0.199 0.035 
Texas -0.090 0.197 0.649 
Utah 0.561 0.203 0.006 
Virginia -0.061 0.199 0.761 
Vermont 0.093 0.539 0.863 
Washington 0.284 0.203 0.161 
Wisconsin -0.002 0.198 0.993 
West Virginia 0.562 0.218 0.010 
Wyoming (Omitted)   
Constant -3.763 0.199 0.001   
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Table 6.3: Propensity score deciles, by chronic opioid use 
Decile Nonuser User Total 
1 54,819 115 54,934 
2 54,708 226 54,934 
3 54,509 425 54,934 
4 54,184 750 54,934 
5 53,665 1,269 54,934 
6 52,679 2,255 54,934 
7 50,854 4,080 54,934 
8 47,321 7,612 54,933 
9 40,975 13,960 54,935 
10 27,420 27,514 54,934 
Total 491,134 58,206 549,340   
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Figure 6.1: Propensity prediction for chronic opioid use 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 135 
Figure 6.2: Annualized medical charges based on chronic opioid 
use  
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Figure 6.3 Medical charges, grouped by propensity to 
receive chronic opioid therapy decile 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 137 
Figure 6.4: Annualized prescription charges based on 
chronic opioid use 
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Figure 6.5: Prescription charges, grouped by propensity to use 
chronic opioid therapy decile  
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Figure 6.6: Ratio of healthcare costs for chronic opioid users 
versus nonusers  
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Chapter 7: A propensity score matched assessment of costs 
associated with fibromyalgia syndrome 
Chapter 2 through Chapter 5 focuses on revealing 
characteristics associated with chronic opioid use in 
fibromyalgia syndrome. Identification of these characteristics 
highlights the fact that finding a comparison group for patients 
suffering from fibromyalgia syndrome is a difficult endeavor. 
Using propensity score techniques identified in the previous 
chapter, this study constructs a matching algorithm based on the 
likelihood of a patient receiving a fibromyalgia diagnosis 
considering characteristics at the state-, provider-, and 
patient-level. 
A: Background 
Fibromyalgia syndrome, also labeled FMS or simply 
fibromyalgia, is an idiopathic, functional disorder characterized 
by chronic widespread pain and diffuse tenderness.2 This disorder 
affects over 6 million patients in the United States and is 
associated with significant clinical and economic burden to 
patients, the healthcare system, and society as a whole. There 
are several characteristics, physiological and clinical, that 
separate fibromyalgia patients from those with general chronic 
nonmalignant pain. Though the theoretical case is strong, there 
is a lack of evidence specifically analyzing utilization and cost 
characteristics of patients using opioids chronically in this 
disease state. 
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Although the hallmark symptom of fibromyalgia is dispersed 
pain, the syndrome is also characterized by fatigue, non-
restorative sleep, and cognitive difficulties.2 There are many 
unanswered questions regarding both etiology and treatment of 
fibromyalgia. Although the literature has grown due to the recent 
introduction of medications approved for the indication of 
fibromyalgia, research addressing issues such as cost of care, 
off-label treatment patterns, or healthcare utilization for 
patients receiving medications other than those currently under 
patent is less than rigorous, outdated, or nonexistent.  
Although the etiology of fibromyalgia remains unclear, it 
is becoming increasingly evident that disordered central pain 
processing is the primary source of the syndrome.4 Research has 
shown that fibromyalgia patients have shifted pain response 
profiles when exposed to either pressure5 or thermal6 stimuli. 
Fibromyalgia is not an organic disorder characterized by a 
structural or functional abnormality; rather it is considered a 
functional somatic syndrome.  These disorders are identified by 
symptoms, suffering, and disability.7 Other examples of somatic 
pain syndromes include irritable bowel syndrome, 
temporomandibular disorder, and vulvodynia.  Each of these 
syndromes is characterized by nondescript, regional pain without 
an underlying mechanistic cause.4 
Idiopathic chronic generalized musculoskeletal pain is 
present in 10% to 12% of the general population.8 Most patients 
suffering from this type of chronic pain also meet the clinical 
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criteria often used to identify patients suffering from 
fibromyalgia syndrome.  Despite the similarities in description 
however fibromyalgia is only diagnosed in approximately 5% of 
women9 and 1.6% of men10 in the general population. The difference 
in diagnosis rates seen between chronic nonmalignant pain and 
fibromyalgia syndrome can partially be attributed to the nature 
of fibromyalgia, which is not a homogeneous pain condition. 
Rather, the disorder can be observed along a spectrum where at 
one end pain and tenderness are the exclusive symptoms, and at 
the other, pain is accompanied by significant psychological and 
cognitive detriment.11 This spectrum is multidimensional and is 
not a definite indicator of severity. Patients may exhibit severe 
pain symptoms exclusively or have moderate pain but suffer from 
mental clouding, irritable bowel, or numerous other symptoms.  
Fibromyalgia is generally considered a disorder that occurs 
in women between 20 and 50 years of age. Although this is the 
typical presentation, fibromyalgia occurs in males, children, 
adolescents and the elderly.  Fibromyalgia is increasingly 
prevalent until age 80, after which prevalence declines.12 Higher 
prevalence rates are seen in relatives of patients suffering from 
fibromyalgia suggesting both environmental and genetic factors 
leading to the disorder.9 
 Patients suffering from fibromyalgia have been shown to be 
burdened with increased healthcare utilization and costs compared 
to similar controls. Several studies examining the costs of 
fibromyalgia in various forms, and in comparison to various 
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control groups, have been conducted. In 1999 a study, utilizing a 
US-based health-insurance database, found that total annual 
healthcare costs for fibromyalgia sufferers averaged $9573 versus 
$3291 for age and sex matched controls.19 Statistically 
significant differences were seen across all cost types 
including: inpatient care, outpatient care, pain-related 
medications, other medications, and other medical care.19  
In 2003, Robinson et al compared fibromyalgia claimants 
with a general sample of privately insured individuals. Using 
this approach, fibromyalgia patients had total annual costs of 
$5945 versus only $2486 for controls. The authors suggest, “when 
a claim for FM is present, considerable costs are involved”, but 
also “disability and comorbidities greatly increase the burden of 
FM”.87 
Two years later in an attempt to compare fibromyalgia to 
more similar patients, Boonen et al looked at fibromyalgia, 
chronic low back pain, and ankylosing spondylitis. This study 
employed a cost journal approach and found both low back pain 
(8533EU) and fibromyalgia (7813EU) to be significantly more 
expensive than ankylosing spondyloses (3205EU) due mainly to 
direct non-medical costs and productivity costs.88 
The London Fibromyalgia Epidemiology Study, published in 
2007, compared four groups: fibromyalgia patients, patients with 
widespread pain but no fibromyalgia diagnosis, patients accessing 
healthcare without widespread pain, and a group of controls. This 
study showed fibromyalgia patients accessing pain-related 
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medication more often and having significantly greater average 
healthcare cost than those with general widespread pain.10  
In 2009, Silverman et al compared fibromyalgia patients to 
rheumatoid arthritis patients. Using a large secondary claims 
database of privately insured individuals with fibromyalgia, 
rheumatoid arthritis, or both, this study showed that expenses 
for fibromyalgia patients ($10911) are similar to those with 
rheumatoid arthritis ($10716).89 Direct medical costs for 
fibromyalgia patients were approximately equal to those seen in 
rheumatoid arthritis patients, and while both groups had high 
prevalence of comorbidities fibromyalgia patients had more 
emergency department, physician, and physical therapy 
appointments than rheumatoid arthritis patients.89 
Most recently Palacio et al used a propensity score 
approach that compared fibromyalgia patients to a random sample 
taken from a private health insurance database and matched 
according to sex, age, and the Deyo-Charlson modified comorbidity 
index, an index looking at 17 comorbidities. Using this approach, 
mean annualized medical costs were calculated to be $6407.28 for 
FMS patients and only $4274.88 for matched controls.90 
Corresponding prescription costs were $1604.76 and $1086.72, 
respectively.90 The Palacio study is the best example of a control 
sample being used to date, but as admitted by the authors, this 
study was limited by the lack of matching for conditions not 
contained in the comorbidity index used, “conditions that were 
more frequent among fibromyalgia patients”.90 
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The development of the cost literature surrounding the 
disease of fibromyalgia over the past ten years, with the 
culmination in the recent article published by Palacio et al 
shows the struggle for an adequate control group for comparison 
with this disease state. Previous work by this author has shown 
that the approach taken by Palacio et al is not sufficient to 
control for the factors that go into determining costs of 
patients suffering from fibromyalgia syndrome. This work shows 
that determinants of costs differ at not only the patient level, 
but the provider and structural (geographic) level as well.72,85,86 
In addition, the use of a propensity score measure that looks 
only at age, sex, and a small set of comorbid conditions may not 
be sufficient to control for patient factors such as other 
comorbidities not contained in the index, as well as concurrent 
medications that differ in fibromyalgia patients compared to 
these controls. 
The purpose of this study is to compare medical and 
prescription costs between fibromyalgia patients and a well-
matched control group. A propensity score taking into account 
demographics, geographic location, diagnosing provider type, 
comorbid conditions, and concurrent medication classes will be 
used to match patients. Based on previous literature we 
hypothesize that although patients suffering from fibromyalgia 
syndrome will have elevated medical and prescription costs this 
elevation has been exaggerated in previous literature and will be 
tempered by the use of an appropriately chosen control group. 
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B: Materials and methods 
Data source 
The University of Kentucky Institute for Pharmaceutical 
Outcomes and Policy has a licensing agreement for the i3 Invision 
Data Mart (IVDM) for the years 2007-2009. We obtained patient 
information from January 1, 2007 to December 31, 2009 from the 
IVDM. The IVDM is a nationally representative de-identified 
sample of 15 million patients from commercial health plans across 
the United States. Data are collected at the patient level, and 
consist of eligibility and enrollment information (eligibility 
date, eligibility span, health plan type), demographic 
information (gender, age, state), medical claims (inpatient, 
outpatient, professional services, including ICD-9-CM, DRG, CPT-4, 
revenue code and links to participating providers), pharmacy 
claims (prescriber, NDC, day supply, quantity), and laboratory 
claims (type of test and results) for approximately 15 million 
patients each year. For the purposes of this study the entire 
three-year data slice was considered as a single cross-section. 
Study cohort definitions 
The dataset was queried for patients with fibromyalgia 
syndrome as identified by International Classification of Disease, 
Ninth Revision, Clinical Modification (ICD-CM-9) code 729.1 
(myalgia and myositis unspecified). Patients with at least one 
claim between January 1, 2007 and December 31, 2009 were included 
in the sample. Only patients between ages 18 and 64 were 
considered for this study. The reasons for this restriction are 
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utilization patterns may differ for children, and missing data 
problems are more common for those eligible for Medicare. 
Patients with malignancies were excluded from analysis because 
medical care patterns may differ for these patients. The 
University of Kentucky Institutional Review Board provided 
approval for this study.  
A control group was selected using the same inclusion and 
exclusion criteria as for the patients except where ICD-9 code 
729.1 was used for the identification of fibromyalgia syndrome a 
list of ICD-9 codes for related disorders was used for 
identification of controls with similar disease states. The list 
of diseases and corresponding IDC-9 codes can be found in Table 1. 
Outcome variables 
  Two outcome variables of interest were collected: medical 
costs and prescription costs. These were collected based on 
medical and prescription charges collected in the IVDM. Charged 
amounts were used in all analyses of healthcare costs. Charges 
were summed at the patient level and then annualized to control 
for differing eligibility spans across the sample. The top and 
bottom one-percent of annualized medical and annualized 
prescription charges were dropped to control for outliers. 
Independent variables 
 Independent variables were collected at the state, provider, 
and patient level as described previously. The variables were 
used to develop a propensity index using logistic regression 
coefficients. Propensity to be diagnosed with fibromyalgia 
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syndrome was determined from these variables and then, using a 
simple matching nearest neighbor algorithm, a one-to-one match 
was constructed of fibromyalgia patients and controls. 
Data analysis 
Natural log of medical and prescription costs were examined 
due to the skewness of cost data unless otherwise noted. The 
statistical significance cost differences between fibromyalgia 
patients and controls was calculated using two-group t-tests 
before and after the matching algorithm was carried out. Data 
extraction was completed using Oracle SQL Developer and SAS v10, 
the matching process was carried out using Fortran, and all 
statistical analyses were completed in STATA v12. 
C: Results 
 A total of 1919409 controls were identified in the IVDM to 
match to 494369 fibromyalgia patients. Table 2 shows demographic 
information, comorbid conditions, concurrent medication classes, 
diagnosing provider types, and geographic locations for the 
patients and controls before the matching process was completed. 
Using the propensity for being diagnosed with fibromyalgia 
syndrome as evidenced by the coefficients obtained from a 
logistic regression, patients and controls were matched one-to-
one using a nearest neighbor algorithm matching the closest 
propensity scores. These coefficients and the resulting 
characteristic balance can also be seen in Table 2. 
 The algorithm resulted in 445912 matched pairs of controls 
and patients for a sample total of 891824. Calculating the 
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coefficient of variation for all included variables shows that 
variation among controls and patients across all variables was 
reduced from 20% to 4%. Significant differences among patients 
and controls are designated with an asterisk both before and 
after the matching schema, as are significant coefficients 
obtained from the first stage logistic regression.  
 The matching results in a sample that is an average of 44 
years old and two-thirds female. As expected in a population with 
fibromyalgia, many pain comorbidities are present at rates 
elevated from the general population, including back pain, 
neuropathic pain disorders, as well as fatigue and sleep 
disorders. We also see that medication classes typically used to 
treat these disorders see increased use: these include 
benzodiazepines, NSAIDs, hypnotics, and muscle relaxants. 
Diagnosing provider varies, but chiropractors and primary care 
physicians are most common. Geographic variation between patients 
and controls varies by state but is controlled sufficiently by 
the matching process. 
 Figure 1 shows the distribution of the natural log of 
annualized medical costs for the entire population. The natural 
log of these costs resembles a normal distribution though 
kurtosis is slightly elevated. Figure 2 shows the same figure for 
prescription charges, which are skewed left of normal. 
 Overall, medical costs were higher for fibromyalgia 
patients both before and after the matching process. Fibromyalgia 
patients had annualized medical costs of $14315 for the total 
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patient sample of 494369 compared to $13007 for the 1919409 
controls. This is a 10% elevation in annualized medical costs for 
patients over controls before the propensity score matching. 
After the matching, we see medical costs of $13941 for 445912 
fibromyalgia patients and $13802 for their matched pairs. This is 
a difference of only 1%. A 90% reduction in the difference is 
seen. 
 Similar results are seen for prescription charges, though 
somewhat larger differences are seen. Before matching, 
fibromyalgia patients had mean annualized prescription charges of 
$2463, compared to only $1974 for controls. This is a 25% 
difference between patients and controls. After matching the 
charges are $2378 and $2266, respectively. This is a difference 
of only 5% and represents a reduction of 80% as a result of the 
matching process. 
D: Discussion 
 This study is a first for the fibromyalgia literature, 
employing an extensive propensity score matching technique that 
attempts to balance patients and controls on comorbid conditions, 
concurrent medications, diagnosing providers, and geographic 
location. The literature to date has shown elevated costs among 
fibromyalgia patients as compared to various control sets with 
the only consensus being that fibromyalgia patients have a 
significantly higher burden of illness. 
 Table 2 highlights the results of the propensity score 
matching. Because the study sample is so expansive, containing 
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nearly half a million matched pairs, significant differences in 
individual variables are seen both before and after the matching 
process. However, the variation between the groups overall is 
reduced 5-fold by the matching process. This reduction in 
variation in observed variables serves to create a more 
appropriate control group so the association of a diagnosis of 
fibromyalgia with healthcare costs can be examined. 
 Based on previous published literature19,88,89 and unpublished 
work by this author72,85,86, we predicted fibromyalgia costs were 
overstated due to the use of disparate and inappropriate control 
groups in the past. As seen in Figures 3 and 4, the differences 
in healthcare costs is considerably reduced when comparing 
fibromyalgia patients to a well-matched control group. Though the 
differences are reduced drastically, both medical and 
prescription costs associated with fibromyalgia remain elevated 
by a statistically significant amount. 
 Until recently, studies comparing fibromyalgia patients to 
controls matched on age and sex at best. Using this approach 
various results were collected including costs overall being 
about three times higher for fibromyalgia patients.19 A recent 
study utilized a more advanced model, matching patients using the 
Charlson-Deyo comorbidity index. The authors found medical and 
prescription costs to be elevated by approximately 50%, signaling 
a decrease in cost differences between cases and controls as 
variation in observed variables was reduced. The present study 
extends this work by employing an extensive propensity score 
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model built on multiple classes of observed variables reducing 
the difference seen in fibromyalgia patients and controls further. 
Though a difference is still seen in cost measures this 
difference is reduced by approximately 90% through the matching 
process. 
E: Limitations 
 In addition to limitations generally applicable to 
secondary database research such as the possibility of miscoding 
and the use of charges as a proxy for actual healthcare costs, 
the following limitation are worth noting. First, the validity of 
ICD-9 code 729.1 as an identifier of fibromyalgia within the IVDM 
has not been validated; however, the decision to use the code is 
consistent with previous research done in this area. 
Identification of concurrent medications also has a significant 
omission. Patients were not identified according to use of 
opioids in the dataset. This omission was a conscious decision of 
the researcher as chronic opioid use among fibromyalgia patients 
may be endogenous to other comorbid conditions. This research 
question is examined elsewhere. Despite this omission opioid use 
is balanced after the matching process to an extent similar to 
other concurrent medication classes with differences between 
fibromyalgia patients and their matches being approximately one 
percent. Finally, there is a possibility of “overmatching” due to 
the lengthy list variables controlled for in the propensity score. 
Each group of variables has been shown to vary significantly 
among fibromyalgia patients, however.72,85,86 Given this variation 
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and the large number of matched pairs available for analysis, 
“overmatching” is not a significant concern. 
F: Conclusions 
 Both medical and prescription costs were shown to be 
significantly elevated in fibromyalgia patients when compared to 
well-matched controls. The introduction of an extensive 
propensity score-matching schema reduces the elevation seen in 
costs by approximately 90%; however, costs remain elevated by 1% 
for medical costs and 5% for prescription costs. The reductions 
seen in these measures draws into question whether the elevations 
seen in costs associated with fibromyalgia seen in previous 
literature are a result of the diagnosis itself or the 
complicated nature of the disorder which is associated with 
increased comorbidity prevalence and concurrent medication use, 
as well as differing healthcare utilization patterns and 
geographic variation.  
 While using a well-matched group of controls largely 
controls the contribution to healthcare costs associated with a 
fibromyalgia diagnosis, the impact of chronic opioid therapy on 
patients with and without fibromyalgia is not addressed in this 
study. Using similar techniques and a propensity score 
identifying the likelihood of being a fibromyalgia patient 
receiving chronic opioid therapy, the following chapter analyzes 
the effect this treatment choice has on healthcare costs. 
 
Copyright © Jacob T. Painter 2012  
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Table 7.1: List of disease states used for control identification 
Diseases of the musculoskeletal 
system 
 
--Back pain 722.92-722.93, 722.4-722.5, 722.81, 722.91, 723.1, 723.5-723.6 
--Arthritis 711.00-716.xx 
Symptoms, signs and ill-defined 
conditions 
 
--Fatigue 780.71, 780.79 
--Headache 784 
--Chest pain 786.5-786.5x 
--Abdominal pain 789.0-789.0x 
--Anxiety-related symptoms 780.4, 785.0-785.1, 786.01, 786.05, 786.09 
--Gastric-related symptoms 787.0, 787.01-787.03, 787.1-787.3, 787.9, 787.91, 787.99 
Painful neuropathic disorders  
--Diabetic neuropathy 250.6x, 357.2 
--Post-herpetic neuropathy 531.x 
--Back pain with neuropathic 
involvement 
721.41-721.42, 721.91, 722.1, 
722.10, 722.11, 722.2, 722.70, 
722.72-722.73, 724.0x, 724.3, 724.4 
--Neck pain with neuropathic 
involvement 
721.1, 722.0, 722.71, 723.0, 723.4 
--Causalgia 337.2x, 353.2-353.4, 354.4, 355.7x, 355.9, 729.2 
--Phantom limb pain 353.6 
--Trigeminal neuralgia 350.1 
--Atypical facial pain 350.2, 352.1 
--Other painful neuropathies 353.0, 353.1, 353.8, 353.9, 354.0-354.5, 354.8, 354.9, 355.0-355.6, 
355.8 
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Table 7.2: Patient characteristics, before and after propensity 
score match 
 All Pr(FMS) Matched 
 Contro
 
FMS  Control FMS 
 Demographics 
Female 0.611 0.663* -0.006* 0.657 0.655 
Age 44.6 44.2* 0.044* 44.0 44.2* 
 Comorbid conditions 
Diabetes 0.110 0.110 -0.010 0.106 0.109* 
Anxiety 0.153 0.195* -0.009 0.189 0.188 
Depression 0.116 0.154* 0.001 0.149 0.147* 
Tension headache 0.023 0.033* 0.147* 0.034 0.032* 
Migraine 0.086 0.114* 0.045* 0.111 0.109* 
Circulatory system 0.450 0.471* -0.011* 0.458 0.466* 
Respiratory system 0.633 0.698* 0.137* 0.694 0.689* 
GERD 0.172 0.206* 0.038* 0.198 0.199 
Gastritis 0.000 0.000* 0.003 0.001 0.001 
Back pain 0.360 0.335* -0.030* 0.351 0.341* 
Arthritis 0.196 0.242* 0.231* 0.228 0.230 
Fatigue 0.271 0.376* 0.311* 0.362 0.358* 
Headache 0.000 0.000* 0.330* 0.001 0.001 
Chest pain 0.217 0.257* 0.026* 0.247 0.250* 
Abdominal pain 0.247 0.304* 0.080* 0.295 0.294 
Anxiety-related 
 
0.243 0.295* 0.053* 0.285 0.285 
Gastric-related 
 
0.175 0.227* 0.086* 0.218 0.217 
Diabetic neuropathy 0.019 0.013* -0.565* 0.012 0.013* 
Post-herpetic 
 
0.005 0.006* -0.161* 0.006 0.006 
Back pain with 
 
0.305 0.267* -0.286* 0.279 0.273* 
Neck pain with 
 
0.152 0.161* 0.139* 0.167 0.161* 
Causalgia 0.085 0.089* -0.070* 0.092 0.089* 
Trigeminal 
 
0.003 0.003* -0.348* 0.003 0.003 
Atypical facial 
 
0.004 0.005* 0.008 0.004 0.005 
Other neuropathic 
 
0.119 0.102* -0.165* 0.099 0.102* 
Sleep disorders 0.145 0.194* 0.099* 0.187 0.185* 
 Concurrent medications 
Anticonvulsants 0.145 0.209* 0.269* 0.196 0.195 
Benzodiazepines 0.195 0.239* 0.041* 0.232 0.231 
Glucocorticoids 0.297 0.329* 0.003 0.320 0.322 
NSAIDS 0.410 0.436* 0.007 0.423 0.429* 
Muscle relaxants 0.289 0.335* 0.131* 0.321 0.326* 
Hypnotics 0.129 0.170* 0.079* 0.165 0.162* 
TCAs 0.045 0.076* 0.312* 0.069 0.069 
SSRIs 0.193 0.234* 0.012* 0.229 0.227* 
SNRIs 0.073 0.120* 0.271* 0.112 0.110* 
NDRIs 0.056 0.071* -0.001 0.070 0.068* 
SARIs 0.036 0.056* 0.121* 0.052 0.051 
Triptans 0.056 0.074* -0.008 0.071 0.070* 
Anti-migraine 
 
0.027 0.036* 0.001 0.035 0.035 
 Practitioner type 
Chiropractor 0.364 0.358* -
 
0.435 0.377* 
General surgery 0.004 0.007* 0.573* 0.006 0.006* 
Emergency medicine 0.023 0.034* 0.318* 0.026 0.031* 
Family medicine 0.234 0.273* 0.070* 0.240 0.267* 
Internal medicine 0.137 0.159* 0.052* 0.135 0.155* 
Orthopedic surgery 0.106 0.010* -2.500* 0.010 0.011 
Nurse practitioner 0.002 0.003* 0.353* 0.002 0.003* 
Physician assistant 0.002 0.002* 0.279* 0.002 0.002* 
Rheumatology 0.022 0.051* 0.524* 0.042 0.043* 
Neurology 0.037 0.017* -0.940* 0.016 0.018* 
Physical medicine 0.034 0.041* 0.120* 0.039 0.040* 
Anesthesiology 0.036 0.045* 0.103* 0.045 0.045   
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Table 7.2: Patient characteristics, before and after propensity 
score match (continued) 
 State 
Alabama 0.007 0.008* -0.051* 0.007 0.007* 
Arkansas 0.009 0.010* -0.043* 0.010 0.010 
Arizona 0.038 0.039* -0.070* 0.041 0.039* 
California 0.047 0.050* 0.092* 0.053 0.051* 
Colorado 0.035 0.036* -0.017 0.037 0.036 
Connecticut 0.006 0.006* 0.144* 0.006 0.006 
District of Columbia 0.001 0.001* -0.208* 0.001 0.001 
Delaware 0.001 0.001* -0.260* 0.001 0.001 
Florida 0.114 0.101* -0.140* 0.100 0.102* 
Georgia 0.084 0.080* -0.105* 0.079 0.080 
Iowa 0.009 0.009* 0.008 0.009 0.009 
Idaho 0.003 0.003* -0.234* 0.003 0.003 
Illinois 0.028 0.028 0.027* 0.030 0.029* 
Indiana 0.016 0.016* -0.019 0.016 0.016 
Kansas 0.010 0.011 -0.015 0.011 0.011* 
Kentucky 0.009 0.009 -0.111* 0.009 0.009 
Louisiana 0.016 0.014* -0.154* 0.014 0.014* 
Massachusettes 0.010 0.009* -0.102* 0.009 0.009* 
Maryland 0.018 0.018* -0.004 0.017 0.018* 
Maine 0.001 0.001* -0.217* 0.001 0.001 
Michigan 0.008 0.007* -0.149* 0.007 0.007 
Minnesota 0.047 0.051* 0.040* 0.050 0.050 
Missouri 0.037 0.037 -0.036* 0.039 0.038* 
Mississippi 0.007 0.008* 0.063* 0.007 0.007 
Montana 0.001 0.001* -0.224* 0.001 0.001 
North Carolina 0.034 0.035* -0.007 0.034 0.034* 
North Dakota 0.002 0.003* 0.317* 0.003 0.003* 
Nebraska 0.008 0.008* 0.078* 0.008 0.008 
New Hampshire 0.002 0.001* -0.335* 0.001 0.001 
New Jersey 0.019 0.021* 0.075* 0.020 0.021 
New Mexico 0.007 0.006* -0.249* 0.006 0.007 
Nevada 0.006 0.006* 0.014 0.006 0.006 
New York 0.029 0.036* 0.228* 0.037 0.035* 
Ohio 0.058 0.057* -0.129* 0.054 0.057* 
Oklahoma 0.010 0.010* -0.168* 0.010 0.010 
Oregon 0.006 0.005* -0.174* 0.005 0.006 
Pennsylvania 0.015 0.013* -0.115* 0.013 0.013* 
Rhode Island 0.012 0.010* -0.257* 0.010 0.010* 
South Carolina 0.010 0.011* 0.017 0.010 0.011 
South Dakota 0.002 0.003* 0.264* 0.003 0.003* 
Tennessee 0.020 0.022* 0.045* 0.022 0.022* 
Texas 0.120 0.126 -
 
0.129 0.124* 
Utah 0.007 0.007 -0.107* 0.007 0.007 
Virginia 0.020 0.022* 0.133* 0.022 0.022 
Vermont 0.000 0.000* -0.216 0.000 0.000 
Washington 0.012 0.008* -0.497* 0.008 0.008* 
Wisconsin 0.036 0.033* -0.081* 0.031 0.034* 
West Virginia 0.002 0.002 -0.184* 0.002 0.002* 
Wyoming 0.001 0.001* -0.058 0.001 0.001*   
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Figure 7.1: Distribution of annualized medical charges, histogram 
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Figure 7.2: Distribution of annualized prescription charges, 
histogram 
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Figure 7.3: Annualized medical charges, before and after 
propensity score match 
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Figure 7.4: Annualized prescription charges, before and after 
propensity score match 
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Chapter 8: A propensity score matched assessment of costs 
associated with chronic opioid use in fibromyalgia syndrome 
 Chapter 7 focuses on the impact a diagnosis of fibromyalgia 
has on healthcare costs. However issue equally important to 
clinical practice is the effect the use of chronic opioid therapy 
in fibromyalgia patients has on healthcare costs. This chapter, 
using propensity matching introduced in Chapter 7, analyzes the 
impact of the interaction of chronic opioid therapy and 
fibromyalgia syndrome. 
A: Background 
Chronic pain research is a difficult endeavor due to the 
subjective and heterogeneous nature of the disorder.  One 
approach to answering these research questions is to look at 
individual chronic pain ailments. Fibromyalgia syndrome, due to 
the nature of the disorder, the recent development of medication 
with proven safety and efficacy, the significant burden of 
illness it inflicts on sufferers, and the wide range of treatment 
alternatives currently in use without efficacy evidence, is an 
ideal disease state for this goal. 
Fibromyalgia syndrome, also labeled FMS or simply 
fibromyalgia, is an idiopathic, functional disorder characterized 
by chronic widespread pain and diffuse tenderness.2 This disorder 
affects over 6 million patients in the United States and is 
associated with significant clinical and economic burden to 
patients, the healthcare system, and society as a whole. Over the 
past decade a troubling trend has manifested, the increased 
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prescribing and utilization of opioids for the treatment of 
chronic nonmalignant pain.  
In his book Powerful Medicines, Dr. Jerry Avorn describes 
medication use according to a triad of characteristics: benefits, 
risks, and costs. By applying this theoretical framework to 
chronic opioid use in fibromyalgia syndrome, a clear case against 
their use can be formulated. The benefits of use of these 
medications in this disorder are not clear.  There is no evidence 
supporting the efficacy of opioid use in this disorder. The risks 
associated with use of these medications are severe and varied; 
both personal and societal risks are described in detail below. 
Finally, the costs of opioid use in this population are 
negligible when only the prescription cost is considered.  
However, when considering treatment failure, adverse effects, and 
indirect costs, both to the individual and society, the cost 
becomes a serious concern. 
There are several characteristics, physiological and 
clinical, that separate fibromyalgia patients from those with 
general chronic nonmalignant pain. Though the theoretical case 
against use of this therapy choice is strong, there is a lack of 
evidence specifically comparing utilization and cost 
characteristics of patients using opioids chronically in this 
disease state and those receiving evidence-based therapy. 
Treatment of fibromyalgia syndrome typically focuses on the 
two most troublesome aspects of the disorder: pain and lack of 
restorative sleep.  Treatment is generally multimodal, consisting 
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of pharmacologic agents and non-pharmacologic therapies such as 
massage or acupuncture. According to a 2004 review published in 
the Journal of the American Medical Association, pharmacologic 
therapies for fibromyalgia can be divided according to the level 
of existing efficacy evidence: strong, modest, weak, or none.21 In 
addition to classifying medications with moderate and strong 
evidence for efficacy, the authors of the 2004 clinical review on 
fibromyalgia treatment also described classes of medications with 
no evidence for efficacy.  The following medication classes were 
designated as such: corticosteroids, non-steroidal anti-
inflammatory drugs, benzodiazepines, and other hypnotics.  Opioid 
analgesics are also included in this category.  However, despite 
the lack of evidence supporting the use of opioids for the 
treatment of fibromyalgia, evidence suggests widespread and 
increasing clinical utilization.4 
Opioid use in chronic nonmalignant pain is a divisive 
subject in the current literature. Current guidelines suggest 
guarded use of opioids chronically in nonmalignant pain and these 
recommendations are based on moderate quality evidence at best.32 
The use of opioids chronically in fibromyalgia patients deserves 
extra scrutiny for several reasons. First, the use of opioids in 
fibromyalgia patients ignores the complicated presentation of the 
disorder discussed above.  Although opioids may temporarily 
control the pain experienced in this disorder, their use ignores 
the other aspects of the disorder including non-restorative sleep, 
fatigue, and irritable bowel. 
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 Patients suffering from fibromyalgia may also have altered 
endogenous opioid activity.  A study utilizing positron emission 
tomography found that patients suffering from fibromyalgia 
syndrome exhibit decreased mu-opioid receptor availability in 
areas of the brain key to pain and nociception processing.48 There 
are two possible explanations for the demonstrated reduced 
availability. First, endogenous enkephalins levels are elevated 
in patients with fibromyalgia, even when compared to patients 
suffering from chronic low back pain.49 Elevated endogenous 
ligands in these patients may explain the reduced availability of 
receptors to opioids, decreasing their effectiveness in 
fibromyalgia patients. Another possible explanation is the 
increased presence of endogenous ligands may lead to down 
regulation of opioid receptors. 
Not only is the failure rate of opioid use a greater 
concern in patients with fibromyalgia, there is also an increased 
concern of misuse or abuse among this population due to 
characteristics commonly seen in these patients. Risk factors 
commonly associated with nonmedical use of opioids include 
anxiety and mood disorders, each a common comorbidity seen in 
patients with fibromyalgia.50 In addition low self-rated health 
status, commonly seen in fibromyalgia, increases the propensity 
toward misuse or abuse of opioids.50 
 Beyond these reasons there is also increased concern of 
adverse effect presentation in patients with fibromyalgia for 
several reasons. Fibromyalgia patients report adverse effects and 
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intolerance to treatment at elevated rates.51 In addition to the 
increased reporting of adverse effects in general there are also 
concerns with the way certain specific adverse effects seen with 
opioid use may affect fibromyalgia patients.  Constipation is a 
hallmark effect seen with opioid use and may be of increased 
concern in patients suffering from the irritable bowel symptoms 
commonly associated with fibromyalgia.  Other adverse effects 
such as sedation and mental clouding are also of particular 
concern in patients with fibromyalgia due to the possible pre-
existing presence of these problems due to the disorder. 
 Despite all these concerns, the use of opioids in the 
treatment of fibromyalgia continues with 37.4% of patients 
receiving short-acting opioids and 8.3% receiving long-acting 
opioids with an average of 124 and 243 days of therapy annually, 
respectively.51  
There have been no previous studies into the effect of this 
treatment choice on healthcare costs associated with fibromyalgia 
syndrome. However, unpublished work by this author shows that 
variation exists in geographic location, diagnosing provider 
type, comorbid conditions, and concurrent medications among 
fibromyalgia patients receiving chronic opioid therapy compared 
to those who are not.72,85,86,91 Given this variation identification 
of the effect of chronic opioid use on healthcare costs is a 
difficult endeavor. 
In order to isolate the effect of this treatemnt choice in 
fibromyalgia patients we will employ a difference-in-difference 
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model that examines the difference seen in costs associated with 
chronic opioid use in fibromyalgia patients compared to the 
difference seen in control patients. Using this technique, we 
predict that both medical and prescription costs for fibromyalgia 
patients receiving chronic opioid therapy will be significantly 
elevated. The introduction of well-matched pairs will temper the 
difference between cases and controls but fibromyalgia patients 
receiving chronic opioid therapy will have significantly greater 
costs than their matched counterparts. 
B: Materials and methods 
Data source 
The University of Kentucky Institute for Pharmaceutical 
Outcomes and Policy has a licensing agreement for the i3 Invision 
Data Mart (IVDM) for the years 2007-2009. We obtained patient 
information from January 1, 2007 to December 31, 2009 from the 
IVDM. The IVDM is a nationally representative de-identified 
sample of 15 million patients from commercial health plans across 
the United States. Data are collected at the patient level, and 
consist of eligibility and enrollment information (eligibility 
date, eligibility span, health plan type), demographic 
information (gender, age, state), medical claims (inpatient, 
outpatient, professional services, including ICD-9-CM, DRG, CPT-4, 
revenue code and links to participating providers), pharmacy 
claims (prescriber, NDC, day supply, quantity), and laboratory 
claims (type of test and results) for approximately 15 million 
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patients each year. For the purposes of this study the entire 
three-year data slice was considered as a single cross-section. 
Study cohort definitions 
The dataset was queried for patients with fibromyalgia 
syndrome as identified by International Classification of Disease, 
Ninth Revision, Clinical Modification (ICD-CM-9) code 729.1 
(myalgia and myositis unspecified). Patients with at least one 
claim between January 1, 2007 and December 31, 2009 were included 
in the sample. Only patients between ages 18 and 64 were 
considered for this study. The reasons for this restriction are 
utilization patterns may differ for children, and missing data 
problems are more common for those eligible for Medicare. 
Patients with malignancies were excluded from analysis because 
medical care patterns may differ for these patients. The 
University of Kentucky Institutional Review Board provided 
approval for this study.  
A control group was selected using the same inclusion and 
exclusion criteria used for the patients except where ICD-9 code 
729.1 was used for the identification of fibromyalgia syndrome a 
list of ICD-9 codes was used for identification of controls with 
similar disease states. The list of diseases and corresponding 
IDC-9 codes can be found in Table 1. 
Outcome variables 
  Two outcome variables of interest were collected: medical 
costs and prescription costs. These were collected based on 
medical and prescription charges collected in the IVDM. Charged 
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amounts were used in all analyses of healthcare costs. Charges 
were summed at the patient level and then annualized to control 
for differing eligibility spans across the sample. The top and 
bottom one-percent of annualized medical and annualized 
prescription charges were dropped to control for outliers. 
Independent variables 
 Independent variables were collected at the state, provider, 
and patient level as described previously.72,85,86 The variables 
were used to develop a propensity index using logistic regression 
coefficients. Propensity to be diagnosed with fibromyalgia 
syndrome and treated with chronic opioid therapy was determined 
from these variables and then using a simple matching algorithm a 
one-to-one match was constructed of fibromyalgia patients and 
controls. 
Data analysis 
Natural log of medical and prescription costs were examined 
due to the skewness of cost data unless otherwise noted. The 
difference-in-difference of cost outcomes is determined in two 
methods. The first is difference-in-difference by ordinary least 
squares. This method assumes fixed effects for chronic opioid use 
and fibromyalgia with an interaction between the effects. With 
these assumptions a simple linear regression of the fixed effects 
and the interaction will difference attributable to chronic 
opioid use in this disease state. The second method uses the 
propensity for a patient to be diagnosed with fibromyalgia 
syndrome and treated with chronic opioid therapy to match 
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patients to controls. After matching the statistical significance 
of cost differences between fibromyalgia patients receiving 
chronic opioid therapy and controls was calculated using two-
group t-tests before and after the matching algorithm was carried 
out. Data extraction was completed using Oracle SQL Developer and 
SAS v10, the matching process was carried out using Fortran, and 
all statistical analyses were completed in STATA v12. 
C: Results 
 A total sample of 2413778 was identified in the IVDM as 
meeting inclusion criteria. Of these 50159 were fibromyalgia 
patients receiving chronic opioid therapy. The comparison of 
various independent variables in these two groups can be seen in 
Table 2. Table 2 also reports logistic regression coefficients 
used to match fibromyalgia patients receiving chronic opioid 
therapy to controls based on propensity to meet both of these 
conditions, and the resulting independent variables for matched 
patients and controls. Differences in these variables that are 
significant at p < 0.05 are denoted with an asterisk as are 
statistically significant logistic regression coefficeints. 
Although many independent variables remain different for the 
48333 matched pairs of patients and controls the coefficient of 
variation among of the variables as a whole is decreased from 50% 
to 5%. 
 The difference-in-difference for fibromyalgia patients 
receiving chronic opioid therapy compared to others was derived 
via two methods. The first utilized a simple linear regression 
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that took into account fibromyalgia status, chronic opioid 
therapy receipt, and the interaction between the two. Using this 
limited variable set we found that the difference-in-difference 
attributable to chronic opioid therapy in fibromyalgia syndrome 
is 7.3% for annual medical charges and 1.3% for annual 
prescription charges. 
 To better grasp these differences we then used a propensity 
score matching technique to identify 48333 pairs of individuals 
who were matched based on their propensity to be fibromyalgia 
patients receiving chronic opioid therapy. Matching results in a 
sample that is an average of 47 years old and that is three-
fourths female. As expected in a population with fibromyalgia 
patients receiving chronic pain treatment, many pain 
comorbidities are present at rates elevated from the general 
population, including back pain, neuropathic pain disorders, as 
well as fatigue and sleep disorders. We also see that medication 
classes typically used to treat these disorders see increased 
use: these include benzodiazepines, NSAIDs, hypnotics, and muscle 
relaxants. Diagnosing provider varies but primary care physicians 
as well as anesthesiologists (pain treatment), rheumatologists, 
and neurologists are abundant. Geographic variation between 
patients and controls varies by state but is controlled well by 
the matching process. 
 Overall, medical costs were higher for fibromyalgia 
patients receiving chronic opioid therapy both before and after 
the matching process. Fibromyalgia patients receiving chronic 
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opioid therapy had annualized medical costs of $28552 for the 
total patient sample of 50159 compared to $12946 for the 2363619 
controls. This is a 120% elevation in annualized medical costs 
for patients over controls before the propensity score matching. 
After matching, we see medical costs of $28209 for 48333 
fibromyalgia patients and $24471 for their matched pairs. This is 
a difference of only 15%; nearly a 90% reduction in the 
difference is seen. 
 Similar results are seen for prescription charges, though 
larger differences are seen. Before matching fibromyalgia 
patients receiving chronic opioid therapy had mean annualized 
prescription charges of $7075, compared to only $1968 for 
controls. This is a 260% difference between patients and controls. 
After matching the charges are $7012 and $4861, respectively. 
This is a difference of only 44% and represents a reduction of 
over 80% as a result of the matching process. 
D: Discussion 
 Little reseach has been done looking at the effect of 
treatment using chronic opioid therapy in patients suffering from 
fibromyalgia syndrome. Although anecdotal evidence suggests that 
response to this therapy is poor,51 the true effect is unknown. 
This study is novel for the fibromyalgia literature for several 
reasons. It is the first study to attempt to see the unique 
effects that may be present in fibromyalgia patients being 
treated with opioids chronically, it is the first to utilize an 
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extenisive propensity score to isolate this effect, and it is the 
first to examine the economic outcomes of this treatment choics. 
 Fibromyalgia patients present with a unique pathophysiology 
that is not fully understood. Many of the characteristics that 
set this disease apart from other neuropathic disorders also 
increase the concern associated with the use of opioids 
chroncically for these patients. Because of this we set out to 
see if fibromyalgia patients treated with chronic opioid therapy 
would be affected to a greater extent than others as indicated by 
increased medical and prescription costs. 
 We had two sets of findings. The first uses the principles 
ordinary least squares to isolate the interaction of chronic 
opioid therapy in fibromyalgia patients above the effects seen 
from fibromyalgia or chronic opioid therapy individually. This 
approach showed that, in addition to the increase seen in 
consequences associated with chronic opioid use or fibromyalgia, 
the interaction of the two, or the difference-in-difference, was 
7.3% annually for medical charges and 1.3% for prescription 
charges. This represent nearly $2000 in medical costs and $100 in 
prescription costs annually. 
 Our second set of findings utilized propensity score 
methods to balance patients and controls based on their 
propensity to be a fibromyalgia patient receiving chronic opioid 
therapy. Propensity score matching allowed us to balance these 
patients across a large number of observed variables, resulting 
in 48333 matched pairs of individuals. We predicted that the 
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costs associated with chronic opioid use in fibromyalgia patients 
would be tempered through the use of well-matched pairs but would 
still represent a significant portion of both annual medical and 
prescription costs. This was shown to be the case, as even after 
the use of propensity score matching, chronic opioid therapy in 
patients suffering from fibromyalgia syndrome was associated with 
a 15% increase in annual medical costs and a 44% increase in 
annual prescription costs. 
E: Limitations 
 These two sets of findings may seem to be at odds with each 
other. However, the first approach using ordinary least squares 
assumes fixed effects for both fibromyalgia syndrome and chronic 
opioid use with an interaction term, while the propensity score 
model does not require these assumptions. The propensity score 
model balances patients and controls across all observed factors 
while the difference-in-difference model utilizes the entire 
sample.  
 Aside from the assumptions imposed by the ordinary least 
squares model other limitations to these findings exist. 
Limitations generally applicable to secondary database research 
such as the possibility of miscoding and the use of charges as a 
proxy for actual healthcare costs are applicable here. In 
addition, the validity of ICD-9 code 729.1 as an identifier of 
fibromyalgia within the IVDM has not been validated, however the 
decision to use the code is consistent with previous research 
done in this area. Finally, there is a possibility of 
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“overmatching” due to the lengthy list variables controlled for 
in the propensity score. Each group of variables has been shown 
to vary significantly among fibromyalgia patients, however.72,85,86 
Given this variation and the large number of matched pairs 
available for analysis however “overmatching” is not a 
significant concern. 
F: Conclusions 
 Both medical and prescription costs were shown to be 
significantly elevated in patients suffering from fibromyalgia 
syndrome and receiving chronic opioid therapy, even when using a 
well-matched group of controls. The propensity score used for 
matching reduced variation across independent variables by 90%; 
however, costs remain elevated by 15% for medical costs and 44% 
for prescription costs. There is no literature currently 
available examining the effect of chronic opioid therapy in 
fibromyalgia syndrome, unpublished work by this author though 
shows that in well-matched individuals a fibromyalgia diagnosis 
results in a 1% increase in annual medical costs and 5% increase 
in annual prescription costs. These differences are an order of 
magnitude smaller than the differences associated with chronic 
opioid therapy in these individuals.  
 Given the theoretical balance of risk and benefits 
associated with chronic opioid therapy in fibromyalgia syndrome 
the detrimental effect of this treatment choice is not 
surprising. This study is the first to provide strong evidence of 
increased healthcare costs associated with the utilization of 
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chronic opioid therapy, a practice not supported by evidence, in 
patients suffering from fibromyalgia syndrome. 
The effect the interaction of chronic opioid therapy and 
fibromyalgia has on healthcare costs is a complicated issue. 
Taking the finding of this chapter in the context of the previous 
seven chapters is necessary. Chapter 9 will summarize the results 
and conclusions of each of the previous chapters and explain how 
these findings fit together, as well as how they fit into the 
greater fibromyalgia literature. 
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Table 8.1: List of disease states used for control identification 
Diseases of the musculoskeletal 
system 
 
--Back pain 722.92-722.93, 722.4-722.5, 722.81, 722.91, 723.1, 723.5-723.6 
--Arthritis 711.00-716.xx 
Symptoms, signs and ill-defined 
conditions 
 
--Fatigue 780.71, 780.79 
--Headache 784 
--Chest pain 786.5-786.5x 
--Abdominal pain 789.0-789.0x 
--Anxiety-related symptoms 780.4, 785.0-785.1, 786.01, 786.05, 786.09 
--Gastric-related symptoms 787.0, 787.01-787.03, 787.1-787.3, 787.9, 787.91, 787.99 
Painful neuropathic disorders  
--Diabetic neuropathy 250.6x, 357.2 
--Post-herpetic neuropathy 531.x 
--Back pain with neuropathic 
involvement 
721.41-721.42, 721.91, 722.1, 
722.10, 722.11, 722.2, 722.70, 
722.72-722.73, 724.0x, 724.3, 724.4 
--Neck pain with neuropathic 
involvement 
721.1, 722.0, 722.71, 723.0, 723.4 
--Causalgia 337.2x, 353.2-353.4, 354.4, 355.7x, 355.9, 729.2 
--Phantom limb pain 353.6 
--Trigeminal neuralgia 350.1 
--Atypical facial pain 350.2, 352.1 
--Other painful neuropathies 353.0, 353.1, 353.8, 353.9, 354.0-354.5, 354.8, 354.9, 355.0-355.6, 
355.8 
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Table 8.2: Patient characteristics, before and after propensity 
score match 
 All Pr(FMS) Matched 
 Control FMS,Op  Control FMS,Op 
 Demographics 
Female 0.619 0.738* 0.002* 0.730 0.735 
Age 44.5 46.8* 0.058* 
 
46.9 46.8 
 Comorbid conditions 
Diabetes 0.110 0.146* 0.008 0.145 0.146 
Anxiety 0.158 0.345* 0.009 0.333 0.340* 
Depression 0.120 0.294* -0.010 0.278 0.289* 
Tension headache 0.025 0.050* -0.056* 0.048 0.049 
Migraine 0.088 0.268* 0.244* 0.248 0.262* 
Circulatory system 0.451 0.591* 0.021 0.586 0.588 
Respiratory system 0.645 0.705* -0.169* 0.693 0.703* 
GERD 0.176 0.282* -0.050* 0.271 0.279* 
Gastritis 0.001 0.001* -0.047 0.001 0.001 
Back pain 0.352 0.492* -0.026* 0.489 0.487 
Arthritis 0.200 0.446* 0.595* 0.430 0.441* 
Fatigue 0.289 0.457* 0.077* 0.438 0.453* 
Headache 0.001 0.001* 0.391 0.001 0.001 
Chest pain 0.223 0.322* -0.084* 0.311 0.320* 
Abdominal pain 0.256 0.392* 0.020 0.382 0.389* 
Anxiety-related 
 
0.251 0.358* -0.148* 0.344 0.355* 
Gastric-related 
 
0.182 0.328* 0.040* 0.315 0.323* 
Diabetic neuropathy 0.017 0.026* -0.135* 0.026 0.025 
Post-herpetic 
 
0.005 0.014* 0.221* 0.014 0.014 
Back pain with 
 
0.293 0.484* 0.246* 0.487 0.479* 
Neck pain with 
 
0.151 0.279* 0.184* 0.270 0.274 
Causalgia 0.084 0.185* 0.136* 0.180 0.181 
Trigeminal 
 
0.003 0.007* -0.035* 0.007 0.007 
Atypical facial 
 
0.004 0.010* 0.067 0.009 0.010 
Other neuropathic 
 
0.114 0.171* -0.081* 0.167 0.169 
Sleep disorders 0.151 0.326* 0.029* 0.313 0.322* 
 Concurrent Medications 
Anticonvulsants 0.149 0.583* 0.937* 0.569 0.572 
Benzodiazepines 0.197 0.524* 0.610* 0.514 0.517 
Glucocorticoids 0.301 0.446* -0.077* 0.433 0.442* 
NSAIDS 0.413 0.550* -0.237* 0.545 0.549 
Muscle relaxants 0.290 0.674* 0.789* 0.675 0.667* 
Hypnotics 0.132 0.381* 0.380* 0.364 0.375* 
TCAs 0.048 0.197* 0.418* 0.184 0.192* 
SSRIs 0.197 0.387* 0.126* 0.376 0.383* 
SNRIs 0.078 0.318* 0.538* 0.293 0.311* 
NDRIs 0.057 0.132* 0.024 0.127 0.130 
SARIs 0.037 0.149* 0.271* 0.134 0.146* 
Triptans 0.056 0.213* 0.575* 0.192 0.207* 
Anti-migraine 
 
0.027 0.106* 0.317* 0.093 0.102* 
 Practitioner type 
Chiropractor 0.369 0.0
 
omitted- 0.073 0.087* 
General surgery 0.004 0.0
 
1.209* 0.005 0.006 
Emergency medicine 0.025 0.0
 
1.049* 0.022 0.025* 
Family medicine 0.242 0.2
 
1.183* 0.290 0.282* 
Internal medicine 0.141 0.1
 
1.161* 0.154 0.157 
Orthopedic surgery 0.088 0.0
 
-0.858* 0.011 0.014* 
Nurse practitioner 0.002 0.0
 
1.539* 0.004 0.004 
Physician assistant 0.002 0.0
 
1.615* 0.004 0.004 
Rheumatology 0.026 0.0
 
1.902* 0.087 0.095* 
Neurology 0.033 0.0
 
0.578* 0.040 0.038* 
Physical medicine 0.034 0.0
 
1.712* 0.098 0.092* 
Anesthesiology 0.034 0.2
 
2.13* 0.212 0.197*   
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Table 8.2: Patient characteristics, before and after propensity 
score match (continued) 
 State 
Alabama 0.007 0.012
 
0.324* 0.011 0.012 
Arkansas 0.009 0.013
 
0.197* 0.014 0.013 
Arizona 0.038 0.048
 
0.372* 0.048 0.048 
California 0.048 0.030
 
0.005 0.029 0.030 
Colorado 0.035 0.034 0.169* 0.035 0.034 
Connecticut 0.006 0.005
 
0.019 0.005 0.005 
District of Columbia 0.001 0.001
 
-0.679* 0.001 0.001 
Delaware 0.001 0.001 -0.051 0.001 0.001 
Florida 0.110 0.136
 
0.176* 0.141 0.136
 Georgia 0.083 0.072
 
-0.088* 0.074 0.072 
Iowa 0.009 0.008
 
0.211* 0.007 0.008 
Idaho 0.003 0.003 0.264* 0.003 0.003 
Illinois 0.028 0.019
 
-0.041 0.018 0.019 
Indiana 0.016 0.021
 
0.393* 0.021 0.021 
Kansas 0.010 0.009
 
0.180* 0.009 0.009 
Kentucky 0.009 0.013
 
0.457* 0.013 0.013 
Louisiana 0.016 0.017
 
-0.099* 0.016 0.017 
Massachusetts 0.010 0.006
 
-0.140* 0.006 0.006 
Maryland 0.018 0.021
 
0.195* 0.021 0.020 
Maine 0.001 0.001
 
0.066 0.001 0.001 
Michigan 0.008 0.008 0.284* 0.007 0.008 
Minnesota 0.048 0.033
 
0.049 0.031 0.033
 Missouri 0.038 0.030
 
0.010 0.030 0.030 
Mississippi 0.007 0.011
 
0.283* 0.010 0.011 
Montana 0.001 0.001 0.337* 0.001 0.001 
North Carolina 0.034 0.044
 
0.280* 0.045 0.044 
North Dakota 0.002 0.001
 
0.370* 0.001 0.001 
Nebraska 0.008 0.006
 
-0.011 0.006 0.006 
New Hampshire 0.002 0.001
 
-0.242 0.001 0.001 
New Jersey 0.020 0.010
 
-0.270* 0.010 0.010 
New Mexico 0.007 0.007 -0.001 0.007 0.007 
Nevada 0.006 0.009
 
0.545* 0.010 0.009 
New York 0.031 0.015
 
-0.281* 0.015 0.015 
Ohio 0.058 0.073
 
0.300* 0.075 0.073 
Oklahoma 0.010 0.012
 
0.277* 0.013 0.012 
Oregon 0.006 0.009
 
0.570* 0.008 0.009 
Pennsylvania 0.014 0.014 0.293* 0.015 0.015 
Rhode Island 0.012 0.009
 
-0.152* 0.010 0.009 
South Carolina 0.010 0.013
 
0.225* 0.012 0.013 
South Dakota 0.002 0.001
 
0.193 0.001 0.001 
Tennessee 0.020 0.031
 
0.468* 0.031 0.031 
Texas 0.122 0.116
 
omitted
 
0.114 0.116 
Utah 0.007 0.012
 
0.523* 0.011 0.011 
Virginia 0.020 0.019
 
0.136* 0.018 0.019 
Vermont 0.001 0.001
 
-0.447 0.001 0.001 
Washington 0.011 0.010
 
0.159* 0.011 0.010 
Wisconsin 0.036 0.032
 
0.166* 0.031 0.032 
West Virginia 0.002 0.004
 
0.539* 0.004 0.004 
Wyoming 0.001 0.001 0.181 0.001 0.001   
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Figure 8.1: Annualized medical charges, before and after 
propensity score match 
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Figure 8.2: Annualized prescription charges, before and after 
propensity score match 
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Chapter 9: Conclusion, theory, and contribution to the literature 
The treatment of chronic nonmalignant pain currently 
receives a large amount of attention in the literature. The most 
contentious issue is the use of opioids chronically in the 
management of this group of disorders. There is evidence in many 
chronic nonmalignant pain conditions that shows opioids are 
effective for symptomatic control. However, the primary clinical 
concern that divides the treatment of nonmalignant pain from 
malignant pain is the expected length of treatment course. 
Initiating a chronic nonmalignant pain patient on opioid therapy 
may result in the continuation of that treatment, including the 
inevitable dose increases to counter tolerance, over the lifetime 
of the patient. There are several reasons for this tendency, 
including clinical inertia as well as the physical and 
psychological dependence seen in many patients. 
Chronic nonmalignant pain is a term that refers to a wide 
variety of conditions ranging from low back pain to headache. 
These conditions also range from purely organic conditions 
characterized by pain resulting from tissue damage to somatic 
disorders characterized by suffering and disability rather than 
specific tissue damage. Given the wide assortment of conditions 
that this term is applicable to, it is no surprise that the 
appropriateness of the use of chronic opioid therapy also varies.  
Fibromyalgia syndrome is an example of a functional somatic 
syndrome characterized by abnormal central pain processing. 
Fibromyalgia is an ideal condition to study chronic opioid use 
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because, of the chronic nonmalignant pain conditions, 
fibromyalgia has one of the strongest theoretical cases against 
the use of opioids chronically. This case is built primarily on 
the pathophysiology of fibromyalgia patients, which may make them 
more susceptible to detriment from adverse effects such as 
opioid-induced hyperalgesia.  
The research goals of this dissertation are to identify key 
characteristics at the structural-, practitioner-, and patient-
levels associated with chronic opioid use in patients suffering 
from fibromyalgia syndrome and to elucidate outcomes associated 
with this treatment choice. My central hypothesis is that 
characteristics at the state-, practitioner-, and patient- levels 
are associated with chronic opioid use, and, independent of these 
characteristics, chronic opioid use will be correlated with 
poorer outcomes in fibromyalgia patients. This research track was 
undertaken for several reasons: (1) the increased use of opioids 
chronically in nonmalignant pain is troublesome given the 
individual and societal adverse effects associated with use, (2) 
fibromyalgia is an ideal condition for this research because of 
the strong theoretical case against chronic opioid therapy for 
treatment of this disorder, (3) the theoretical predilection of 
this patient population for adverse effects associated with 
chronic opioid use, and (4) the current gap of empirical evidence 
in the fibromyalgia literature surrounding this topic. 
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To test my central hypothesis and accomplish the objective 
of this dissertation the following specific aims were 
accomplished: 
1. Identify characteristics at the state, practitioner, and 
patient level associated with chronic opioid use in 
fibromyalgia patients.  
2. Determine outcomes associated with chronic opioid use in 
fibromyalgia patients.  
Chapter 1 of this dissertation served as an introduction to 
fibromyalgia syndrome, chronic opioid use and the interaction of 
the two in clinical practice. A review of the literature 
surrounding the use of opioids chronically in fibromyalgia 
syndrome yields little in the way of empirical evidence. The bulk 
of the literature surrounding this topic consists of reviews and 
guidelines, which highlight the lack of evidence supporting the 
use of opioids in this disease state. Reviews published in The 
Journal of the American Medical Association, The Journal of Pain, 
and International Journal of Rheumatic Diseases, each point this 
out. Guidelines from the American Pain Society, the European 
League Against Rheumatism (EULAR), and the Association of 
Scientific Medical Societies (AWMF) each caution against the use 
of opioids chronically in fibromyalgia syndrome. 
There are several reasons for this caution that are made 
apparent in the literature describing the pathophysiology and 
behavioral characteristics of fibromyalgia patients. The 
mechanism of action of opioid agonists only masks the pain 
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symptoms by treating the pain triggers rather than treating the 
central pain itself. Contrast this with other medications used in 
the treatment of fibromyalgia pain, including those approved by 
the Food and Drug Administration (pregabalin, duloxetine, and 
minalcipran), which act via central mechanisms to affect the 
action of afferent or efferent neurons resulting in lessened pain. 
Beyond the inefficacy of opioids in the treatment of fibromyalgia 
syndrome there is also concern pertaining to opioid-induced 
hyperalgesia. This disorder, which results in an independent pain 
condition separate from the pain the opioid was meant to treat, 
can occur as a result of opioid use in any pain disorder. However, 
the pathophysiology of fibromyalgia patients may result in an 
increased susceptibility to this condition. Each of these 
concerns shifts the risk-benefit ratio associated with the use of 
opioids chronically for the treatment of fibromyalgia syndrome 
away from use. 
With a clear theoretical case against the use of opioids 
chronically in fibromyalgia syndrome, Chapters 2 through 6 set 
out to identify characteristics that were associated with the use 
of this treatment choice in patients. Chapters 2 and 3 identified 
structural characteristics associated with state-level variation 
in the level of chronic opioid use among patients suffering from 
fibromyalgia syndrome. The chapters use two different approaches 
to describe this variation. The first used a three-year cross 
section of data as a whole. The results of the study suggest that 
geographic variation in chronic opioid use among patients with 
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fibromyalgia syndrome is similar to that seen in the previous two 
studies of opioid use. Factors associated with chronic opioid use 
at the state-level were generally as predicted based on previous 
studies. Percentage of patients that were female and previous 
illicit opioid use rate each were associated with an increase in 
chronic opioid use among patients. Physician prevalence, state 
population, percent of the state population between 45 and 64 
years of age were all negatively associated with chronic opioid 
use.  
Chapter 3 uses the same data slice described in Chapter 2, 
but breaks the data into a panel separated by year. The level of 
variation is constant across the three years with a fivefold 
difference between states with low chronic opioid use in these 
patients and those with high use and a coefficient of variation 
of 36.5%. Using fixed-effects estimation techniques it was shown 
that within state variation is a significant source of variation 
overall for this dataset, meaning that identity as a certain 
state has an association with chronic opioid use in fibromyalgia 
patients. 
The next chapters look at characteristics at higher levels 
of granularity: provider- and patient-level factors. Chapter 4 
demonstrated that chronic opioid use in fibromyalgia patients was 
strongly correlated with diagnosing provider type. Patients 
diagnosed by specialists were more likely to be treated with 
chronic opioid therapy than those diagnosed by primary care 
practitioners including midlevel practitioners. One very 
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interesting finding is the very strong negative correlation 
chiropractic treatment had on chronic opioid therapy.  
The following chapter examined patient-level 
characteristics including demographics such as age and sex, 
comorbid conditions, and concurrent medications. While age and 
female sex were both associated with increased chronic opioid use 
in patients, comorbid conditions and concurrent medications were 
more complicated. In general, those diseases associated with an 
independent pain condition are found to have large and positive 
marginal effects on chronic opioid use in this patient population, 
while disorders with little correlation with pain such as 
diseases of the respiratory, digestive, and circulatory system 
were found to have little association with chronic opioid use.  
Concurrent medication use was very high in this population with 
four-fifths receiving a medication other than an opioid in the 
data. Nearly three-fifths received an opioid prescription during 
their eligibility, a number significantly elevated over the 
general population, which generally sees rates of about 20% for 
annual opioid prescription receipt.  
These chapters all built the case that characteristics 
aggregated at various levels each vary significantly and are 
associated with chronic opioid use in fibromyalgia patients. The 
fibromyalgia literature surrounding these characteristics is 
sparse, but even more troubling is the lack of outcomes studies 
in these patients. The lack of evidence in this area is the 
result of several contributing factors; one of the most important 
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of these is that the use of secondary databases to study 
fibromyalgia patients suffers from a significant weakness, the 
identification of a comparable control group. The next three 
chapters of this dissertation took the characteristics shown to 
be associated with chronic opioid use in fibromyalgia syndrome 
and used propensity score techniques to develop an appropriate 
control group for comparing outcomes. 
Chapter 6 took patients with fibromyalgia syndrome and 
divided them according to their propensity to be chronic opioid 
users. Patients were stratified into deciles based on this 
propensity and compared within strata. A comparison of the two 
groups as wholes resulted in medical costs being 3-times higher 
for chronic opioid users and prescription costs being 6-times 
higher. However, inspection of individual strata showed that the 
relationship between costs and chronic opioid use was a 
heterogeneous one that varied according to propensity to use 
chronic opioids. While both medical and prescription costs remain 
elevated for all groups receiving chronic opioid therapy, as the 
propensity to receive this therapy increases, the differences 
seen in cost comparisons decreases. 
While Chapter 6 focused on the effect of chronic opioid use 
within fibromyalgia syndrome, Chapter 7 focused on the cost 
effects of a fibromyalgia diagnosis. While there is literature 
previously available showing that fibromyalgia syndrome is 
associated with a significant disease burden the control groups 
in these studies are varied and generally lacking in 
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comparability. To improve on these previous studies, we used an 
extensive propensity score to match patients based on their 
propensity to be diagnosed with fibromyalgia syndrome. Matching 
on this propensity reduces the differences seen in medical and 
prescription costs by 90%, resulting in differences of 1% and 5% 
respectively. While the differences seen are still significant 
the use of a well-matched control population shows that the 
impact of a fibromyalgia diagnosis on costs is generally 
overstated.   
Finally, Chapter 8 looks at the effect of the interaction 
of a fibromyalgia diagnosis with the receipt of chronic opioid 
therapy. Due to the unique theoretical predilection of these 
patients to have higher medical and prescription costs the 
difference-in-difference resulting from this interaction was 
examined. While Chapter 7 showed that a fibromyalgia diagnosis 
only resulted in a 1% increase in medical costs and a 5% increase 
in prescription costs, Chapter 8 highlights the large increase 
seen in costs over an above this increase. Even for well-matched 
individual balanced on a large set of observed variables, 
increases of 15% for medical costs and 44% for prescription costs 
are seen.  
The findings of these final two chapters serve to show that 
although a fibromyalgia diagnosis may result in slightly 
increased costs for similar patients, the introduction of a 
treatment alternative that is has a strong theoretical case 
against use is severely detrimental to the patients receiving the 
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therapy. The utilization of chronic opioid therapy in the 
treatment of fibromyalgia syndrome is a practice based not on the 
evidence available to practitioners but on other variables, both 
observable and unobservable. The chapters of this dissertation 
help to fill the gap in the current literature regarding the 
identification of these characteristics, as well as describing 
the effects of this treatment choice on patient outcomes. Given 
the profound lack of evidence supporting the use of opioids in 
fibromyalgia, their prevalence as a treatment option is 
mysterious.  Couple this lack of efficacy with the increasing 
armamentarium that does have evidence of safety and efficacy 
supporting use and with the clear societal and personal adverse 
effects of chronic use of opioids, and the prevalence of their 
use in fibromyalgia becomes very troubling.  Beyond all of these 
concerns, which are common to the treatment of most chronic non-
malignant pain conditions, the pathophysiology of fibromyalgia 
and the increased risk of opioid-induced hyperalgesia that 
results from this pathophysiology, make the use of opioids in 
this condition ill advised. 
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